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Aquaculture provides a signiﬁcant proportion of the global food supply. Ma-
rine ﬁsh aquaculture, like intensive farming of many other species, is vulnerable
to signiﬁcant losses due to pathogens, particularly viral infections. Novirhab-
doviruses, such as Viral Haemorrhagic Septicaemia virus (VHS virus) are impor-
tant pathogens of cold water ﬁshes, and to date there are no eﬀective vaccines
or other treatments. Quarantine and physical separation are the only eﬀective
preventative measures available against VHS virus.
Since the discovery of RNA interference (RNAi) in 1998, there has been signiﬁ-
cant development of RNAi as an antiviral treatment. In particular, short-hairpin
RNA (shRNA) and RNAi-based transgenesis has been demonstrated to eﬀectively
reduce viral titres in VHS virus-challenged ﬁsh. Additionally, cassettes and vec-
tors that produce multiple small interfering RNA can potentially target positions
across the entire viral transcript providing a useful strategy to inhibit viral es-
cape. The zebraﬁsh is an important model for aquaculture as it is the only teleost
species to have a complete and well-annotated genome sequence available. This
makes the zebraﬁsh suitable for testing an anti-viral strategy for future application
in aquaculture.
The work in Chapter 3, identiﬁed and isolated a functional zebraﬁsh RNA poly-
merase III promoter, H1 , and a new U6 (U6-4) promoter, along with a variant
of the latter. shRNAs were be expressed from these, and three other previously
characterised zebraﬁsh U6, promoters in a zebraﬁsh cell line (ZF-4), but not in
the mammalian West African monkey kidney (Vero) cells. The converse was also
demonstrated, ie, two control polymerase III promoters from mice and chicken
allowing expression of shRNAs in Vero cells but not the ZF-4 cell line. This
Chapter also showed that the newly-identiﬁed U6 promoter showed similar lev-
els of activity to previously characterised zebraﬁsh U6 promoters, and that the
H1 promoter showed a lower level of activity as measured by activity of an en-
hanced green ﬂuorescent protein (EGFP) reporter. Finally, it was demonstrated
that species-matched promoters, but not necessarily homologous promoters, are
required for eﬀective expression of, and knockdown by, shRNAs. This supports
previous evidence that there are inherent diﬀerences between mammalian and
avian U6 promoters compared with their teleost counterparts.
Chapter 4 details the design and evaluation of VHS virus-speciﬁc shRNAs, target-
ing 21 nucleotide sequences of either the VHS virus glycoprotein (G) gene or the
VHS virus polymerase (L) gene. To test their function, shRNAs were expressed in
ZF-4 cells utilising the U6-2 promoter (identiﬁed as the strongest), and the cells
were then inoculated with VHS virus at Multiplicity of Infections (MOI) between
101 - 10−5 MOI. Five of the six shRNA molecules successfully reduced VHS virus
replication between 2 and 4 logs in titre relative to an irrelevant control shRNA
at all MOIs and also reduced viral mRNA as measured by RT-qPCR. The shRNA
molecule that did not induce RNAi silencing formed an improper hairpin when
analysed in silico providing an explanation for its observed lack of activity. To
ensure that observed reductions in viral titre were dependent on shRNA silenc-
ing and not interferon induction induced non-speciﬁcally by the dsRNA shRNA
molecules, the interferon response was analysed by RT-qPCR. Only the defec-
tive shRNA induced an interferon response as measured by fold change of both
zebraﬁsh interferon and Mx.
Chapter 5 describes the generation of zebraﬁsh harbouring potential anti-VHS
virus transgenes. However, following microinjection of single-cell embryos with
Tol2 constructs expressing shRNAs a signiﬁcant dose-dependent decrease in the
number of viable zebraﬁsh embryos, and an increase in developmental defects
was observed, This was associated with a signiﬁcant decrease in the levels of na-
tive microRNAs, leading to the hypothesis that these changes were due to the
introduction of excessive shRNA molecules, above the level sustainable by the
endogenous miRNA machinery. Over-expression of human Exportin-5 (hXpo-5)
eﬀectively increased the toxicity of the shRNA vectors, but this eﬀect was rescued
by human Argonaute 2 (hAgo2) co-injection, leading to the hypothesis that the
Xpo5-mediated export mechanism may act as a brake on the levels of silencing
RNAs in the cytoplasm. Decreasing the dose of shRNAs by rational deletion of
elements of polymerase III promoters eﬀectively rescued both embryo viability
and normal development of the zebraﬁsh. Utilisation of the H1 and modulated
U6 promoters did eventually generate fertile adult transgenic zebraﬁsh providing
evidence that the approach was sound.
The results presented in this thesis further support the hypothesis that eﬃcient and
safe use of RNAi, either directly as a therapeutic or indirectly as a virus-speciﬁc
transgene, is dependent on (i) eﬀective and speciﬁc shRNA design to avoid IFN-
type responses or partial or complete binding of siRNA RISC to unintended mRNA
targets, and (ii) the dosage of interfering molecules which should be carefully
controlled to limit the eﬀects on the native miRNA pathway.
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Literature review
1.1 General introduction
Aquaculture, both wild caught and farmed, is the fastest growing food industry
globally, producing between 157-175 million tonnes annually, which is estimated
to provide about 16% of total protein consumed worldwide. The majority of
this production comes from wild caught ﬁsh reserves; however, the proportion
of farmed ﬁsh is rapidly increasing, particularly in Asia. The annual production
increase in aquaculture products has remained steady at around 7% per annum
since 1994 [98,398]. However, even with this growth, farmed aquaculture still only
amounts to less than a quarter of the total ﬁsheries harvest. Farmed ﬁsh stocks
will only become more and more important in the coming years as many wild
ﬁsh stocks are considered to be overexploited [98,234,264] or declining [283]. Indeed,
the use of so-called “super-trawlers” has been the subject of signiﬁcant debate
and legislation in the Australian Parliament within the last 12 months because of
this [275].
By further increasing aquaculture, wild schools and stocks can be preserved and
protected whilst also providing the necessary food resources for increasing pop-
ulations. However, before aquaculture can continue to expand to meet current
demand a number of hurdles, both technical and social, must be overcome. The
1
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nature of ﬁsh farms, like many high density animal farms, makes them sus-
ceptible to many pathogens, such as the parasite Gyrodactylus salaris aﬀecting
salmonoid species [166], a number of signiﬁcant bacterial agents, particularly the
potentially zoonotic Vibrio parahaemolyticus and vulniﬁcus, [19] the ﬁsh viruses
koi herpesvirus [120,355] and spring viraemia of carp virus (SVCV) [116,120], and sig-
niﬁcantly for this project viral haemorrhagic septicaemia virus (VHS virus) of
ﬁsh [141,233,337].
The use of transgenic animals to improve productivity, as well as animal and
human health, is hotly debated and polarising within both the scientiﬁc commu-
nity and the lay population. The press and popular response to the AquAdvan-
tageTMgrowth hormone-enhanced salmon developed by AquaBounty provides a
direct example of this as the US FDA invitation for comment on the approval
of these salmon for production in the USA provoked a great deal of debate (for
example as described in Ledford et al. 2013 [200]). However, the use of a minimal
transgene that induces a response which,results in improvements in animal or hu-
man welfare and food security may prove more palatable than a transgenic where
productivity and proﬁtability are the major motivating factors [105,241,398].
The zebraﬁsh is a model organism of unique beneﬁt for the aquaculture industry.
While the zebraﬁsh is genetically distinct from most ﬁsh species important in
aquaculture - with the exception of carp, which, like zebraﬁsh, belong to the family
Cyprinidae - it is signiﬁcantly closer than any other available model organism
with the major separation event theorised to be approximately 150 million years
ago (reviewed in [83]). In addition, the much anticipated recent publication of
the zebraﬁsh genome sequence [153], continuing the analysis of the genome of the
zebraﬁsh initiated by the Welcome Trust Sanger Institute in 2001 and ﬁrst made
public in 2002, suggests that approximately 70% of the human protein-coding
genes have a zebraﬁsh orthologue [153]. The subsequent annotation of the sequences
will only enhance the zebraﬁsh utility as a model, especially when the carp and
trout sequencing projects are completed.
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The zebraﬁsh is among the most widely utilised model organisms for the study
of developmental genetics, diseases and embryonic development as well as being
an excellent model for aquaculture research [83]. This chapter will focus on the
zebraﬁsh as a model of infectious disease and immunity for aquaculture species,
and VHS virus will be of particular focus. It will also discuss the utility of the
zebraﬁsh to be modiﬁed by RNA interference (RNAi) as well as providing an
overview of mechanisms and inducers of the RNAi response.
1.2 The zebraﬁsh model
The overwhelming majority of zebraﬁsh research has focused upon vertebrate de-
velopment, however, this is rapidly expanding to include studies of disease, includ-
ing cancer and infectious disease. The Zebraﬁsh Information Network (ZFIN) is
thriving as a community of researchers and provides invaluable resources for the
husbandry and laboratory utilisation of the zebraﬁsh. The primary advantages
which, separate the zebraﬁsh from other laboratory animals of note is that de-
velopment occurs ex vivo with the developing zebraﬁsh being transparent, thus
allowing real-time, whole body visualisation and staining. Zebraﬁsh possess an
almost complete complement of the immune functions and lymphoid organs found
in mammals [246,267,397]; however, as with many phylogenetically ‘lower’ organisms,
zebraﬁsh depend more heavily on the innate immune response to infection than
‘higher’ organisms [4,344]. Zebraﬁsh development can be split into a number of dis-
tinct stages broadly summarised in Table 1.1. For excellent detailed descriptions
of zebraﬁsh embryo development, the publication by Kimmel et al 1995 [186] is un-
surpassed. Zebraﬁsh innate immunity is additionally summarised and reviewed by
Sullivan and Kim in 2008 [344].
The zebraﬁsh immune system develops in a number of distinct stages in the em-
bryonic and juvenile zebraﬁsh. Macrophages are present in the yolk sac from one
day post fertilisation (dpf) [142] and the intermediate cell mass [88] from the same
time. However, lymphoid cells only appear from 3 dpf with the adaptive immune
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system not considered to be completely active until 4 - 6 weeks post fertilisation
(wpf) when functional lymphocytes fully mature [88,267,381]. As well as temporal
separation of innate and adaptive immunity, the temperature of challenge also has
signiﬁcant impact on the expression of immune genes in zebraﬁsh [93].
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Table 1.1: Developmental stages of the zebraﬁsh
Name Time (28 ◦C) Stage Length
Zygote 0min to 45min 1 cell
Cleavage 0.75 h to 2.25 h 2 - 64 cells
Blastula 2.25 h to 5.25 h 128 cells - 30% epiboly
Gastrula 5.25 h to 10.33 h 50% epibody - Tail bud
Segmentation 10.33 h to 24 h 1 somite - 26 somites 0.9mm to 1.6mm
Pharyngula 24 h to 48 h Prim-5 - Rudimentary pec ﬁn 1.6mm to 2.9mm
Hatchling 48 h to 72 h Elongated pec ﬁn - Fully formed pec ﬁn 1.9mm to 3.3mm
Larval 4 d to 30 d 3.3mm to 10mm
Juvenile 30 d to 90 d 10mm to 14mm
Adult ≥ 90 Sexual maturity ≥14mm
Modiﬁed from [186] and ZFIN. Timing of developmental stages is approximate and heavily dependent on
outside factors including temperature and water quality. Observational staging is generally preferred.
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1.3 Viral diseases of zebraﬁsh
At the time of writing there have been no natural viruses of zebraﬁsh identi-
ﬁed [75,224,267,344]. However, there have been a number of publications describing
laboratory viral infection of zebraﬁsh (summarised in Table 1.2), with VHS virus,
snakehead rhabdovirus (SHRV), SVCV, and infectious haematopoietic necrosis
virus (IHNV) being the most well-characterised in this model.
Despite the description of a viral infection of zebraﬁsh with VHS virus dating
back over thirty years [326], the use of zebraﬁsh as a model of viral infection re-
mains in its infancy when compared to rodent models or to the use of zebraﬁsh
as a model of development and genetics. Indeed, the majority of virology and im-
munology researchers work in mammalian models, mostly with small laboratory
rodents, while ﬁsh immunologists and virologists have traditionally focused upon
rainbow trout (Oncorhynchus mykiss), Atlantic salmon (Salmo salar), common
carp (Cyprinus carpio) and other commercially important farmed ﬁsh (reviewed
excellently in [245,266,267,336]). While these studies are important, the zebraﬁsh oﬀers
researchers a unique model for exploring the innate immune system independent
of the adaptive immune system. The wealth of data on the development of the ze-
braﬁsh immune systems (as reviewed recently in [246,267,344,402] allows for the study
of immune responses at speciﬁc levels of immune development. In addition, there
is a high level of conservation between the zebraﬁsh and human immune systems.
For ﬁsh immunologists and virologists, the zebraﬁsh oﬀers a model, which, is far
more easily housed than most commercially-important ﬁsh, and genetic tools and
methodologies are available which, dwarf those validated or tested in any other ﬁsh
species. The zebraﬁsh are a particularly good model for diseases of carp that be-
long to the same family (Cyprinidae)). Despite these advantages, there has been
relatively little consideration of the zebraﬁsh as a model for viruses of aquatic
organisms.
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1.3.1 The zebraﬁsh as a model for viral infection
The zebraﬁsh is perhaps an odd choice for the study of human viral diseases, as
despite the ubiquitous nature of viral infections, viruses are frequently extremely
speciﬁc, often to the species level, due to the requirement of speciﬁc receptor
proteins or other systems in the host for successful replication. This speciﬁcity is
most apparent in pathogens of higher vertebrates [26], where inﬂuenza A is perhaps
the most well known exception with humans, pigs, dogs, waterfowl and other birds,
a variety of small laboratory mammals and most recently bats hosting a variety
of inﬂuenza A subtypes; but inﬂuenza A virus remains the exception rather than
the rule [24,311,348,358]. However, among lower vertebrates, it is more common for
a virus to have a variety of hosts and there are a number of studies exploiting
zebraﬁsh as a model for viruses from hosts as diverse as frogs and humans including
herpes simplex type 1 (HSV-1) [55], Chikungunya virus [277] (CHIKV), and Tiger
Frog virus [228].
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Table 1.2: Viruses that have an established zebraﬁsh model
Virus Family Age at infection Reference(s)
Chikungunya virus (CHIKV) Alphaviridae Larval [224]
Herpes simplex virus type 1 Herpesviridae Adult [55]
Infectious hematopoietic necrosis virus (IHNV) Rhabdoviridae 72 h Larvae, and Adults [198,224]
Infectious pancreatic necrosis virus (IPNV) Birnaviridae Adults [198]
Infectious spleen and kidney necrosis virus (ISKNV) Iridoviridae Adults [369,388]
Lymphocystis disease virus (LCD) Iridoviridae Adults [347]
Nervous necrosis virus (NNV) Nodaviridae Adults [220]
Spring viraemia of carp virus (SVCV) Rhabdoviridae Adults [9]
Snakehead rhabdovirus Rhabdoviridae 24 h Embryos, Juveniles, and Adults [6,289]
Tiger frog virus (TFV) Iridoviridae In Vitro ZF4 cells [228]
Viral haemorrhagic septicemia virus (VHS virus) Rhabdoviridae 24 h Embryos - 29 d Juveniles, and Adults [93,265,326]
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As mentioned previously, much of the power of the zebraﬁsh model comes from
their transparency and relative ease of generation of mutants and transgenics. Re-
cently, a number of groups, spearheaded by Professor Jean-Pierre Levraud of the
Pasteur Institute, have been exploiting established zebraﬁsh methods and com-
bining them with modern and classical virology and bacteriology to establish the
zebraﬁsh as a unique and critically important model which, can set the zebraﬁsh
apart from established rodent or other small laboratory mammals. In their 2011
publication in the journal PloS Pathogens [224] they describe the “whole-body” in-
fection of zebraﬁsh larvae with a heat-adapted IHNV virus. This publication relied
on both the transparency of the zebraﬁsh and the availability of unique relevant
ﬂuorescent mutants to track the infection throughout the larvae. This publication
is signiﬁcant as it is among the ﬁrst to utilise the power of the zebraﬁsh model
for imaging, and to combine it with an infection model. Live imaging, ﬂuorescent
viruses, whole-mount in situ hybridisation (WISH), and transgenic knock-in or
knock-out zebraﬁsh will hopefully become a more widely-used tool to elucidate
the patterns of viral infection in this important model [208,224].
1.4 Viral haemorrhagic septicaemia
Viral haemorrhagic septicaemia (VHS) is a disease of ﬁsh caused by the viral
haemorrhagic septicaemia virus (VHS virus). Previously VHS and VHS virus have
been known as Egtved disease and Egtved virus, respectively, but this has fallen
into disuse. VHS virus has a negative-sense single stranded RNA genome of around
11 kb and belongs to the orderMononegavirales, the family Rhabdoviridae, and the
genus Novirhabdovirus. The virus is contained within an enveloped, bullet-shaped
virion 180 nm × 50 nm and is covered in glycoprotein peptomers of between 5 -
15 nm (Figure 1.1).
VHS virus infection of farmed ﬁsh species causes signiﬁcant and long term losses,
both in loss of ﬁsh stocks as a direct result of disease, as well as the loss of market
share caused by restrictions on the movement and sale of ﬁsh caught or farmed
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Figure 1.1: Structure of VHS virus under the electron microscope [406].
A VHS virus particles maturing on the surface of RTG-2 cells. × 262,000. B
Negatively stained VHS virus particle × 300,000 C Cross-section of VHS virus
particle × 617,000.
in waters known to be infected by VHS virus [106,258]. It is, therefore, considered
to be a major threat to a number of ecologically and economically signiﬁcant ﬁsh
species, particularly the major farmed species of salmon and trout.
VHS virus, like the related IHNV, consists of 6 open reading frames encoding the
viral genes in the order 3′-N-P-M-G-NV-L-5′ (Figure 1.2) [320]. The genes encode
the nucleoprotein (N), phosphoprotein (P), matrix protein (M), glycoprotein (G),
non-structural viral protein (NV), and the polymerase (L) genes. As with most
negative-sense single stranded RNA viruses, VHS virus gene expression is greatest
closest to the 3′ end of the RNA strand and reduces towards the 5′ (Figure 1.2).
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Figure 1.2: VHS virus genome.
The VHS virus genome consists of 6 genes: the nucleoprotein (N), phosphopro-
tein (P), matrix protein (M), glycoprotein (G), non-structural viral protein
(NV), and the polymerase (L) genes. RNA expression of VHS virus is greatest
closest to the 3′ end of the genome and decreases in a linear manner towards
the 5′ end.
The NV gene is speciﬁc to the novirhabdoviruses and is among the most variable
regions within the genome [115,148]. The NV gene is a non-structural protein that
is not found within the mature VHS virus virion but only within infected cells.
The presence of the NV gene has been shown to be crucial for pathogenicity
in some species, particularly rainbow trout [319,357]; however, the speciﬁc regions
that diﬀerentiate highly pathogenic VHS virus from less virulent VHS virus have
not been determined [57]. The G gene has also been identiﬁed as important in
determining the virulence of VHS virus [12]. The highly pathogenic Great Lakes
strain of VHS virus (M1030GL) diﬀers signiﬁcantly from the other type IV VHS
virus isolates [12,57].
Clinically, VHS virus causes rapid onset of mortality, which is preceded by lethargy,
darkening of the skin, exophthalmia, anaemia (pale gills), distended abdomen,
haemorrhages and redness at the base of the ﬁns, gills, eyes and skin, as well as
behavioral changes, including abnormal swimming, such as ﬂashing and spiraling,
as well as disorientation [272]. Mortality rates following infection with VHS virus
vary depending on the genotype of virus and environmental factors including the
temperature of the water. Small fry infected with VHS virus often show 100%
mortality, while older rainbow trout, salmon and paciﬁc herring show mortalities
between 5 % and 90 % under experimental conditions [236,272].
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Diagnosis of VHS virus in the laboratory is accomplished via a number of methods
including electron microscopy, where it appears as a typical bullet shaped rhab-
dovirus between 60-70 nm in diameter (Figure 1.1) [104]. For VHS virus infection
to be deﬁnitively established, the virus must be rescued and grown in cell culture
in either BF-2 (bluegill sunﬁsh (Lepomis macrochirus [384]), or EPC (Epithelioma
papulosum cyprini [from fathead minnow (Pimephales promelas ] cells. It should
be noted in passing that EPC cells that were originally characterised as carp epi-
dermal cells and are considered to be contaminated at the lowest available passage
with fathead minnow cells [382]) cells. BF-2 or EPC cells should be examined for
CPE every 24 - 48 hours [253]). If CPE is detected, identiﬁcation via antibody
methods such as neutralisation immunostaining or enzyme-linked immunosorbent
assay (ELISA), or molecular methods such as reverse transcription polymerase
chain reaction (RT-PCR) are required, using antibodies and RT-PCR primers,
respectively, deﬁned by the World Organisation for Animal Health (OiE) within
the Manual of Diagnostic tests for Aquatic Animals [272]. Typical CPE of rhab-
dovirus infection of EPC and CHSE (Chinook Salmon Epithelial Cells) includes
cell lysis, rounding of cells, syncytia formation, and detached cells which, tend
to clump and bloat into grape-like formations [106,161,272]. Importantly, there are
a number of quantitative RT-PCR (RT-qPCR) primer sets using either SYBR
greenTM, or TAQ-man based probes, which, can then be used to determine the
relative amounts of virus present [58,81,151,236]. These RT-qPCR reagents have not
been certiﬁed for the diagnosis of VHS virus by the OiE; however, they are widely
used for research purposes [272].
1.5 RNA interference (RNAi)
RNAi is an ancient and highly conserved cellular process that appears to be ubiq-
uitous in eukaryotes. Evidence of functional RNAi pathways exists in plants [262];
worms such as Caenorhabditis elegans [C. elegans] [110]; insects such as fruit-ﬂy
Drosophila melanogaster [178] and crickets Acheta domesticus [194]; other inverte-
brates such as shrimp, Penaeus monodon, as well as ﬁsh including zebraﬁsh [371],
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and Nile tilapia, Oreochromis niloticus [46]; and mammals, including humans [102]
and mice [23], along with many other species. Endogenously, the microRNA (miRNA)
pathway exists as both a regulatory [349] and anti-viral [285] mechanism. To regulate
transcription and degradation of messenger RNA (mRNA), the RNAi pathway
utilises small, mostly non-coding, miRNAs [314]. The following sections will dis-
cuss the RNAi pathway, mechanisms and inducers of RNAi silencing as well as
limitations and oﬀ-target eﬀects of RNAi, with a particular focus on teleosts, and
speciﬁcally zebraﬁsh, research.
1.5.1 The RNAi pathway and history of RNAi-induced si-
lencing
The initial discovery of dsRNA-induced gene silencing in plants occurred in 1990
through eﬀorts to enhance the purple colour of petunias by over-expressing via the
injection of the chalcone synthase gene that synthesises this pigment [262]. However,
plants with the introduced gene produced either white and/or patterned ﬂowers
instead of the hypothesised purple colour [262]. Unfortunately for these researchers,
this discovery was treated as a curiosity and its signiﬁcance not realised until al-
most 10 years later when, in 1998, two independent studies demonstrated that
gene silencing was initiated by dsRNA molecules in the nematode Caenorhabditis
elegans (C. elegans) [110] and again in tobacco plants [373]. The mechanism of action
remained elusive until Fire and colleagues demonstrated that by injecting a com-
bination of RNA sense and antisense strands into C. elegans, more eﬃcient gene
knockdown was achieved compared to either one of these strands independently.
Prior to this experiment, modulation of gene expression had been described in C.
elgans using either sense or antisense RNAs. However, the introduction of dsRNA
vastly increased potency of the gene knockdown .
The natural functions of RNAi and its related processes were ﬁrst suggested to
involve protection of the genome against mobile genetic elements such as integra-
tive viruses and transposons. More recently, this theory has been expanded to
include a broader role that RNAi inducers regulate the expression of genes via
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the degradation of, or transcriptional blockage of, endogenous mRNA via endoge-
nous RNAi inducing molecules called microRNAs (miRNAs) [61,293,395]. The ﬁrst
miRNA, lin-4, was discovered in the early 1990s [201,380], and miRNAs are now
known to control gene expression in numerous fundamental cellular processes, in-
cluding cellular diﬀerentiation, apoptosis, developmental timing, and regulation
of transposable elements. The functions and actions of miRNAs have been the
subject of massive research interest since the discovery of lin-4 and are covered
frequently in reviews [53,136,181,290]. The role of RNA silencing is critically important
throughout the lifecycle of the organism and it has been estimated that miRNAs
acting via the RNAi pathway, may regulate up to a third of all human genes [209]
(Figure 1.3) [ [110]].
From the initial discovery of RNAi, it was suggested that this pathway plays an
important role in anti-viral immunity. This was ﬁrst demonstrated in plants when
it was illustrated [294] that transgene-induced viral immunity [30,213] was initiated
by the expression of viral mRNA. Following infection, all viruses may produce
dsRNA that can potentially be recognised by the endogenous RNAi machinery
(Figure 1.3). In addition, a number of viruses encode and utilise factors that act
via the RNAi pathway. In particular, miRNAs are expressed by a number of viruses
including Simian virus 40 (SV40) [345], Herpesvirus family members [60,288,309] and
human immunodeﬁciency virus type-1 (HIV-1) [33,273]. In addition, host-encoded
miRNAs are also known to directly or indirectly aﬀect the replication of many
viruses, such as retrovirus primate foamy virus type-1 (PFV-1) [199], and hepatitis
C virus [168,255,312], while it is also believed that saturation of host RNAi pathway
components, to prevent viral degradation, is achieved by the adenoviral-expressed
virus associated (VA) RNAs [130]. Human cytomegalovirus expresses a number of
miRNAs that speciﬁcally target genes to facilitate persistence and replication in
cell culture [123,249], and additionally encodes an inhibitory molecule speciﬁc to the
human miRNA miR-27 [212]. Understanding the underlying processes by which,
the RNAi pathways function in cells and organisms are fundamental to our ability
to harness this pathway to speciﬁcally modulate genes of interest for both research
and therapeutic applications.
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The principle of externally introduced RNAi with genes in a sequence speciﬁc
manner was ﬁrst identiﬁed in petunias [262], when plasmids designed to over-express
chalcone synthase (CHS) proteins in petals resulted instead in the reversible degra-
dation of CHS mRNA and a distinctive petal phenotype [99,262]. This study sug-
gested that the introduction of anti-sense RNA was the catalyst for the observed
knockdown of mRNA, a phenomenon that was also observed in fungus, where it
was termed “quelling” [303]. However, it was the identiﬁcation of dsRNA as a “po-
tent and speciﬁc inhibitor” [110] of mRNA transcription in C. elegans that truly
sparked the scientiﬁc interest in RNAi. In the landmark study, injection of puri-
ﬁed sense and anti-sense RNAs corresponding precisely to a region of the unc-22
gene produced a phenotype of characteristic behavior and mottling identical to
that observed in the unc-22 knockout. Crucially, this study also identiﬁed that
the introduction of both sense and anti-sense RNAs was several orders of magni-
tude more eﬀective at inducing knockdown of the gene than the injection of either
strand alone [110].
Following this study, long dsRNAs were also used to successfully knockdown genes
in plants [373], in D. melanogaster [178] and also in ﬁsh [371]. In the latter study, ze-
braﬁsh were injected with long dsRNA designed against three characterised genes:
ﬂoating head (ﬂt), no tail (ntl) and pax2.1/no isthmus (noi). These produced
Figure 1.3 (preceding page): The natural inducers of the RNAi pathway.
A Endogenous miRNA genes express miRNA precursors that are processed and
exported from the nucleus by the Xpo5 RanGTP complex. B Virus encoded
microRNAs (miRNAs) are expressed upon viral infection to form miRNA pre-
cursors. These miRNA precursors can be either encoded by the virus, target
cellular processes and repress native genes, or be cleaved by cytoplasmic en-
zymes and repress viral mRNA as a primitive anti-viral response. These viral
or endogenous-derived miRNA precursors are enzymatically processed into ma-
ture miRNAs that are then incorporated into RISC. C Transposon or pathogen
exogenous dsRNA is recognised within the cell and processed into active siR-
NAs. Both siRNA and miRNA are then further processed within RISC where
unwinding of the RNAi inducer and passage to the corresponding cellular mRNA
occurs. The RNAi-inducing molecules then cause the nucleolytic degradation
of the target or repression of translation by either sequestering mRNA within
p-bodies or by blocking translation by proteases.
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eﬀective interference that was dependent on the concentration of the dsRNA in-
jected [371]. This paper was followed by a ﬂurry of research into the eﬀectiveness
of RNAi as a method of gene knockdown in ﬁsh [211,232,269,371].These studies were
inconclusive as to the speciﬁcity of the knockdown; in each of these studies, pheno-
types which, were either highly variable or signiﬁcantly diﬀerent from the knockout
animal were observed. The authors suggested that any phenotypes resulting from
the speciﬁc interference caused by injected dsRNA were being swamped by non-
speciﬁc eﬀects related to the injection of the RNA [269,323,404]. It seems likely that
the inconclusiveness of these ﬁndings coupled with the nearly simultaneous de-
velopment of additional genetic tools for gene knockdown [97,346] and rescue in the
zebraﬁsh model have resulted in RNAi tools being less developed in zebraﬁsh [323].
More recently, a number of explanations have been proposed for the seemingly
contradictory nature of these results using RNAi. Firstly, diﬀerences in the mi-
croinjection methods used and the amount of dsRNA injected have likely played
a role in inducing non speciﬁc defects [111]. However, the results from titration
experiments, makes it clear that the concentration of RNA alone is unlikely to
be responsible for the lack of speciﬁcity of the interference [232,269,323]. Double-
stranded RNA has long been understood to activate the type 1 interferon (IFN)
immune response via the Toll like receptor 3 (TLR3) pathway as well as pathways
that detect intracyctoplasmic dsRNA such as the retinoic acid-inducible gene 1
(Rig-I) like receptors (RLRs) as well as the protein kinase regulated by RNA
(PKR) [163,238]. Indeed, synthetic dsRNAs such as polyI:C are used deliberately to
induce such a response [89]. It has, therefore, been additionally proposed that the
“non-speciﬁc” defects noted in these papers following the introduction of dsRNA
could be the result of an interferon response [323]. Zebraﬁsh and other ﬁsh species
have functional interferon present at 18 - 24 hours of embryonic development with
poly:IC shown to induce an upregulation of IFN production [66,207,300,323].
More recent studies using dsRNA in zebraﬁsh [2,154] and Xenopus [261] have shown
that reproducible and speciﬁc defects can be observed in ﬁsh. One study used
both morpholinos and injected dsRNA targeting the 3′-end of the Myostatin gene
and was able show that the same phenotype was produced by both methods of
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transient knockdown [2]. In this case, signiﬁcantly less dsRNA was used ( 1fg/L),
despite targeting a gene encoding a protein ubiquitously expressed throughout the
organism [2,111].
1.5.2 The endogenous mechanisms of RNAi
Primary miRNA transcripts (pri-miRNAs) are transcribed within the nucleus by
RNA polymerase II transcription. These short 100 - 300 nt transcripts can be
produced either from independent genes or alternatively spliced from the introns
of protein-coding genes, from either the 3′ or 5′ untranslated regions [62]. In each
case the pri-microRNAs are further processed in the nucleus by the Drosha/ DRG8
protein complex into 70 nt - 100 nt pre-miRNAs [202,399].
Pre-miRNAs form hairpins that are transported from the nucleus into the cyto-
plasm by Exportin-5 [44,50,130,226,391] (Xpo-5). Until recently this was presumed to
be the only role for Xpo-5 within the microRNA pathway. However, in a recent
study [34] ablation of Xpo-5 expression using siRNA molecules simultaneously re-
duced Dicer but not Drosha or other associated miRNA pathway members. It
also demonstrated that the over-expression of Xpo-5 increased Dicer protein level.
Most importantly for this study, they also demonstrated that expression of large
quantities of pri-mir30 from the pol II CMV promoter saturated the Xpo-5 protein
that concomitantly reduced Dicer protein availability in the cytoplasm [34]. This is
among the ﬁrst evidence that the relative abundance of individual microRNAs has
a cross-regulatory eﬀect on the expression of RNAi pathway members, and pro-
vides further evidence of Xpo-5 as a limiting factor in miRNA abundance within
the cytoplasm.
The ﬁrst step of the cytoplasmic RNAi mechanism is based on the cleavage of
dsRNA of greater than 30 nt, processed into 21 - 23 nt active siRNAs by the
RNase III enzyme Dicer [102]. Like all RNase III enzymes, Dicer cleaves dsRNA
and leaves 3′ overhangs of either two or three nucleotides with 5′-phosphate and 3′-
hydroxyl termini [102,164]. Dicer activity is dependent on the adenosine triphosphate
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(ATP)-dependent translocation of the enzyme along its target prior to dsRNA
cleavage [38]. Dicer has four distinct domains: an amino-terminal helicase domain,
dual RNase III motifs, a dsRNA-binding domain, and a PAZ domain (named after
the proteins Piwi, Argo, and Zwile/Pinhead) [64,349].
The cleaved strand of the duplex selected for incorporation into the RNA Induced
Silencing Complex (RISC) is most frequently the strand which, is the least ther-
modynamically stable, which, is dependent on the nucleotides surrounding the 5′
end [179,321]. This strand is colloquially known as the guide or targeting strand, and
is responsible for the sequence-speciﬁc interaction of RISC with the target messen-
ger RNA (mRNA). The complementary strand, known as the passenger strand, is
less frequently incorporated into RISC [374], and is typically degraded [135]. If the
guide strand is completely identical in sequence to the target mRNA then the
mRNA is cleaved and degraded, which, throughout the remainder of this doc-
ument will be described as siRNA degradation. If there are a small number of
mismatches between the target mRNA and the miRNA seed region, located at
nucleotides 2-7 from the 5′ end of the miRNA, then the mRNA is sequestered
within P-bodies in the cell resulting in translational repression (miRNA repres-
sion) [94,179,188]. Where miRNAs have two eﬀective strands, the strands partner
with separate RISC entities and can both result in mRNA degradation or inhibi-
tion of translation [299]. As well as microRNAs and synthetic siRNAs and shRNAs,
endogenous dsRNA from repetitive sequences such as transposons and exogenous
dsRNA from pathogens, particularly of viral origin, additionally trigger the RNAi
pathway. Post-Dicer cleavage, the siRNA then binds to a multiprotein complex
to form the RNA-induced silencing complex (RISC). Activation of RISC is depen-
dent on unwinding of the siRNA duplex via Argonaute-mediated cleavage of the
unincorporated passenger strand [122,237,291], and the antisense strand is guided to
the target mRNA. Binding of the homologous siRNA strand to the target mRNA
results in the RISC-mediated cleavage of the target mRNA.
Most recently, deep sequencing has elucidated whole additional families of short
ncRNAs. Some are processed by the canonical RNAi pathway, others interact
with one or more members, frequently either Dicer or Argonaute proteins with or
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without the RISC complex with an accompanying post-transcriptional targeting
and mRNA modiﬁcation. Along with the piRNAs, tiRNAs and other families of
short ncRNAs, RNA-seq and other sequencing technologies have recently identiﬁed
scores of additional siRNA molecules within both the cytoplasm and the nucleus.
These additional families of ncRNAs have exposed ﬂaws within the models of
RNAi silencing proposed so far. Among the most accepted of new hypotheses
from these studies are suggestions that there are a number of RISCs and that the
downstream consequences of RNAi silencing are dependent upon the RISC within
which the siRNA, miRNA, piRNA or other potential substrate is incorporated.
The speciﬁc Argonaute protein that the RISC is built around may be responsible
for the diﬀerences in outcome from the same substrate.
The original model of RNAi suggested that siRNA/shRNA and miRNA molecules
shared key components of the miRNA pathway (see [351] for a review). For the
transport and processing molecules Xpo-5 [34,129,391] and Dicer [65,113,126,276,298], re-
spectively, this appears largely to be the case. There are certain limited exceptions,
however, with molecules including mir-451 having Dicer; independent, [70,280,389]
Argonaute; dependent processing requirements. As well as, shRNAs of 18-19 nt
having RNAi silencing ability thought to be Dicer independent [118,218,334]. However,
these views are limited to three separate publications at this time, and this thesis
will treat shRNA molecules as Dicer-dependent unless otherwise noted speciﬁ-
cally. However, there is an alternative theory that siRNAs and perfect match
miRNAs enter an siRNA-dependent siRISC, deﬁned by its “slicing” activity and
by a miRISC where the outcome of miRNA-target mRNA binding is sequestration
of target mRNA within cytoplasmic P-bodies [215,304,327].
While both siRNA strands have the potential to facilitate selection during the
transition of the siRNA/miRNA duplexes into RISC [374], the end which is the
more weakly paired thermodynamically is preferentially selected to enter RISC,
and to bind target mRNA. Upon the ﬁnal binding of the unwound mature siRNA
or microRNA within RISC to the target homologous mRNA, cleavage occurs at
a single site in the centre of the duplex region, 10 nt from the 5′-end of the
siRNA [102]. Although this process is not ATP dependent [268], successive rounds of
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mRNA cleavage are more eﬃcient in the presence of ATP [156]. The ﬁnal loaded
RISC complex catalyses hydrolysis of the target RNA phosphodiester linkage and
is reminiscent of the reaction where Dicer generates siRNA from dsRNAs [235,322].
1.6 Synthetic inducers of the RNAi pathway
1.6.1 siRNA
Synthetic interfering RNA molecules are artiﬁcially-created 19 - 23 bp duplexes
designed with 3′ overhangs to facilitate entry into the endogenous miRNA path-
way [179]. siRNA molecules are designed with guide and passenger strands: the
guide strand is identical to the mRNA sequence to be silenced and the passen-
ger stand is the exact complement. In order for speciﬁc silencing to occur the
passenger strand enters the RISC complex and binds to the mRNA. The siRNA
is constructed so that there are 2 uracil bases overhanging at the 3′ end. This
overhang assists in guiding the correct strand into the RISC complex [16,363].
As previously mentioned, the design of siRNA molecules is crucial for the eﬃciency
of the knockdown, and there are a number of published algorithms available on-
line for the purposes of designing siRNAs [102]. As miRNAs are frequently not
completely complementary to the sequence being targeted and bulges and slight
mis-matches are common, it is possible for a single miRNA to act on multiple
targets. Thus, if the introduced siRNA is partially complementary to an unde-
sired target, particularly around the 5-12 bp seed region, the siRNA may bind
to an undesired mRNA, which could then be targeted via RISC for cleavage or
incorporated into a P-body and sequestered [217]. Therefore, speciﬁc use of siRNA,
and RNAi in general, absolutely requires that the genome sequence of the organ-
ism into which the interfering molecule is being introduced be known, and that
multiple controls including scramble/irrelevant interfering molecules are included
as part of any experimental design. An alternative to synthetic production of
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siRNAs is to synthesise longer, 27 bp transcripts as the base molecules to be in-
troduced into the cell. These longer dsRNA molecules enter the RNAi pathway
downstream of the RISC complex and are cleaved into Dicer substrates, which are
potentially more eﬃciently loaded into RISC and induce eﬀective silencing [181].
dsRNA Dicer substrates (DsiRNA) have been used eﬀectively in Chinook Salmon
Embryo (CHSE-214) cells to speciﬁcally silence VHS virus [43] without silencing
the heterologous virus IHNV. Whether longer 23 b to 30 b DsiRNA molecules or
shorter 17 – 21 bp siRNA are more eﬀective silencers is only one small consid-
eration when RNAi silencing molecules are being designed. The additional costs
involved in synthesising longer molecules and the ready availability of commercial
siRNA is likely to ensure that DsiRNA molecules are less widely utilised.
1.6.1.1 siRNA delivery in ﬁsh
When properly designed, siRNAs are an eﬀective method of knocking down mRNA
levels within a cell. However, due to the short half-life of RNA within the cell, they
are only eﬀective for a short period, generally for between 3 - 5 days [102,108]. This
transience has led to the development of vector-based approaches to allow more
sustained production of siRNA molecules in vivo [51]. There has been considerable
proof of principle work to show that RNAi molecules can be eﬀective in cell cul-
ture as siRNAs or in transgenic animals as shRNAs [221]. However, before eﬀective
RNAi treatments can be developed for control of disease, robust delivery systems
are required [221,305]. Many of the RNAi methods were developed to achieve high
levels of transfection in mammalian cell culture using reagents speciﬁcally designed
to transfect at the temperature and conditions which suit mammalian cells [139,297].
Unfortunately, transfection of ﬁsh cell lines is particularly diﬃcult, with many
standard chemical and lipid-based transfection reagents being ineﬀective at trans-
porting nucleic acids across cell membranes [85] at the lower temperatures required
for the healthy growth of ﬁsh cell cultures. Cell lines stably expressing plasmid
derived RNAi molecules have been produced in EPC (ATCC CRL2875) [183,306,307]
and BF-2 (ATCC CCL-91) [85,328] cells, although, again, these studies have shown
mixed results. Electroporation of the zebraﬁsh cell line ZF4 (ATCC CRL-2050)
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has proven to be an eﬀective method of introducing plasmid DNA, however this
requires speciﬁc expensive equipment (Invitrogen Nucleofector TM) that makes this
method less common [137,362].
The ﬁrst study utilising siRNA molecules in ﬁsh was the knockdown of eGFP
in rainbow trout embryos using siRNA molecules targeting eGFP but not with
scrambled (irrelevant) siRNA molecules [45]. The same siRNA molecules were also
directly injected into the F3 strain of transgenic rainbow trout and were eﬀective
at inducing knockdown of a stably expressed eGFP transgene. Approximately
10% of the injected embryos were found to have non-speciﬁc and frequently lethal
phenotypes, and the number of defects observed increased rapidly when more than
5 ng of siRNA was used [323]. A signiﬁcant thrust of research in ﬁsh involves the
generation of antiviral RNAi, using plasmid based shRNA molecules to target a
viral gene either in vivo or in vitro.
RNAi molecules targeting viral genes to induce resistance in the host have been
used in a number of ﬁsh species and cell lines to mixed eﬀect. siRNAs targeted to
the MCP gene of the Iridovirus-tiger frog virus were transfected into FHM cells.
The siRNA molecules were successful at reducing viral titre and delaying CPE for
up to 36 hours [387]. This successful early result was contrasted by another study
targeting the G gene of VHS virus published in the following year. In this study,
three siRNA molecules targeting the G protein of VHS virus and 3 control siRNAs
with between 1 and 4 mismatches were produced and transfected into EPC cells
using the TransIT-TKO siRNA transfection reagent. These molecules were capable
of protecting the cell monolayers from infection for up to 96 hours post transfection.
However, there was also signiﬁcant induction of interferon as measured by real-
time PCR of the MxA gene. These siRNA molecules also protected against the
related ﬁsh rhabdovirus spring viraemia of carp virus, which led the authors to
conclude that the protection against the virus was the result of up-regulation of the
interferon response, rather than speciﬁc silencing from the siRNA molecules [307,324].
As with most ﬁsh cell culture studies, transfection eﬃciency was relatively poor,
and the authors recommended ﬁnding alternatives to the transient knockdown
provided by the siRNAs.
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1.6.2 Polymerase III promoters for shRNA expression
As mentioned, siRNA molecules have only a transient eﬀect on the cell before they
are cleared and destroyed. In order to overcome this limitation, Brummelkamp et
al [51] designed a plasmid vector containing, in order: a polymerase III promoter,
such as the H1 promoter; 21 bases exactly complementary to the target sequence; a
region of 9 bases, which forms a loop when transcribed; 21 reverse complementary
bases, which will become the guide strand of the siRNA molecule; and, ﬁnally,
a termination sequence [51]. This structure mimics naturally encoded Pri-miRNA
molecules, and it enters the RNAi pathway in the nucleus of the cell before being
exported to the cytosol by Xpo-5, in the same manner as miRNA molecules [51].
These synthetic short-RNA hairpins are termed shRNA. Following this study, there
has been a vast array of designs and types and terms for these synthetic interfering
molecules AmiRNA and SmiRNA, artiﬁcial microRNA and synthetic microRNA,
respectively, are among the most common alternative terms utilised. For the
purposes of brevity and simplicity, this document will use the term shRNA for all
short RNA hairpins, which enter the endogenous RNAi pathway, are exported from
the nucleus via Xpo-5, are processed into siRNA molecules by either Argonaute-2
or Dicer and are incorporated into RISC.
Small nuclear RNA genes are frequently transcribed by RNA polymerase III in
eukaryotes. Polymerase I (pol I) synthesises large ribosomal RNA (rRNA), pol II
synthesises mRNA, snRNA [143] and miRNA [203] and pol III synthesises 5S rRNA,
transfer RNA (tRNA), 7SL RNA, U6 snRNA and a number of other small sta-
ble RNAs notably the H1 RNA component of RNase P [22,282]. Pol III promoters
can be further categorised into type 1, 2 and 3 RNA pol III promoters that are
diﬀerentiated by their alternative promoter structures (Figure 1.4). However, the
majority of these promoters share the unusual feature of the requirement for se-
quence elements downstream of the +1 position of the transcriptional startsite
region. The 5S rRNA gene is a prime example featuring this typical structure.
The human U6-1 promoter is the best characterised type 3 RNA pol III promoter
and comprises a promoter core region featuring a TATA box between -30 and -25,
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and a Proximal Sequence Element (PSE) between -66 and -47. The TATA box is
characteristic of type 3 promoters, and is located at a ﬁxed distance downstream
of the PSE [239]. The TATA box is recognised by the TATA-binding protein (TBP),
which is one of three polypeptides in a multi-subunit complex, transcription factor
IIIB (TFIIIB) [317,356]. The PSE is recognised by a multi-subunit protein complex
known as the snRNA activating protein complex (SNAPC) [143,308]. The binding of
SNAPC and TBP, and their subsequent interaction with the DNA strand, leads to
the recruitment of RNA pol III [69]. Located further upstream, the distal sequence
element (DSE) generally functions as an enhancer for the activation of transcrip-
tion from the promoter core region [143]. This region commonly consists of an
octamer element (OCT) and a staf motif known as the SphI post-octamer homol-
ogy (SPH) element [193,259,313,318]. The OCT motif is bound by Oct-1 [144], and the
SPH recruits staf, a septamer zinc-ﬁnger transcriptional factor [313]. The zebraﬁsh
U6 promoters diﬀer signiﬁcantly from the mammalian U6 promoters in that the
SPH element for the PSE is translocated and the DSE appears to consist of the
OCT motif alone [46,71,133]. There currently has been no research comparing the
SNAPC and TBP binding proteins from human and zebraﬁsh models to identify
whether the zebraﬁsh TFIIIB complex is signiﬁcantly diﬀerent to the mammalian
orthologue. As the pol III type 3 promoters consist of elements entirely prior
to the start of transcription, they are uniquely suited for use to speciﬁcally and
eﬃciently express diﬀerent shRNA molecules [51].
A number of the most recent studies in ﬁsh cells using vector-based shRNA
molecules targeted either the G or L genes of VHS virus. Firstly, Ruiz et al and
Dang et al in 2008, and then Kim and Kim in 2010 successfully created stable cell
lines transfected with various plasmids expressing shRNAmolecules [85,183,307]. Ruiz
Figure 1.4 (preceding page): The structure of RNA polymerase III promoters.
Examples of each of the three types of RNA pol III promoters are illustrated
with the various promoter elements and the locations of the promoter elements
relative to the start of transcription. Transcription start sites are indicated
by the arrow and +1 and the termination site of transcription is indicated by
Tn for type I, type II and the hybrid promoters, and by TTTTT for type III
promoters. Figure is modiﬁed from [282,316] and includes additional data from [71].
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et al found that the three plasmids expressing diﬀerent siRNA molecules targeting
the L gene provided diﬀerent levels of protection against VHS virus. However, this
protection was also not speciﬁc to VHS virus, with the shRNA molecules addi-
tionally able to provide protection against IHNV, a related novirhabdovirus. One
of the stably generated cell lines showed increased levels of unhealthy cells prior to
infection, including cells showing poor adherence to the ﬂask and each other, and
also increased numbers of bloated and ﬂoating cells. As no increased IFN response
was observed by real-time PCR of the MxA gene, the authors suggested that the
shRNA molecules produced by the particular expression plasmid may be inter-
fering with the endogenous miRNAs present in the cells [307]. This observation is
supported by a number of papers that have suggested that ﬁsh may be particularly
sensitive to the expression of additional shRNA or siRNA molecules by interfering
with the natural miRNA pathway [112,216]. However, another study using the same
method of generating stable cell lines, but using a diﬀerent promoter to express
the interfering hairpins, showed speciﬁc silencing of VHS virus and complete pro-
tection of EPC cells against VHS virus, with little induction of interferon and no
cross protection against IHNV. By using a weaker ﬁsh U6 promoter, the Fugu
U6 promoter [401], rather than the enhanced CMV promoter used by others [307],
no unhealthy cells or potential oﬀ-target eﬀects were observed [183]. There remains
a pressing need for further studies in alternative cell lines and using alternative
methods of expressing hairpins to conﬁrm the impact of using a weaker promoters
on reducing such oﬀ-target eﬀects.
In 2012, two publications in the journal Zebraﬁsh [71,298], one published from the
work performed in Chapter 3 of this thesis [71] and a third in early 2013 in Ge-
netics [96], oﬀered alternatives for the expression of shRNA molecules in both cell
culture [71] and transiently transgenic zebraﬁsh [96,298]. Clarke et al [71] utilised native
zebraﬁsh polymerase III promoters and characterised the relative strength of these
promoters, and Dong et al [96] used a modiﬁed intron to deliver an shRNA utilising
a miRNA backbone to the cells and zebraﬁsh. Both of these methods may be of sig-
niﬁcant importance in over-coming oﬀ-target eﬀects of over-expression of shRNA
molecules in ﬁsh, ﬁrstly, by providing alternative native polymerase III promoters,
Chapter 1. Introduction 28
including the weaker H1 promoter [71] and secondarily by coupling an shRNA to a
native intronic miRNA and controlling the dosage of the shRNA to a known toler-
ated level [96,298]. Due to the eﬀectiveness of alternative methods of gene ablation,
in particular the TALE nucleases used by Professor Stephen Ekkers group [32], and
the exciting developments in clustered, regularly interspaced, short palindromic
repeat (CRISPR) - Cas9 RNA nuclease combinations, excellently reviewed in [310],
the major utility of RNAi in ﬁsh remains to target exogenous mRNA, particularly
from viruses.
1.6.3 Oﬀ-target eﬀects of synthetic RNAi in ﬁsh
A number of papers have used EPC cells to either transfect siRNA molecules or
shRNA plasmids to generate stable cell lines producing siRNA molecules target-
ing VHS virus. However, there have been discordant results [183,307,324,325]. One
potential explanation for this is the recent report that all known lineages of EPC
cells were contaminated with cells from fathead minnow, Pimephales promelas [382].
One obvious consequence of the misidentiﬁcation of EPC cells is that any scan-
ning or trawling of the draft Carp genome or available carp sequences by Ruiz et
al for potential oﬀ target eﬀects by the shRNA molecules was performed against
the wrong species. This might possibly explain the large induction of interferon
and consequential cross protection of cells against IHNV by some of the molecules
used by Ruiz et al, through binding unknown endogenous mRNA from what were
in fact minnow cell lines
Sequence independent oﬀ-target eﬀects have been observed in detail both in mice,
where adenoviral vectors expressing shRNAs from U6 pol III promoter induced
signiﬁcant liver damage, and in Xenopus, where polymerase II and III vectors in-
duced signiﬁcant developmental deformities and mortality. This dose dependent
inhibition of endogenous miRNAs oﬀers an alternative explanation for the dif-
ferences in the results observed by Ruiz et al [306] and Kim and Kim (2010) [183].
Kim and Kim used a native ﬁsh (Fugu U6) promoter to express their shRNA
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molecules. This promoter is likely weaker than the commercially available hu-
man cytomegalovirus CMV enhanced promoter used by Ruiz et al, as described in
Zenke 2008 [401]. By utilising a weaker promoter Kim and Kim may have avoided
interfering with the endogenous miRNA pathways. However, signiﬁcantly more
research is required into the eﬀects of diﬀerent levels of siRNA (shRNA) molecules
on zebaﬁsh if the development of an RNAi transgenic ﬁsh free from non-speciﬁc
defects is to be achieved. The saturation and inhibition of the native miRNA path-
way by exogenous dsRNA molecules will be discussed in further detail (Section
1.7).
To begin to study the non-speciﬁc inhibitory eﬀect of siRNA molecules on miRNAs
in more detail, Fjose and Zhoa [112,403] knocked down Dicer in zebraﬁsh embryos
using anti-sense morpholinos. This blocked the miRNA pathways with no miRNA
speciﬁc-silencing being observed [403] leading to marked and terminal non-speciﬁc
mutations. There was a marked eﬀect on one speciﬁc miRNA, mir-430 that has
been identiﬁed as a crucial regulator of the removal of maternal mRNA early in
embryonic development. Non-targeted (irrelevant) siRNAs were injected into the
developing embryo, and similar disruptions in mRNA, and speciﬁcally to mir-430,
were observed in a dose dependent manner [112,403].
1.7 Saturation of the endogenous microRNA path-
way by exogenous dsRNA molecules
The concept of the saturation of the endogenous miRNA pathway following ex-
pression of high doses of synthetic interfering dsRNA molecules has been champi-
oned by Grimm et al [47,126–129]. They showed that high doses of shRNA molecules
delivered from an adenoviral vector into mice livers led to hepatocellular death
and cancers [128]. Supported by utilising two independent publications [390,391], they
hypothesised that Xpo-5 was the likely cause of the problem. This concept has im-
portant implications for the development of shRNA molecules that can potentially
minimise interactions with vulnerable components of the microRNA pathway. For
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instance, modulating shRNA design to facilitate the bias of shRNA molecules away
from incorporation into miRISC if possible, may allow for the maximization of the
numbers of molecules without interference.
Xpo-5 was ﬁrst identiﬁed as a RanGTP-dependent binding protein that strongly
associated with dsRNA, and the association of dsRNA was a limiting factor in its
eﬃcacy of translocation between the nucleus and the cytoplasm [50]. The following
year the connection between a dsRNA binding translocation protein and miRNAs
was established and Xpo-5 was conﬁrmed to be the protein responsible for translo-
cation of miRNAs and shRNAs from the nucleus into the cytoplasm [44,130,391] in
mammalian cells. However, the signiﬁcance of the latter was established by the
observation that over-expression of Xpo-5 in the human immortalised T-cell line
(HEK293 T) [ATCC CRL-11268] signiﬁcantly enhanced the eﬀectiveness of ob-
served silencing by both endogenous levels of miRNAs and by transfection of Pol
III delivered shRNAs. Interestingly, no additional pathogenicity was observed in
cells with these vectors and the vast amount of research utilising high doses of
shRNA molecules in cell culture suggest that shRNA dose is less important in
immortalised cells than in in vivo models.
Expression of discrete shRNAs from either transgenic constructs or plasmid vectors
is dependent upon the endogenous RNAi pathway during export from the nucleus.
It is logical to assume that this single protein-dependent step will be the most
vulnerable to saturation and repression by the expression of exogenous shRNA
molecules and this is precisely what was observed in the original studies. Xpo-5
has previously been shown to preferentially bind to a mini-helix structure in ncR-
NAs [130] and this mini-helix or hairpin structure is a characteristic of both shRNAs
and miRNAs, with the RNA-binding domain of the of the Xpo-5 protein binding
to the RNA hairpin in a RanGTP-dependent manner [130]. Whilst there have been
a number of publications which have identiﬁed that Xpo-5 is a limiting factor in
either miRNA and / or shRNA transport [34,44,50,119,126,128–130,134,177,225,227,390,391,403],
saturation of downstream cytoplasmic molecules such as the argonaute proteins
have additionally been identiﬁed as responsible for some of the oﬀ-target pheno-
types observed.
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1.7.1 Saturation of Argonaute
The Argonaute (Ago) proteins are catalytic proteins which are present in the RNA
induced silencing complex (RISC) [214,270] as well as involved in non-canonical cleav-
age of pre-miRNAs into mature microRNAs [65,70,389]. Research into the saturation
of Ago proteins has focused upon the presence of Ago within RISC and not on
its role as a precursor cleavage RNase. However, while a number of studies have
demonstrated that suppression of the most well known non-canonical miRNA,
miR-451 [65,70,389] is required for normal erythroid development in mice, zebraﬁsh
and mammalian cell culture [218,280,281,359], it remains possible that this is one of the
underlying mechanisms observed in early embryo toxicity induced by RNAi. This
potential additional mechanism will have implications on the development of even
shorter Ago-dependent, Dicer-independent silencing molecules as these molecules
will utilise Ago2 as both a dependent RNase cleavage protein and during RISC
incorporation [218].
As well as the potential of shRNAs and exogenous hairpin RNA molecules to out-
compete endogenous miRNAs for access to Dicer and prevent or inhibit translo-
cation from the nucleus into the cytoplasm, it has additionally been reported that
both saturation of Xpo-5 and knockdown of Xpo-5 both signiﬁcantly reduce Dicer
mRNA levels in the cytoplasm, preventing its export and translocation [34]. This
prevention of translocation is directly related to the presence of small RNAs that
contain either a hairpin structure or a similar RNA-helix [34]. This suggests that the
presence of Dicer within the cell is dependent on Xpo-5 availability and that there
may be a secondary mechanism of action occurring following the over-expression
of an XPo-5 substrate preventing normal processing of miRNAs. This Dicer-Xpo-5
binding competition is proposed to be additionally relevant in adenoviral infection
where the adenoviral VA1 ncRNA has been repeatedly demonstrated to have an
inhibitory eﬀect on the RNAi pathway [34,37,90,130,132,223,225,391]. Prior to the con-
nection between Xpo-5 availability and Dicer being made, it had been assumed
that the VA1 RNA was acting as a competing Dicer substrate [130,223,225]. However,
the presence of micro-helix structures within the VA1 RNA suggest that the Dicer
Chapter 1. Introduction 32
inhibition maybe a downstream side eﬀect of the Xpo-5 binding, and Dicer is gen-
erally not considered to be a primary checkpoint in the generation of miRNAs in
the presence of high-doses of shRNAs [129] (reviewed in [126]).
Interestingly, current evidence suggests that the two RNase III enzymes involved
in the miRNA pathway, Drosha and Dicer, appear free from saturation by exces-
sive shRNA doses [129]. However, in the case of Drosha, all of the investigations
to this time have utilised distinct shRNA hairpins expressed from either pol II
or III promoters that enter the miRNA / RNAi pathway downstream of Drosha
interaction. So, it remains possible that the expression of longer transcripts of
pri-miRNAs that do require Drosha for processing and nuclear export by Xpo-5
will induce a similar eﬀect. Resistance by Dicer to saturation is completely con-
sistent with reports that over-expression of Dicer does not increase the eﬃcacy of
shRNAs or miRNAs [92] or siRNAs [367] in cell culture. These observations are addi-
tionally consistent with the delay in mortalities of both Dicer -\- mice [206,248,342,389]
or zebraﬁsh [31,70,250] compared to either Argonaute knockout [237] or miRNA sat-
uration by shRNA expression [129]. However, a number of studies have suggested
that Dicer is inhibited by expression of longer viral ncRNA transcripts, which can
act as either Dicer RNase III substrates or potentially be inhibiting the RNAi
pathway via Xpo-5 saturation. The Dicer inhibition is then a downstream con-
sequence of Xpo-5 saturation and ineﬃcient processing of miRNA molecules into
the cytoplasm [34,37].
Most recently, stable integration of human Ago2 into three human cell lines HeLaP4
(a HeLa derivative overexpressing primary and secondary HIV-1 receptors), 293T
(human embryonic kidney cells modiﬁed with the SV40 large T antigen) and
Huh7.5 (a hepatocarcinoma cell line subclone with increased permissiveness for
HCV) [47] resulted in increased RNAi eﬃciency and reduced oﬀ target eﬀects [47]. In
addition, the addition of Ago2 expression cassette to lentiviral vectors expressing
shRNAs, alleviated previously observed deleterious eﬀects on miRNA expression
and liver function and disease [47,128].
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1.7.2 Viral saturation and inhibition of the RNAi pathway
Viral saturation of RNAi pathway members by expression of small RNA molecules
was ﬁrst observed following Adenovirus infection of HEK293 cells [14,223] as well as
Hela cells [223], Adenovirus expresses two ncRNA molecules, VA RNAI and VA
RNAII. Expression of the VA RNAI transcript from a CMV promoter resulted
in ablation of mature miR-30 expression and to a lesser extent synthetic miR-30
expressed from a similar construct [223]. This aﬀect was demonstrated to be rel-
evant in viral replication in a following study where the eﬀect on the synthetic
and endogenous miR-30 were replicated using live virus [14]. However, the same
VA RNAI ncRNA additionally perturbed the interferon response, and so the eﬃ-
cacy and importance of viral RNAi pathway suppression in vertebrates remains a
relatively controversial topic.
It was originally theorised that viruses which solely infect vertebrate hosts may
not encode suppression of RNA silencing (SRS) molecules, since interferon induc-
tion following accumulation of dsRNA within the cytoplasm generates a rapid
and powerful inhibitory response on viral and host gene expression via MxA and
protein kinase PKR signaling (reviewed in [54,352,368]). There is an array of viral re-
pressors of the interferon system and these methods are again excellently reviewed
in [292].The eﬀectiveness of the interferon system at modulating gene expression
following dsRNA accumulation has led to the relevance of the mammalian RNAi
system in response to viral infection becoming a controversial topic within this
ﬁeld. So while the RNAi system is conserved, the absence of an ampliﬁcation
step generated from an RNA-dependent RNA polymerase (RdRp) - such as that
conserved within invertebrates [176,222,365,394] and plants [84,254] - in mammalian cells
has led to suggestions that any Dicer-derived RNAi response will be unimportant
when compared to the interferon system.
This theory is, however, slowly bowing to weight of evidence that the RNAi re-
sponse is important in vertebrate anti-viral responses. In particular, back-to-back
publications in Science in October 2013 by Maillard et al [230] and Li et al [210] as well
as additional work by Li Seo et al [329] suggest that RNAi interference of viruses is
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fundamental to the normal anti-viral response in primary undiﬀerentiated mouse
cells as well as hamster cells and suckling mice, respectively. These publications
have come under signiﬁcant criticism from tenOever et al [78]. However, these po-
tential responses must be taken into account when discussing modulation of the
RNAi pathway to express artiﬁcial RNAs that may interfere with the endogenous
RNAi pathway.
1.7.2.1 Antiviral RNAi in ﬁsh
At this time, there is a paucity of data about the importance of the RNAi response
to viral infection in ﬁshes. These data may prove crucial in determining whether
RNAi transgenes and therapeutics have a future as potential treatments for viral
disease in aquaculture, particularly when the reduction of eﬃcacy in low temper-
atures on the interferon response in teleost ﬁshes is accounted for [93]. However,
there has been a single publication dealing with a member of the betanodaviridae
family, Greasy grouper nervous necrosis virus (GGNNV). The betanodaviridae [107]
viruses encode a small non-structural B2 protein that appears to inhibit the RNAi
response by preventing Dicer cleavage. This has been additionally demonstrated in
the familial virus Nodamura Virus(NoV) [167] and viruses from the related Alphan-
odaviridae family, including Flock House virus (FHV) that also encode a conserved
B2 nonvirion protein.
Dios et al demonstrated that accumulation of the viral RNA1 and RNA2 RNAs
within the cell correlated with reduced eﬃcacy of shRNA induced knockdown
of a co-transfected eGFP marker [107]. This publication was almost immediately
followed by a second supporting paper in which a second betanodavirus, Striped
jack nervous necrosis virus (SJNNV), was also shown to express a B2 protein.
Viral extracts containing the B2 protein in anAgrobacterium-mediated transient
expression system which was inﬁltrated into leaves of Nicotiana benthamiana (N.
benthamiana) demonstrated comparable silencing of eGFP reporter proteins to
the siRNA control [160].
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These two publications provided signiﬁcant supporting evidence that the B2 pro-
tein is a strong suppressor of RNAi silencing in ﬁsh. However, to the knowledge of
the author there has been no follow up work in ﬁsh viruses. The second publica-
tion in particular leaves signiﬁcant room for improvement. The diﬀerences between
plant and vertebrate RNAi responses, speciﬁcally the presence of multiple plant
Dicers, and the intercellular nature of plant RNAi responses and intercellular small
RNA and RNAi signaling in plants, make these results interesting but inconclusive
as to the physiological relevance of these anti-RNAi interactions in teleosts.
Saturation of the RNAi system by over-expression of shRNA molecules has pheno-
typically similar outcomes to the eﬀect of a number of strategies employed by an
array of viruses to avoid this pathway. While these strategies are most common
in viruses with invertebrate hosts, there is signiﬁcant evidence that vertebrate
viruses employ similar strategies in conjunction with interferon avoidance and
immune modulation to avert the host immune system. While there is minimal
evidence for the relevance of the RNAi system as a potent anti-viral response
in teleosts, the presence of a conserved nodavirus B2 protein with an anti-Dicer
eﬀect suggests that the response is important enough for viruses to have devel-
oped and retained defenses against this ancient regulatory system. Coupled with
deep sequencing evidence that siRNAs, along with miRNAs, piRNAs and other
small ncRNAs are generated by Dicer proteins and have physiologically relevant
eﬀects within the cell, this demonstrates the need for further research within this
ﬁeld. This research becomes important for deeper understanding of the anti-viral
response, and host-virus interactions as well as being an obligatory requirement
before RNAi transgenes or treatments could potentially become a reality as a
treatment for disease in ﬁnﬁsh.
To summarise, it has become apparent that there is variation in the observed
eﬀects of shRNA / siRNA molecules upon the endogenous RNAi following trans-
fection and expression. Observations in vitro and in vivo systems suggest that
there is unlikely to be a single answer for the generation of RNAi transgenics
free of side-eﬀects and oﬀ-target eﬀects. The complexities of the RNAi pathway,
shRNA sequence eﬀects, changing loops and including pri-miRNA type sequences
Chapter 1. Introduction 36
3′ and 5′ as well as changing and varied dependence and sensitivities of diﬀerent cell
types for normal levels of miRNAs all need to be considered. The export proteins
Xpo-5 as well as the catalytic Argonaute proteins have been proposed as being
the primary molecules vulnerable to saturation by RNAi molecules across a range
of models. Viral inhibitors of the RNAi response occur in a wide variety of hosts,
and act to inhibit this pathway in a similar manner by including Dicer or RISC
substrates. This suggests that this is a powerful mechanism for inhibiting an RNAi
response, and that it can prevent normal host-processes including viral defenses
from acting upon the virus. To avoid these eﬀects, dose-modulation of shRNAs
by varying promoter choice, incorporating shRNAs as miRNAs or alongside en-
dogenous miRNAs without additional promoters, and modifying the shRNAs to
include speciﬁc loops and sequences have each been utilised with varying degrees of
success at reducing oﬀ-target eﬀects from shRNAs. However, despite this progress,
further work is needed before shRNA silencing molecules can become palatable to
regulators and the general public as safe and eﬀective therapeutics.
1.8 Research rationale and summary
shRNAs represent a powerful approach to elicit an anti-viral response. However, it
is clear that the levels at which shRNAs are transcribed within cells is also funda-
mental to eﬃcient and safe gene knockdown. As a consequence, the development
of an optimal expression unit is crucial to the development of potential transgenes
and treatment utilising RNAi, and the identiﬁcation of eﬀective species-speciﬁc
promoter sequences are critical. Considering that currently the use of RNAi in
the zebraﬁsh is both controversial and poorly-developed compared to other species,
it will be advantageous to develop this technology for application in zebraﬁsh and
teleosts more broadly. The goal of the current study was to develop an optimised
expression system for the expression of shRNAs in zebraﬁsh cells, and then to
utilise these optimised expression constructs to test novel shRNA molecules, ﬁrst
in cell culture and then in transgenic zebraﬁsh expressing antiviral constructs.
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Analysis of the literature suggests that there is a paucity of data comparing the
eﬀectiveness of pol III promoters in native and non-native cells. The use of a
zebraﬁsh promoter for shRNA expression therefore represents an opportunity to
mediate enhanced and controlled delivery. Since the use of type 3 RNA pol III
promoters for shRNA expression has become widespread and extremely success-
ful, one aim of this study was to characterise previously identiﬁed pol III type 3
promoters in zebraﬁsh, as well as to identify any new promoters of this subtype
for the expression of shRNAs in zebraﬁsh cells. Such native promoters may re-
sult in enhanced target gene suppression compared to native type 3 RNA pol III
promoters, and may indeed be required for the transgenic application of RNAi in
zebraﬁsh.
RNAi can be a highly eﬀective technique for the suppression of virus replication
and infection. However, the high mutation rate of RNA viruses in particular,
such as rhabdoviruses, allows escape from RNAi strategies targeting only a sin-
gle sequence [36,189,372] due to the high sequence speciﬁcity of RNAi. Therefore, a
strategy where multiple sequences are targeted is required before the generation
of transgenic animals resistant to viral infection can be considered. A successful
inhibition strategy involves careful selection of the molecules that will be incorpo-
rated into the construct and also the type of construct that will be used to express
these molecules. This study also aims to further the knowledge of the use of RNAi
for the targeting of genes in the context of creating antiviral transgenes capable
of simultaneously targeting multiple viral genes and therefore preventing the risk
of viral escape.
Finally, in vitro systems act as models and guides to test expression and eﬀective-
ness of individual components of more complex systems. The incorporation of the
identiﬁed endogenous zebraﬁsh promoters along with shRNA sequences derived
in vitro were combined into Tol2 vectors and microinjected into zebraﬁsh em-
bryos at the 1 cell stage [186]. These original vectors resulted in universally lethal
non-speciﬁc mutations to all ﬁsh. Following the hypothesis that saturation of the
miRNA pathway was causing these non-speciﬁc mutations, weaker H1 promoters
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were utilised and the previously characterised promoters further modiﬁed to ab-
late expression by speciﬁc deletion of motifs. These modiﬁed promoters showed
a signiﬁcant relative reduction of lethal and abnormal phenotypes as well as a
corresponding reduction in shRNA expression. To test the theory that satura-
tion of one or more RNAi pathway components was responsible for the observed
phenotypes, two components of the RNAi previously identiﬁed as vulnerable to
saturation; Argonaute and Xpo-5 were over-expressed and this over-expression
also signiﬁcantly reduced embryo lethality and abnormal morphology.
Chapter 2
Materials and Methods
Laboratory work was split over two sites, CSIRO AAHL and Deakin University
Medical School, and there were diﬀerences in standard laboratory protocols and
available equipment at each site. Therefor to limit diﬃculties with analysis, each
individual experiment were performed at a single site and there were no changes
of equipment used within individual experiments; in particular, all RT-qPCR were
performed at CSIRO AAHL.
2.1 Materials
2.1.1 Suppliers
The following companies supplied reagents, equipment and software utilised in this
study:
Adobe Systems Software Australia Ltd, Sydney, NSW, Australia
Aglient Technologies, Santa Clara, CA, USA
Ambion, Austin, TX, USA
Amersham Biosciences, Piscataway, NJ, USA
Addgene, Cambridge, MA, USA
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Applied Biosystems, Foster City, CA, USA
Astral Scientiﬁc, Gymea, NSW, Australia
BD Biosciences, North Ryde, NSW, Australia
Beckman Coulter, Fullerton, CA, USA
Becton Dickinson Labware, Franklin Lakes, NJ, USA
Bio-Rad Laboratories, Hercules, CA, USA
Boehringer-Mannheim, Mannheim, Germany
Eppendorf, Hamburg, Germany
GE Healthcare, Chalfont St Giles, Bucks, United Kingdom
Geneworks, Hindmarsh, SA, Australia
Graph Pad Software, La Jolla, CA, USA
Interpath, West Heidelberg, VIC, Australia
Invitrogen, Mount Waverly, VIC, Australia
Leica Microsystems GmbH, Wetzlar, Germany
Life Technologies, Rockville, MD, USA
Merck-Calbiochem, Darmstadt, Germany
Millipore, Billerica, MA, USA
Minitab Inc, PA, USA
Nalge Nunc International, Roskilde, MA, USA
New England Biolabs, Beverly, MA, USA
Olympus, Shinjuku, Tokyo, Japan
Paciﬁc Laboratory Products Pty Ltd, Blackburn, VIC, Australia
Promega, Madison, WI, USA
Qiagen, Germantown, MD, USA
Roche Diagnostics, Castle Hill, NSW, Australia
Sigma-Aldrich, Castle Hill, NSW, Australia
Thermo Fisher Scientiﬁc, Waltham, MA, USA
Whatman, Middlesex, United Kingdom
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2.1.2 Bacterial strains, plasmids and media
All cloning and vector ampliﬁcation were performed in Escherichia coli (E. coli)
DH5a Top10 electrocompetent cells (Invitrogen) or XL10-Gold Ultracompetent
chemically competent cells (Stratagene). All E. coli cells were grown in Luria
Bertani (LB) broth or on LB agar supplemented with the following antibiotics and
supplements when required: 100 μg/ml ampicillin (Sigma), 25 μg/ml kanamycin
(Sigma), 100 μg/ml X-gal (Promega) and 1 nM Isopropyl-β-D-1-thiogalactopyranoside
(IPTG) [Sigma]. Liquid cultures were shaken at 250 rpm at 37 ◦C in a shaker and
aliquots of broth cultures were preserved at −80 ◦C in 25% (v/v) glycerol (Sigma).
E. coli plated onto solid media were allowed to grow over night at 37 ◦C in air
before colonies were picked.
Plasmids pEGFP-N1 and pGEM-T Easy (Promega) were obtained from Promega.
pUC118 were a kind gift from Dr. Scott Tyack (CSIRO, [AAHL]). The plas-
mids pCMV-Tol2 and pMini-Tol [25] were donated as absorbed ﬁlter paper dots
by Professor Stephen Ekker (Dept. Biochemistry and Molecular Biology. Mayo
Clinic Cancer Center, Rochester, Minnesota, USA). The shRNA expression plas-
mids pCh-U64-shEGFP and pMU-shEGFP were provided by Dr. David Cummins
(CSIRO, AAHL, Geelong, Australia) and the pFugu-shEGFP [401] shRNA expres-
sion plasmid were generously donated by Professor Ki Hong Kim (Department of
Aquatic Life Medicine, Pukyong National University, Korea). Plasmids pQE60-
Exp5 [50] and pIRESneo-FLAG/HA Ago2 [247] were purchased from Addgene.
2.1.3 Primers, probes and oligonucleotides
A list of all primers and oligonucleotide probes used in this study is included
in Appendix A. Polymerase chain reaction (PCR) primers were designed using
Clone Manager 9.0 software (SciEd Central) and obtained from Geneworks. PCR
primers were designed according to the following rules: 18 nt to 24 nt, 40-60% GC
content, 50 ◦C to 65 ◦C melting temperature, 1 nt to 2 nt GC clamp, maximum
polynucleotide repeats (N) = 4. All primers were received as lyophilised DNA
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and were re-suspended in nuclease free water (nfH2O) to a stock concentration
of 100 μM. Working primer stocks were prepared at 5 μM for quantitative reverse
transcriptase PCR (qRT-PCR). One step PCR primers used for construction of
shRNAs (Figure 2.4.6.1) were additionally puriﬁed by High Performance Liquid
Chromatography (HPLC). Locked nucleic acid (LNA) probes were obtained unla-
beled from Sigma-Aldrich.
2.2 DNA methods.
2.2.1 Transformation of E. coli
2.2.1.1 Using electrocompetent E. coli
A 40 μl aliquot of electrocompetent E. coli cells were thawed on ice and 2 μl of
either ligation reaction or diluted plasmid DNA was added. The mixture was
then transferred to a cold 0.2 cm electroporation cuvette (BioRad) and pulsed
using a Gene PulserTM Transformation Apparatus (Bio-Rad) under the following
conditions: 25 μF capacitance, 2.25 kV and the Pulse Controller set to 200Ω. 1ml
of warmed (37 ◦C) LB broth were added to the transformation mix immediately
and the total volume transferred into a 10ml falcon tube. The suspension were
agitated for 1 h at 37 ◦C and then approximately 100 μl (if circular plasmid) or
100 μl and 900 μl (if ligation) suspension were plated onto LB agar plates with the
appropriate antibiotics and incubated overnight at 37 ◦C.
2.2.1.2 Using chemically competent E. coli
An 100 μl aliquot of Stratagene XL10-Gold Ultracompetant E. coli cells were
thawed on ice and between 5 μl to 10 μl of either a ligation reaction or plasmid
DNA was added and incubated on ice for a further 15min before a 45 s heat-shock
at 42 ◦C. Shocked cells were added to a pre-warmed 800 μl aliquot of LB broth,
and the cells were incubated at 37 ◦C for 1 h with shaking at 200 rpm. Cells were
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plated onto LB agar plate containing appropriate antibiotic and once dry were
incubated overnight at 37 ◦C.
2.2.2 Plasmid puriﬁcation
2.2.2.1 Small-volume isolation of plasmid DNA from E. coli
Small-volume plasmid DNA extraction from E. coli were performed using the
QIAprepTMSpin Miniprep Kit (Qiagen) as per the manufacturer’s instructions.
2.2.2.2 Large-volume isolation of plasmid DNA from E. coli
For large-volumes of plasmid DNA, the PureYieldTMPlasmid Maxiprep system
(Promega) were used according to the manufacturer’s instructions.
2.2.3 Nucleic acid manipulation
2.2.3.1 Restriction endonuclease digestion
Digestion of DNA into fragments for cloning or mRNA transcription were ac-
complished using a variety of restriction endonucleases (Promega, New England
Biolabs or MBI Fermentas) following the speciﬁc manufacturer’s instructions for
the enzyme(s). For the most part, digestions were performed at 37 ◦C in volumes
of between 10 μl and 20 μl, which contained between 0.5 μg to 2.0 μg of DNA, and
were incubated for 1 h to 3 h or overnight. The reactions were stopped if recom-
mended by a further incubation of 10min to 30min at 65 ◦C to 80 ◦C.
2.2.3.2 Manipulation of restriction endonuclease digestion fragments
To facilitate blunt-end cloning a number of restriction endonuclease digestions re-
cessed 3′ -terminal ends were ﬁlled in using the DNA Polymerase I Large (Klenow)
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Fragment (Promega) following the manufacturer’s instructions. To improve se-
lection of correctly inserted DNA fragments and to prepare DNA fragments for
further manipulation removal of 5′ phosphate groups was performed using Tem-
perature Sensitive Alkaline Phosphatase (Promega) following the manufacturer’s
instructions.
2.2.3.3 Separation of nucleic acid fragments by agarose gel electrophore-
sis
For analytical and preparative purposes, DNA and RNA samples were separated
on 1% to 3% (w/v) agarose gels in 1 x TAE buﬀer (40mM Tris (pH 8.0), 20mM
acetic acid, and 1mM EDTA) to aid visualisation of nucleic acid under ultraviolet
light 1 μl of either GelRedTM (Biotium) or SybrSafeTM (Invitrogen) per 100ml of
TAE agarose solution was added immediately before pouring the gel. To each
nucleic acid sample, 6 x DNA loading dye (Fermentas) or 2× RNA loading dye
(Fermentas) was added before separation by electrophoresis at between 60V to
120V for between 30min to 120min. To achieve separation of large fragments a
number of samples were run overnight at 50V. Six μl of preprepared molecular
weight marker were loaded in a separate lane to indicate the size of the separated
products. The markers used were, 1 kb GeneRulerTM, 1 kb Plus DNA Ladder
(Fermentas) for all PCR and plasmid DNA, and RiboRulerTM High Range RNA
Ladder for RNA. After separation, the resolved DNA were visualised using a UV-
transilluminator.
2.2.3.4 Extraction of DNA from agarose gels
Isolation of DNA from agarose gels following electrophoresis was performed using
the QIAquick Gel Extraction Kit (Qiagen) following the manufacturer’s directions.
DNA were eluted with 30 μl of EB buﬀer (10mM Tris-HCl, pH 8.5).
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2.2.3.5 DNA ligations
In general, ligations were performed with a 3:1 molar ratio of insert to vector DNA.
Ligation reactions consisted of one unit of T4-DNA ligase (Promega) or Quick
Ligase (New England Biolabs) and 1 × ligase buﬀer supplied by the manufacturer,
they were incubated at room temperature for 2 h to 4 h or at 16 ◦C overnight.
2.2.4 Polymerase Chain Reaction ampliﬁcation of DNA
Polymerase Chain Reaction (PCR) were used for the ampliﬁcation of DNA re-
gions from template DNA sequences using sequence-speciﬁc anti-parallel oligonu-
cleotides (primers) ﬂanking the ampliﬁed region and either Thermus aquaticus
(Taq) or Pyrococcus furiosus (Pfu) DNA polymerase. PCR ampliﬁcation were
performed using Promega GoTaq R© Green HotStart Master Mix (Promega) or New
England Biolabs Phusion High-Fidelity DNA Polymerase Master Mix. Generally
10 n g to 100 n g of cDNA, gDNA or plasmid DNA were added to 10 μl of 2×Master
Mix with 1μl of 10mM speciﬁc primers and made up to 20μl with nfH2O. Where
larger quantities of product were required the components were increased propor-
tionally. Where standard PCR conditions did not result in expected products,
gradient PCR, touchdown PCR or PCR additives Dimethyl sulfoxide (DMSO),
and/or Bovine Serum Albumin (BSA) or a combination of the above were used to
optimise reactions. In particular ampliﬁcation of large ≥ 3 kb products with Pfu
were performed with the addition of 0.6 μl DMSO per 20 μl reaction.
2.2.5 Cloning of PCR products
Taq DNA polymerase has terminal deoxynucleotidyltransferase activity, that causes
the addition of an extra deoxyadenosine (dA) at the 3′-end of the PCR product.
This 3′-dA overhang facilitates direct cloning of PCR fragments into pGEM R©-
T Easy (Promega A1360) as this vector has a complementary 3′-deoxythymidine
(dT). Complementary endonuclease cleaved ends were used to facilitate cloning
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Taq PCR conditions
95 ◦C for 2min
95 ◦C for 15 s
⎫⎪⎪⎪⎬
⎪⎪⎪⎭
30 Cycles55 ◦C to 62 ◦C for 30 s
72 ◦C for 1min/kb
72 ◦C for 10min
4 ◦C
Pfu PCR conditions
98 ◦C for 30 s
98 ◦C for 15 s
⎫⎪⎪⎪⎬
⎪⎪⎪⎭
30 Cycles60 ◦C for 15 s
72 ◦C for 15 s/kb
72 ◦C for 10min
4 ◦C
Table 2.1: Typical PCR conditions
into vectors other than pGEM R©-T Easy. All ligation reactions were performed
according to the manufacturer’s instructions as detailed in 2.2.3.5 on 45.
2.2.6 PCR cleanup
Cleanup of PCR products were performed using the QIAquick PCR cleanup kit
(Qiagen) following the manufacturer’s directions. PCR products were eluted with
30 μl of EB buﬀer (10mM Tris-HCl, pH 8.5).
2.2.7 DNA sequencing
Puriﬁed plasmid DNA and PCR products were sequenced prior to further use.
All infectious samples were sequenced using the ABI PRISM 377XL automated
DNA Sequencer (Applied Biosystems) at CSIRO, AAHL Geelong. Non-infectious
samples were sequenced at Micromon DNA sequencing (Monash University) on a
capillary-platform Genetic Analyser (Applied Biosystems).
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2.2.8 Determination of nucleic acid concentration
The concentration of nucleic acid samples was determined using the NanoDrop R©
ND-1000 Spectrophotometer coupled to an Optiplex GX280 computer (Dell). The
machine were blanked using distilled and autoclaved water, and the concentration
of a 2 μl aliquot of either nuclease-free water or EB buﬀer, as appropriate, were
measured to ensure a low level of background before 2 μl aliquots of nucleic acid
samples were measured.
2.2.9 Tol 2 insertion site analysis PCR
2.2.9.1 Genomic DNA (gDNA) extraction
gDNA was extracted from zebraﬁsh using the QuickExtract
TM
DNA Extraction
kit (EpiBio, illumina) as per the manufacturer’s protocol.
2.2.9.2 Cassette Method
six individual restriction enzyme digests were setup as follows: 5 μg gDNA, 50
U restriction enzyme, 5 μl 10 × buﬀer, 5 μl 100 × BSA if required, nfH2O to
50 μl. Digestions were incubated overnight at 37 ◦C then stabilised with 5 μl 3M
Sodium Acetate (pH 5.2) and precipitated with 137.5 μl cold EtOH and incubated
at −20 ◦C for 1 h. Precipitate were rinsed again with −20 ◦C EtOH and the pellet
left to dry before reconstitution with 10 μl 55 ◦C nfH2O. Ligation of restriction
enzyme and enzyme speciﬁc endcassettes were performed using NEB Quick Ligase
as per 2.2.3.5 at a ratio of 1:2 digested gDNA to cassette. 1μl ligated gDNA
was added to 33.5 μl nfH2O and dissolved at 94 ◦C for 10min and ampliﬁed using
GoTaq Hotstart PCR with Cassette Primer 1 and Tol2 Primer 1.
To perform the secondary PCR 1 μl of cleaned 2.2.6 PCR product was diluted
1:10,000 with nfH2O and a second PCR performed using Cassette Primer 2 and
Tol2 Primer 2 using identical PCR conditions as the previous PCR.
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95 ◦C for 2min
98 ◦C for 20 s
⎫⎬
⎭ 30 Cycles68 ◦C for 12min
72 ◦C for 10min
4 ◦C
Table 2.2: PCR conditions for insertion site characterisation
2.3 RNA Methods
2.3.1 RNA isolation and puriﬁcation
2.3.1.1 Total RNA extraction from cells or zebraﬁsh optimised for
small RNAs using TrizolTM
Conﬂuent cell monolayers were washed twice in PBSA, followed by addition of
1ml of TRIzol Reagent (Invitrogen). Whole zebraﬁsh larvae upto 7 days post
fertilisation were homogenised by freezing in 1ml TRIzol reagent prior to the
addition of 200 μl glass beads and homogenisation by bead beating on a Precellys
homogeniser for 15min at 6000 rpm. All subsequent steps were identical for either
whole zebraﬁsh or cells. To separate the RNA,DNA and protein, 200 μl chloroform
was added to each sample, and mixed by shaking for 15 s. Samples were then
incubated at room temperature for 3min followed by centrifugation at 12 000 g
at 4 ◦C for 15min. The aqueous phase, containing the RNA, was transferred
to a clean RNasefree tube to which 10μg UltraPure Glycogen (Invitrogen) and
500 μl isopropanol were added. Samples were mixed and incubated for 10min at
room temperature, followed by centrifugation at 12 000 g at 4 ◦C for 15min the
supernatant were removed, and the pellet containing the RNA were washed with
1ml 80% (v/v) ethanol with vortexing, followed by centrifugation at 7500 g at
4 ◦C for 5min. Ethanol was removed and the pellet was partially air-dried before
resuspension in 30μl nucleasefree H2O (nfH2O) preheated to 55 ◦C, incubated at
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55 ◦C for 5min before being placed on ice. RNA samples were further puriﬁed by
addition of 90 μl 100% ethanol, 3 μl sodium acetate, and 10 μg UltraPure Glycogen,
mixed by pipetting and incubated for 24 h at -20 ◦C with subsequent precipitation
and washes performed as above.
2.3.1.2 Total RNA extraction using RNeasy
TM
Isolation of RNA from adherent cells, or homogenised zebraﬁsh or zebraﬁsh organs
or ﬁn clips (where small RNAs optimisation and enrichment was not required)
was performed using the RNeasy Mini Kit (Qiagen) following the manufacturer’s
directions. RNA was eluted with 30 μl of EB buﬀer (10mM Tris-HCl, pH 8.5) by
centrifugation.
2.3.2 Extraction of viral RNA
Isolation of viral RNA from adherent cell supernatants, zebraﬁsh or zebraﬁsh
organs or ﬁn clips were performed using the ViralRNA Mini Kit (Qiagen) following
the manufacturer’s directions. Homogenisation of zebraﬁsh organs or tissue were
accomplished as per 2.3.1.1 RNA were eluted with 30 μl of EB buﬀer (10mM
Tris-HCl, pH 8.5) by centrifugation.
2.4 RNase protection assay (RPA)
2.4.1 Radioactive labeling of probe and marker RNA
RNA oligonucleotides complementary to the sense strand of shEGFP [27] were syn-
thesised, and diluted to 1 pmol/μl with nuclease-free water. These were end-
labeled with 32Pγ-dATP (Amersham Biosciences) using the mirVana Probe &
Marker Kit (Ambion) following the manufacturer’s instruction. Brieﬂy, 1 μl of the
diluted probe were end-labeled with 3.34 pmol of 32Pγ-dATP 10mCi/ml, 10 Units
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of T4 PNK, 1× kinase buﬀer, and water up to 10 μl. In addition to the shEGFP
probes, the miRNA miR-16 RNA probe included as a positive control were also
end-labelled with 32Pγ-dATP using an identical reaction. For an indication of the
size of separated RNA fragments by electrophoresis, the Decade Marker (mirVana
Probe & Marker Kit, Ambion) was similarly end-labelled.
2.4.2 Separation of RNA on denaturing agarose gels and
autoradiography
Electrophoretic separation of RNA was performed on denaturing 7M Urea, 15%
(w/v) acrylamide gels. These were prepared as follows: 12.6 g of Urea, 3ml of 10 x
TBE buﬀer (0.9M Tris base, 0.9M Boric acid, 20mM EDTA pH 8.0), and 11.25ml
of 40% (w/v) acrylamide/bis (19:1) made up to 30ml with nuclease-free water.
With stirring to dissolve the urea, and then 150 μl 10% (w/v) ammonium persul-
phate (APS) and 20 μl of N, N, N”, N”-tetramethylethylene diamine (TEMED)
were added. Gels were left at room temperature for approximately 1 h and then
run in a Vertical Gel Electrophoresis System (Bethesda Research Laboratories) at
40mA for 1 hour in 1 × TBE prior to loading of the RNA samples. All RNA
samples were mixed with Gel Loading Buﬀer II (mirVana Probe & Marker Kit,
Ambion) and heated at 95 ◦C prior to loading. Separation was achieved by running
gels at 40mA for approximately 2 h. Gels were then enclosed with one sheet of Hy-
perﬁlm ECL (Amersham Biosciences) in an EC-AWU Cassette (Fuji) and stored
at -80 ◦C for the required exposure time. The exposed ﬁlm were then removed and
developed using an X-ray Processor FPM-100A (Fuji).
Chapter 2. Materials and Methods 51
2.4.3 Quantitation of RNA
2.4.3.1 DNase treatment of RNA samples for cDNA synthesis.
Total RNA was used for cDNA synthesis prior to qRT-PCR. Before cDNA syn-
thesis, all RNA samples were treated with DNaseI (RQ1, Promega) to remove po-
tential genomic DNA contamination. Reactions were performed using 8 μl RNA,
1 μl of 10 × RQ1 Reaction Buﬀer (Promega), and 1 μl RQ1 DNaseI (Promega).
Then incubated at 37 ◦C for 30min, then 1 μl of RQ1 STOP solution (Promega)
were added before a further 10min incubation at 65 ◦C. DNaseI treated samples
were used immediately for cDNA synthesis, or stored at −20 ◦C.
2.4.3.2 First-strand cDNA synthesis
DNAse treated RNA samples were poly-adenylated according to the approach de-
scribed previously [332]. Poly-adenylated reactions contained 8 μl (approximately
1 μg) of DNAseI treated total RNA, 0.25 μl (150 U) of yeast Poly(A) Polymerase
(PAP) (USB), 4 μl 5 × PAP Reaction Buﬀer and 1 μl of 10 nM rATP (Ambion)
and nfH2O (Promega) in a ﬁnal volume of 20 μl. Reactions were incubated at
37 ◦C for 30min then at 95 ◦C for to 5min terminate the reaction. They were
used immediately for ﬁrst-strand cDNA synthesis. First strand cDNA synthesis
were performed using Superscript III (SuperscriptTMIII First Strand Synthesis Su-
permix [Invitrogen]) according to manufacturer’s instructions for oligo-dT primed
RNA. For qRT-PCR, cDNA synthesis was primed using the modiﬁed oligo-dT
primer miR-PTA. The annealing reaction contained 4 μl of poly-adenylated RNA,
3 μl of 25 μM miR-PTA and 1 μl of Annealing Buﬀer and were incubated at 65 ◦C
for 5min. First-strand cDNA synthesis reactions primed with miR-PTA were
incubated at 50 ◦C for 50min, and inactivated by incubation at 85 ◦C for 5min.
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2.4.3.3 Quantitative PCR of shRNA and microRNA expression
Each qRT-PCR was performed using SYBR Green detection reagents and the
StepOnePlus real-time PCR system (reagents, machine and software, Applied
Biosystems). Reactions were analysed in triplicate in 96-well format (MicroAmp
PCR plates, Applied Biosystems). According to optimised parameters, cDNA
were used at either 1:30 or 1:50 dilution and all primers were used at a ﬁnal con-
centration of 200 nM. Every reaction contained 2 μl cDNA, 10 μl SYBR Green
PCR Master Mix (Applied Biosystems), 0.8 μl of forward target sequence spe-
ciﬁc primer, 0.8 μl of PAM-URP and nfH2O to a ﬁnal volume of 20 μl using the
following cycle conditions.
95 ◦C for 10min
95 ◦C for 15 s
⎫⎬
⎭ 40 Cycles60 ◦C for 1min
Melt curve analysis
95 ◦C for 15 s
⎫⎬
⎭ 40 Cycles60 ◦C for 1min ramp +0.3 ◦C
95 ◦C for 15 s
4 ◦C
Table 2.3: PCR conditions for miRNA / shRNA quantitation
2.4.4 Quantitative reverse-transcriptase analysis of mRNA
expression
qRT-PCR analysis of mRNA were performed as per 2.4.3.3 with the substitution
of a second speciﬁc primer for the PAM-URP primer and modiﬁcation of the
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annealing temperature as required by speciﬁc primer pairs. Zebraﬁsh 5S RNA
(5S) was used as the reference control for normalising expression levels.
2.4.5 Data analysis for qRT-PCR
Each qRT-PCR analysis were performed using the comparative Ct method, also
known as the 2-ΔΔCt method [219,315]. Which, generates an expression proﬁle for
the target that is normalised against a reference gene. For miRNA qRT-PCR
results in this thesis, expression levels are shown as a fold diﬀerence relative to
the level of a selected reference sample, where the fold diﬀerence of the reference
sample has a value of 1.
Data analysis Ct values for qRT-PCR were calculated by the StepOnePlus software
(Applied Biosystems) based on a set Ct threshold of 0.1. For 2-ΔΔCt calculations,
ampliﬁcation data were then downloaded in tab delimited format from StepOne-
Plus software and imported into Microsoft Excel (Microsoft Corporation). The
following calculations were then performed for each target per sample:
Step Calculation Excell formulae
1 Mean Ct target/ref. gene =AVERAGE (cell range for triplicate Ct values)
2 ΔCt sample/ref. sample =(mean Ct target)-(mean Ct ref. gene)
3 ΔΔCt sample =(ΔCt sample)-(ΔCt ref. sample)
4 FD value =POWER(2,-(ΔΔCt sample))
Table 2.4: Fold Change calculations
Mean fold diﬀerences (± standard error of the mean, SEM) were calculated for
each target from 3 biological replicates per sample, each replicate obtained from
an independent transfection or injection. Within each experiment two or three
replicate reactions were performed per sample. Statistical comparisons between
samples (i.e. control versus treatment) were performed using an un-paired student
t test or a one-way ANOVA, where the threshold for statistical signiﬁcance was set
at 0.05 (Minitab v16). Graphs were generated using Prism 5 software (GraphPad)
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depicting sample/treatment on the X axis and relative expression (fold) on the Y
axis. Asterisks indicate the level of statistical signiﬁcance ( p ≤ 0.05).
2.4.6 shRNA design and analysis
2.4.6.1 shRNA design and construction
All oligonucleotides used in the construction of shRNAs are described in Table
1. Six shRNAs, three against each of G and L genes, were designed against
VHSV strain (23.75) [FN665788.1] were designed using the Dharmacon siRNA
Design tool. Sequences were designed using the formula (NN) N21 nt and a total
GC content of less than 50%. To generate eﬀective shRNAs, siRNA sequences
were further screened using the criteria outlined previously [353]. Brieﬂy potential
siRNAs were scored for the stability of the duplex formed between nucleotides 6
- 11 on the sense and 14 - 9 on the antisense strands and siRNAs with a central
duplex ΔG of ≥ −12.9 were discarded. ΔG scores were calculated as described
in [114] Table 4. Remaining potential siRNAs were screened for sense 5′ GC and
3′ AT content, and high scoring siRNAs were further screened for the presence of
conserved regions across strains of VHSV to minimise the chances viral escape.
siRNA sequences were also screened against the related virus IHNV. siRNA pairs
were joined with the loop sequence 5′ TTCAAGAGA 3′ [51], and followed by 5
tyrosine (T) bases and on XbaI restriction site. shRNA expression plasmids were
constructed using the one-step PCR method as described [71,383]
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2.5 Tissue culture methods
2.5.1 Immortalised eukaryotic cultured cell lines
Zebraﬁsh embryo ﬁbroblast (ZF-4) cells (ATCC CRL-2050) were maintained in
50% Dulbecco’s Minimal Essential Media / Hams F12 media (Gibco) contain-
ing 10% foetal bovine serum (FBS), 2 μM glutamine, 10mM sodium bicarbon-
ate, 10mM N-2-hydroxyethylpiperazine-N’-2-ethanesulfonic acid (HEPES), sup-
plemented with penicillin 100 μg/ml and streptomycin 100 μg/ml. Cells were grown
(except when necessary for virus growth) at 28 ◦C, 5% CO2 in a humidiﬁed atmo-
sphere. African green monkey kidney (VERO) cells (ATCC CCL-81) were grown
in Eagles Minimal Essential Media supplemented with 10% FBS, 2 μM glutamine,
10mM sodium bicarbonate, 10 μM HEPES, penicillin 100 μg/ml and streptomycin
100 μg/ml. Epithelioma Papulosum Cyprini Flat-head minnow (EPC) epithelial
cells were cultured in Leibovitz - 15 (L15) media, with 10% FCS, 2 μM glutamine,
10mM sodium bicarbonate, 10 μM HEPES, penicillin 100 μg/ml and streptomycin
100 μg/ml at 25 ◦C in air in a humidiﬁed atmosphere. Cells were cultured as re-
quired in 25 cm2, 75 cm2 and 150 cm2 cell culture ﬂasks (Corning) or in 6, 24 or 96
well plates.
2.5.2 Harvesting adherent cell lines
To harvest cell monolayers, growth media were removed, cells were washed 3 × us-
ing phosphate buﬀered saline-A (PBSA), and appropriate volumes of 0.25% (w/v)
trypsin with 380 μg/l ethylene-diaminete-tetra-acetic acid (EDTA) [Gibco]. ZF-4
cells were harvested by adding 0.25% (w/v) trypsin without EDTA to the mono-
layer (Gibco). After 10min to 30min at the appropriate incubation temperature,
the monolayer were completely detached by gently shaking the culture vessel, and
the trypsin inactivated by addition of normal growth media. All cells were counted
using a hemocytometer and plated as appropriate for experiments.
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2.5.3 Transfection of eukaryotic cells
2.5.3.1 Electroporation of plasmid DNA
Transfection of plasmid DNA into ZF-4 and EPC cells were accomplished via elec-
troporation using the Nucleofector 2b electroporator (Amaxa CD-MN029) follow-
ing the manufacturer’s instructions. Brieﬂy, cells were harvested by trypsinization
as described in section 2.5 and aliquots of 2 × 106 cells were pelleted using a bench
top centrifuge at 2000 g . Cell pellets were washed twice in PBSA, resuspended
in 100 μl of electroporation solution V and with 4 μg of plasmid DNA, gently ﬂick
mixed and pipetted into electroporation cuvettes. ZF-4 cells were pulsed using the
preset program T-27. Cell suspensions for each were then mixed with 900 μl of
warm complete media, dispensed into appropriate culturing vessels and incubated
at 37 ◦C. Transfected ZF-4 cells for shRNA detection was dispensed into 6-well
plates (Nunc) and cells for VHSV infection were dispensed into 25 cm2 ﬂasks.
2.5.3.2 Chemical transfection of plasmid DNA
Transfection of plasmid DNA into Vero cells were achieved using Lipofectamine
2000 (Invitrogen 11668019) following the manufacturer’s instructions. Cells were
grown to between approximately 70% and 80% conﬂuence in 25 cm2 ﬂasks for
shRNA expression. For each, 5μg of plasmid DNA were complexed with 10 μl of
Lipofectamine 2000 in 1ml of Optimem R©.
2.5.4 Flow cytometry
Analysis of cells transfected with plasmids expressing ﬂuorescent markers by ﬂuorescence-
activated cell sorting, (FACS) were performed by harvesting cells as described in
section 2.5 prior to being washed in PBSA twice and pelleted at 2000 g before
resuspension in 200 μl FACS buﬀer (0.01% sodium azide and 2% FCS in PBSA)
and analysed on a FACScalibur (LSR II Becton Dickinson). Data analysis was
performed using CELLQuest software (Becton Dickinson) and mean ﬂuorescence
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intensity (MFI) values obtained. All FACS analysis was performed on duplicate
cell populations following triplicate independent transfections. To analyse change
in MFI control ﬂuorescence (pEGFP-N1) were designated as 100% and change in
ﬂuorescence following transfection with shEGFP expression plasmids calculated
as a percentage of the control transfection.
2.6 Virological methods
2.6.1 Viruses and infections
The 23.75 strain of viral haemorrhagic septicemia virus (FN665788.1) were ob-
tained from AAHL stocks and were used for all viral experiments. Infections to
test the eﬃciency of anti VHSV shRNA were performed on approximately 70%
- 80% conﬂuent cells at a multiplicity of infection (MOI) of between 1 and 10-5
in T25 plates 72 hours post-transfection in 1ml complete media. Inoculums were
absorbed onto cells for 1 h at 15 ◦C and then replaced with complete media.
2.6.2 TCID50 determination
Supernatants from VHSV infected ZF4 cells were prepared by centrifugation of
the media at 4000 g for 30min to remove any cell debris. Titrations of clariﬁed
supernatants were performed in 96 well plates on 90% conﬂuent EPC cells using
a starting concentration of 20 μl diluted to 200 μl in complete media and 8 10-
fold serial dilutions. Supernatants were incubated at 15 ◦C for 1 h. Each assay
was performed with 10 replicates per dilution and in triplicate for all transfection
conditions. Viral titres were calculated via the Reed & Muench method [295].
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2.7 Zebraﬁsh methods
2.7.1 General zebraﬁsh care and breeding
Larval and adult zebraﬁsh were housed in an Aquatic Habitats aquarium system
at 28.5 ◦C on a 14 h/10 h light/dark cycle and fed twice daily. Embryos were manu-
ally spawned and maintained in the incubator at 28.5 ◦C in a petri dish containing
aquarium water and 0.00005% (w/v) Methylene blue (Sigma). If imaging was re-
quired 8 hours post fertilization (hpf), methylene blue was replaced with aquarium
water containing 0.003% (w/v) 1-phenyl-2-thio-urea (PTU) to inhibit pigmenta-
tion and to enhance embryo transparency. Embryos were collected at appropriate
time points, and anesthetised with 0.4 μg/μl benzocaine before ﬁxation with 4%
(w/v) paraformaldehyde (PFA) in phosphate-buﬀered saline (PBS). If embryos
were used for breeding or adult experiments, feeding began at day 4 post fertilisa-
tion with 1 feed daily of approximately 500 μl of Paramecia multimicronucleatum.
All experiments were performed under Deakin University Animal Welfare Com-
mittee and Oﬃce of Gene Technology Committee, approvals and A73/10 and
LBC 10-2011, respectively.
2.7.2 Microinjection of zebraﬁsh
Microinjection needles were drawn on a Flaming brown micropipette puller model
P-87 (Sutter Instruments) using a heat setting of 339, pull 45, velocity 80 and
time 150, from a 1.0 mm capillary (SDR Clinical Technologies). Needles were
bent into a ‘Z’ shape by ﬂaming and loaded using pipette tips with either 20 ng/μl
to 30 ng/μl mRNA, 40 ng/μl to 50 ng/μl plasmid DNA, or a mixture of the two. All
nucleic acid were diluted in 1×Danieau buﬀer (58mM NaCl, 0.7mM KCl, 0.4mM
MgSO4, 0.6mM CaCl2, 5.0mM mM HEPES; pH 7.6) containing 1% (w/v) phenol
red. Needles were mounted in a Narishige MN-151 micromanipulator attached
to a Nikon SMZ 645 dissecting microscope. Embryos at the 1 cell stage were
aligned along the end of a microscope slide and the needle positioned so as to
Chapter 2. Materials and Methods 59
enter the yolk and then the cell. Typical injection conditions included a pulse
duration of between 0.3 s to 0.6 s and a gas pressure of 400 kPa. Injection settings
were adjusted as required to maintain an injection bead of approximately 0.1mm
containing approximately 500 pl of injection mix. Embryos were subsequently
allowed to develop on a warming tray prior to incubation.
2.7.3 Fluorescent microscopy
Embryos were visualised using an MVX10 microscope (Olympus) with stage light-
ing provided using LG-PS2 ﬁbre optics light source (Olympus). Digital images
were recorded using CellSens Dimension 1.6 software (Olympus) and DP72 cam-
era (Olympus).
2.7.4 Fixation of zebraﬁsh embryos and larvae
Embryos were euthanised using 0.4 μg/μl benzocaine (Sigma) prior to ﬁxation
in 4% (w/v) paraformaldehyde (PFA) in PBSA with 0.1% (v/v) (PFA/PBS).
Fixed embryos were stored at 4 ◦C for at least 1 day. Embryos were subsequently
dehydrated in 100% (v/v) methanol for long-term storage at −20 ◦C.
2.7.5 Whole-mount in-situ hybridisation of zebraﬁsh em-
bryos (WISH)
2.7.5.1 Digoxigen-labelling of nucleic acids
To produce digoxigenin (DIG)-labeled RNA probes for in situ hybridization, 1 μl
to 2 μl linearized DNA or PCR products, were mixed with 2 μl 10 × DIG labeling
mix (Roche), 2 μl 10 × Transcription buﬀer, 1 μl RNase inhibitor, 2 μl T7 or SP6
polymerase, and the volume was adjusted to 20 μl by adding sterile nuclease-free
water (Amresco). Following incubation at 37 ◦C for 2 h, 2 μl of DNase I (10U/μl)
were added and the sample incubated at 37 ◦C for a further 15min to destroy
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the DNA template. The reaction was terminated by the addition of 2 μl of 0.2M
EDTA. The RNA was further puriﬁed using G-50 gel ﬁltration exclusion micro-
columns (GE Health) as per the manufacturer’s directions.
2.7.5.2 Hybridisation and Staining
Fixed embryos (section 2.7.4) were rehydrated via a decreasing series of 5minwashes
in methanol and PBS-T (PBS plus 0.1% Tween-20) 100% (v/v) , 50%, and 30%
(v/v) before reﬁxing for 20 min in 4% (v/v) PFA/PBS followed by 3 washes in
PBS-T. Embryos older than 26 hpf were then incubated at room temperature in
PBSA containing proteinase K, 24-36 hpf with 10μg/μl proteinase K for 10min,
36 hpf to 7 dpf with 20 μg/μl proteinase K for 30min. Hybridization involved
digoxigenin-labelled antisense RNA probes transcribed from appropriately lin-
earized plasmids or LNAs. Embryos were incubated in 500μl of HYB- (50% (v/v)
formamide, 5 x sodium chloride/sodium citrate (SSC), 0.1% (v/v) Tween20) for
5min at 70 ◦C and replaced with 500 μl of HYB+ (HYB- with 5 μg/μl ribonucleic
acid, 0.05 μg/μl heparin (Sigma)) which were incubated at 70 ◦C for at least 3 h.
Embryos were incubated at 70 ◦C overnight with 150 μl to 300 μl of probe solution
1:50 to 1:300 diluted in HYB+. Embryos were washed in 50% (v/v) formamide/2
× SSC-T for 30min and 60min at 70 ◦C. Embryos were washed for 15min in 2×
SSC-T followed by 2 × 15min washes in 0.2 × SSC-T also at 70 ◦C. This was fol-
lowed by 3 room temperature washes in PBS-T followed by incubation in blocking
solution (0.02% (w/v) zebraﬁsh serum albumin (BSA), 5% (v/v) foetal calf serum
(FCS) in PBS-T) for 2 h at room temperature. Following the incubation embryos
were placed into blocking solution with (0.15U/μl) of alkaline phosphatase (AP)
conjugated anti-DIG antibody (Roche) and incubated at 4 ◦C overnight. Embryos
were washed 6 × 15min in PBS-T at room temperature with gentle rocking and
then 3 × 5min washes in staining buﬀer (0.1 M Tris pH 9.5, 0.05 M MgCl2, 0.1
M NaCl, 0.1% (v/v) Tween 20) containing 25μg/ml levamisol. Following this,
embryos were stained in staining buﬀer containing (0.225mg/ml nitroblue tetra-
zolium (NBT) and 0.175mg/ml 5-bromo,4-chloro,3-indolyl phosphate (BCIP) at
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room temperature in the dark for 1 h to 48 h. Embryos were ﬁnally rinsed in
PBS-T and ﬁxed in 4% PFA/PBS when stained to an appropriate extent.
2.8 Protein methods
2.8.1 Western blot analysis
2.8.1.1 Sample collection and preparation
Zebraﬁsh embryos or larvae were dechorionated if necessary and placed in extrac-
tion buﬀer (10 mM Tris, pH 7.4, 2% Triton X 100,1 mM PMSF,1 mM aprotinin,1
mM leupeptin, 1 mM trypsin inhibitor). Samples were thawed and pelleted by
centrifugation at max speed for 2min and homogenised before boiling for 5min
and centrifugation at 13 000 g for 2min and the supernatant removed and frozen
in SDS buﬀer at −20 ◦C (0.63 ml 1M Tris-HCl, pH 6.8, 1ml glycerol,0.5ml β-
mercaptoethanol, 1.75ml 20% SDS, 6.12ml H2O). .
2.8.1.2 Bradford Assay
Total protein concentration were determined with the addition of 2 μl supernatant,
100 μl nfH2O, and 1ml Bradford reagent, and concentration determined by extrap-
olation to a linear curve generated by A595 concentration of a Bradford assay
[48].
Samples were prepared by adding 1μl of lysate sample to 1ml of 1 × protein as-
say solution. Both samples and BSA controls were mixed by inversion and left at
room temperature for 5min. Absorbance of prepared standard BSA concentration
samples were read at 595 nm and a standard curve were generated in GraphPad
Prism 6.0.
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BSA 1 μg/ml 8 μl 6 μl 4 μl 2 μl 0 μl
Bradford Assay reagent 1ml 1ml 1ml 1ml 1ml
Final BSA Concentration 0.8 μg/μl 0.6 μg/μl 0.4 μg/μl 0.2 μg/μl 0 μg/μl
Table 2.5: Bradford assay dilutions
2.9 Bioinformatics
2.9.1 Data mining
Homology searches were conducted using the BLAST-N server at the National
Centre for Biotechnology Information (NCBI), National Library of Medicine, Bethesda,
Maryland, USA [10]. To identify the zebraﬁsh U6 and H1 promoter sequences, the
zebraﬁsh whole genome shotgun sequences deposited in the genome survey se-
quence (GSS) section of GenBank and the zebraﬁsh genome sequencing project
(ZFIN) Zv9 [340] were searched using the human and mouse U6 snRNA sequences
[RnU6] (GenBank accession numbers M14486 and M10329.1) using BLAST-N
or Megablast with default parameters and a threshold e-value of 0.01. The ze-
braﬁsh ribonuclease P RNA component H1 (H1) [100]had previously been identiﬁed
(NR 036645.1).
2.9.2 Nucleotide sequence data management
All nucleotide sequence data was managed using the Clone manager 6 (Version
9.00) and Serial Cloner (Version 2.50) [Serial Basics].
2.9.3 Image Analysis
Zebraﬁsh larvae were photographed using cellSens Dimension 1.6 software (Olym-
pus) and DP72 camera (Olympus) at 400 × combined magniﬁcation and ﬁles saved
as .tiﬀ. to determine area and standard length (STL) of the zebraﬁsh larvae Image
J analysis software were used with the following protocol. The new macro Image J
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macro zebraﬁshlength.ijm were developed to partially automate zebraﬁsh embryo
batch processing. A brief protocol is included below (see 2.6). This technique
requires clear images of zebraﬁsh embryos with suﬃcient bright light from directly
above the embryo to eliminate shadows, which may obscure the binary mask.
Step Action Image J process
1 Greyscale Image → Type → 8-bit
2 Set Scale Draw a line over the scale bar
3 Set Scale Analyze → Set Scale Known distance = xxxx
4 Determine Area Process → Binary → Make Binary
5 Determine Area Analyze → Analyze Particles
6 Export to Excel Save to clipboard and Paste to Excel
7 Determine Length Edit → Selection → Make Bounding box
8 Export to Excel Save to clipboard and Paste to Excel
Table 2.6: Image J Batch processing. Bold text indicates command path. Italic text
indicates inputs within commands.

Chapter 3
Expression of shRNA molecules
in zebraﬁsh ZF-4 cell culture
The publication “Clarke, B.D., Cummins, D.M., McColl, K., Ward, A.C., & Do-
ran, T.J. Characterisation of zebraﬁsh polymerase III promoters for the expression
of short-hairpin RNA interference molecules. Zebraﬁsh. 2013 (In Press).” includes
results from this chapter.
3.1 Introduction
This results chapter describes the identiﬁcation and characterisation of the ze-
braﬁsh H1 snRNA promoter and U6 snRNA promoters for the expression of
shRNAs as well as the utilisation of the chicken (Gallus gallus) pantothenate
kinase 1 (Pank 1) [NC 006093.3] intron 5 construct to introduce shRNA molecules
into zebraﬁsh cell culture as illustrated in Figure 3.1. The zebraﬁsh promoters
were identiﬁed based on their downstream proximity to the snRNA genes and by
the presence of conserved snRNA polymerase III type 3 elements motifs. The
Pank-1 intron was originally generated to facilitate the introduction of miRNA
based shRNA molecules into chicken eggs by Dr. Kristie Jenkins (CSIRO AAHL)
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[Unpublished data] and is used in this study as an alternative method of intro-
duction of shRNAs. To validate these promoters shRNA expression vectors were
constructed and the shRNA expression driven by the respective promoters tested
by co-transfection and reduction of intensity of the reporter gene, eGFP.
Following the initial descriptions of the application of human snRNA pol III type
3 promoters to transcribe shRNAs [51,276,393], expression of shRNAs from a variety
of pol III type 3 promoters has an invaluable tool for gene knockdown and reverse-
genetics in cell culture. In many cases the promoters of choice have been the U6 or
H1 promoters, however, the 7SK promoters [27,127,195] have also been popular. The
U6 and H1 promoters have been by far the most frequently used for the expression
of shRNA for gene suppression. However, there have been only a pair of studies
that have directly compared the activity of the U6 and H1 promoters for the
expression of shRNAs. Both studies were performed using the human promoters
and both concluded that the U6 was the stronger promoter [42,231].
While there has been signiﬁcant work performed in the identiﬁcation and charac-
terisation of mammalian pol III promoters [51,195,260,302,316,383] and to a lesser extent
the chicken promoters [27,79,383]. Promoters identiﬁed as potentially suitable for use
in teleosts are limited to the zebraﬁsh or fugu U6 promoters [46,182,370,401] and consid-
ering the controversies relating to RNAi based technologies in zebraﬁsh [269,323,370,403]
and implications that the dose of interfering RNA molecules maybe critical for
avoiding signiﬁcant non-speciﬁc results from injections of siRNA [403] therefor the
characterisation of the strength of the zebraﬁsh U6 promoters and the identiﬁca-
tion and cloning for the ﬁrst time of the zebraﬁsh H1 promoter begin the construc-
tion of a potential rational tool kit for the utilisation of polymerase III promoters
in zebraﬁsh to express shRNAs.
Intronic miRNAs were ﬁrst identiﬁed in C. elegans [11] and have since been de-
termined to be among the most populous of all miRNAs [11,251,392]. Synthetically
generated intronic miRNAs have been used successfully in mice [251], chicken (Un-
published Data) and zebraﬁsh [95,298]. Intronic shRNA molecules enter the RNAi
pathway earlier than either siRNA or polymerase III expressed shRNAs Figure 3.1
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Figure 3.1: Induction of RNAi response from polymerase III promoters or
intronic vectors
Schema of induction of RNAi mechanisms through pol III expressed shRNA or
intronic miRNA/shRNA. The intronic miRNA is transcribed by the Polymerase
II CMV promoter and expressed in the intron 4 region of the Pank 1 gene tran-
script (pre-mRNA). After RNA splicing in the splisosome and further additional
processing, the spliced out intron then functions as a pre-miRNA for intronic
miRNA generation and is then excised by Drosha RNases to form a hairpin-like
pre-miRNA template and then exported to the cytoplasm for further process-
ing by Dicer to generate mature miRNAs / shRNAs. The shRNAs generated
from either intron or polymerase III promoters are ﬁnally incorporated into a
RNA-induced silencing complex (RISC) leading to disruption of target mRNA.
Figure modiﬁed from [392].
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and it is hypothesised that by including shRNA molecules into an intron which
already expresses an endogenous miRNA that the dose of the shRNA will be both
tolerated and suﬃcient for eﬀective repression of targeted mRNA.
This chapter describes the identiﬁcation and characterisation of the zebraﬁsh se-
quence with predicted polymerase III promoter activity based on its proximity to
either a U6 or H1 snRNA sequence and the presence of typical type 3 RNA pol III
promoter element motifs. The validation of this sequence for shRNA expression
was achieved by the construction and testing of plasmid vectors targeting an ex-
ogenously expressed reporter gene, eGFP and by RT-PCR and RNase protection
assay to qualify RNA expression.
3.2 Characterisation of and identiﬁcation of ze-
braﬁsh U6 and H1 snRNA promoters for the
expression of shRNAs
3.2.1 U6 promoter identiﬁcation
To identify native U6 promoters the zebraﬁsh genome was analysed using BLAST
for sequences homologous to the previously identiﬁed U6 sequences (U6 1-3) [133],
from both zebraﬁsh and fugu [401]. This search yielded an additional novel zebraﬁsh
U6 promoter located on chromosome 9 (U6 4)[CU651612.3] [59].
These promoters were screened for the presence of known polymerase III promoter
elements such as a TATA-box [86], Octamer motifs [257], PSE like [316], SPH and
STAF [313] elements. All four zebraﬁsh U6 promoters were found to possess a
SPH element immediately upstream of the TATA box, which is diﬀerent to the
previously characterized mouse and chicken U6 promoters (Figure 3.2). The U6
promoters were not highly conserved between the individual promoters (Figure 3.3)
and Clustal W2 [67] multiple sequence alignment clearly analysis identiﬁed the U6 1
promoter as clearly diﬀerent to the other zebraﬁsh U6 promoters, as summarised
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in Table 3.1 and (Figure 3.3), only the U6 4v1 promoter was included in this
analysis as a variant U6 4 promoter was ampliﬁed from a single clone and likely
results from a single animal, pool or PCR ampliﬁcation artifact and sequence
analysis of relevant genomic DNA ampliﬁed from adult zebraﬁsh and from the
zebraﬁsh ZF4 cell line conﬁrmed that the Octamer, SPH and TATA elements were
highly conserved in all promoters against previously published consensus sequences
(Figure 3.2).
Table 3.1: Clustal W2 analysis of ze-
braﬁsh U6 promoters
U6 1 U6 2 U6 3 U6 4
U6 1 100
U6 2 57 100
U6 3 51 72 100
U6 4 52 68 78 100
Numbers indicate % identity
3.2.2 H1 Promoter identiﬁcation
The zebraﬁsh snRNA component of RNase P H1 has also been previously identi-
ﬁed [100]. The H1 promoter was identiﬁed by analysis of the sequence 1 kb up-stream
of the RNase P gene transcriptional start site for polymerase III type 3 promoter
elements. The identiﬁed promoter elements as expected begin with a distal se-
quence element consisting of an Oct-1 and STAF motifs and a proximal sequence
element consisting as expected of a SPH binding site and TATA box. The H1
promoter was also more conserved than the zebraﬁsh U6 promoters in comparison
to orthologous H1 promoters and between the identiﬁed promoter elements and
the published consensus sequence (Figure 3.4 B). The H1 promoter showed higher
conservation each of the identiﬁable promoter elements was conserved when com-
pared to the consensus sequences and the order of the speciﬁc elements was also
conserved (Figure 3.4). In each of the mammalian species the RPPH1 gene is lo-
cated on the antisense strand of the PARP1 gene in the ﬁrst exon in the zebraﬁsh
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    OCT    SPH   TATA 
Consensus      ATTTGCAT  YYWCCCRVMATSCMYYRCR TATA 
 
Zebrafish U6-1 (-339)ATCGTTTg(-331) (-66)CCACC-ACCtTGgAggAAC-----------------TAcATAT(-23)
Zebrafish U6-2 (-224)tTTTGCAT(-216) (-48)aTACCCAGAAGtCCCTtgG-TATATA(-24) 
Zebrafish U6-3 (-218)ATTTGCag(-210) (-47)aTACCCAGAAGtCCCGgGTATATA(-23) 
Zebrafish U6-4v1 (-214)TACGcTTA (-208) (-47)aTACCCAGAAGtCACTGGTATATA(-23) 
Zebrafish U6-4v2 (-214)TAAgtGTA (-208) (-47)aTACCCAGAAGtCACTGGTATATA(-23) 
     
 
         
 
  OCT     SPH 
Consensus      ATTTGCAT     YYWCCCRVMATSCMYYRCR 
Mouse U6  (-235)ATTTGCAT(-228)  (-222)TTTCCtAGtAaCtATaGaG(-202) 
Chicken U6-4 (-194)ATGCAAAg(-187)  (-206)CTTCCCGCCgTGCACCGCG(-216) 
Human U6-8  (-234)ATGCAAAg(-228)  (-247)tTTACCCAgggTGCccgGg(-227) 
Fugu U6        (-247)TTTCCCACAGCCCCCTGGC(-227) 
   PSE     TATA 
Consensus    STSACCGTGWSTGTRAAR(0-3)TG   TATA 
Mouse U6  (-74)CTCACCcTaACTGTAAAG(5)TG--------------TATAAATAT(-27) 
Chicken U6-4 (-66)CTCACCGctACTtaAAAAT(2)TG---------------TAAATA(-24)
Human U6-8  (-68)GTCACCGTaAGTaGAAtA(2)TG---------------TTATAA(-26)
Fugu U6  (-85)CCAACCATGACCCAGAG------(-62)   (-31)TATATATA(-24)
C
Tn
+1
U6 snRNA
TATAPSEOCT SPH
Tn
+1
U6 snRNA
TATAOCT SPH
Mouse U6-1 snRNA Promoter
Zebrafish U6-1 snRNA Promoter
B
A
Figure 3.2: Polymerase III promoter element alignment
A Sequence alignment of the U6 promoter elements. The conserved U6 promoter
elements, the distal sequence element (DSE) comprising SPH and OCT, the
proximal sequence element (PSE) and TATA motif are shown for each zebraﬁsh
U6 promoter. B The equivalent human, mouse, fugu and chicken U6 promoters
for comparison. Nucleotides that matched the consensus sequence for SPH,
OCT, PSE and TATA sequence are shown in uppercase or lowercase to identify
mismatches. Underlined letters represent mismatches observed between variant
U6 4 clones. Dashes (–) indicate spacing between PSE elements. Nucleotide
positions are shown at the relative to the predicted transcription start site (+1).
C Graphical representation of interchanged promoter motifs of the zebraﬁsh and
mouse U6 1 promoters.
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	    1  --CTAGT--- ---TATAGTT TCG--AT--- ----GGGCC- --GTTT-GCT GGCGTCTGAG 39 
	    1  --CTA----- ---TATAGCT CTG--CTCTA GTGAGAGCA- --GCTT-CCT TGTGTCGGAG 44 
	    1  TTCTATAG-- ---TATA-CT CGGTCATTCA GTAAGACGA- --GTTT-CCT GCTCTCGGCG 50 
	    1  --CTATATAT AGATATAGAT TCCAAATGGT GCATGAGGAT GTGTTTAGCA AATCGTGGGA 58 
               ***         ****  *       *        *        * **  *         *   
 
	   40  CATGTTGTCC TCTGGTC--T GCGGCGGGGG AA--GGTCCG CGCATGCCTG -TGGGGGAAG 94 
	   45  TGTTTTGTGC TCTTATC--C AAGGCAGGGG G---GATCTG CGCATGCCTG -TGGGGGGAG 98 
	   50  TCTTTTGT-- TCTGGTCATC AAGGAGGGGG GAATGTTCTG CGCATGCCTG -TGGGGGAGG 107
	   59  GGTGCTGC-- -TGGGTC--- --AACTGGAA AA----TCTA --CATGCATG GTGAAAACGA 104 
               *  **         **          **         **     ***** **  **        
 
	   95  GCGAAGGACA CGAGGACAAA AGATCAGTTA CGTCACA--- GAAG------ AACTCATCCA 145 
	   99  GAGAAGGACA CGTGAACAAA AGCTCCTCGA TGTCACACAG GAAGTTCAGG AACTCATCCA 158 
	  108  GAGAAGGACA CGTCACTGAA AACGTCCCTG CATCACACC- GAGA------ ----CACCCA 156 
	  105  ATGTGGGATG CTTTGATCG- ---TTTGCTT TGTTGTG--- ---------- ----CAACCA 143 
               *  ***   *                       *                       ** *** 
 
	  146  AT-CACACTA GCCTAAAA-C CAGCTTC--- ----CTCTGC -ATATGCTTT ACAGCT-CAA 194 
	  159  AT-CACTCTA AAGAAAAGGC CTGTTTC--- ----CTTCGC -ATACGCTT- ACAGCT-ACA 207 
	  157  AT-CACTCAA GCCGAGA--C CAGATAA--- ----TTTTGC -ATATGCTTT ACAGTTTGAA 205 
	  144  ATGCACTT-- -CCAAAGCCC TTGCTTTAGT GGGACTTTGC CATAGACTAT CCTGACACTA 200 
             ** ***         *    *   * *           *  **  ***  **    * *     * 
 
	  195  AAATACTACG GTAAACCTCC ACA-AAACTG CTGGTTT-CA A-ACTTTGAA G-GTTTTAAG 250
	  208  AAACTCTACG GTAAACCTAC ATA-AA-CTG CTGGTTTTCA A-ATTTTAAA G-AATTTAAG 263 
	  206  AAATACCACA GTAATCCCTC ACACAAACT- CTGGATTTGA G-ATCCTTCA G-GTTTTATC 262 
	  201  ATTTCCCCCT GT------CC ATA-AACTTG GTGACCTACT GCATCAATCA GTGTGCCTAG 253 
             *    *  *  **       * * * **  *   **   *      *      * *          
 
	  251  CATTTGCAGG TTTTCTCTGA ---AGAGGTT TACTGTCAT GTTTGAG-GT AAATGAGTTGA 306 
	  264  GGTTTACAGG TTTACTACTA CACAGTGATT TACTGACAC ATGTAAGTGT AAATGAGTTGA 323 
	  263  AGTTTGCAGG TTTA-TGTCA C--CATGATA TAGGGTCAG ACTTGAT-CT AAGGGAGCTGA 318 
	  254  CACTGACAGG GCCAAAGCTC T---GTAGTG CACGG-CAT AC-------- AAGTGG---GA 298 
                *  ****                    *   *  * **             **  *    ** 
 
	  307  ATAAGTAGGT TTATCCACTT ACCACATGGC AGAAACATAC CCAGAAGTC CCGG-GTATAT 365 
	  324  ATAAGTAAGT A-AGCCATAT ACCACACATG AAACACATAC CCAGAAGTC ACTG-GTATAT 381 
	  319  ATAAGT-GGT TTAGTCACTC ACCACCTCCC AAAAACATAC CCAGAAGTC CCTG-GTATAT 376 
	  299  ACATGGCTCT CCAGGT-CCC ACCACCTTGG AGGAACATTG CTGGGACTC AAGGCGTACAT 357 
             * * *    *   *        *****      *   ****   *  * * **    * *** ** 
 
	  366  ATAGCAGTCC TCCAGGCTCC TAGT-TCA-C AATC- 397 
	  382  ATAGCCGTCC TCCAGACTCC CAGC-TCAAT AGTC- 414
	  377  ATAGCTCTCC CTCCAGCTCT TGGT-TCGAA CATC- 409 
	  358  AT-GCCCTGA GCCTGACTGC TGATCTTATA CCTCG 391 
             ** **  *     *   **        *       ** 
ZF U61
ZF U63
ZF U62
ZF U64
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the RPPH1 gene has been translocated to the sense strand and occurs in the ﬁnal
exon of the antisense METTL17 gene which is approximately 10 kb downstream
of the PARP1 gene (Figure 3.4 A).
3.2.3 shRNA expression vector construction
To validate the predicted promoter activity of the polymerase III promoters,
shRNA expression vectors were constructed encoding these promoter sequences
upstream of shRNA molecules that, target eGFP. The eGFP shRNA sequence used
was previously validated and was found to be the most eﬀective of all molecules
tested [27]. The loop sequence between the shRNA stem sequences was a sequence
used by many other researchers, the “Brummelkamp loop” 3′-TTC AAG AGA-
5′ [51]. The termination sequence consisted of a stretch of ﬁve thymidine residues
which has previously been described to cause eﬃcient pol III termination [51,242],
with an additional termination sequence 5′-GGA A-3′ added to the end of this
sequence was included to promote termination and eﬃcient silencing [51].
In a one-step PCR, the forward primer speciﬁc to the promoter was paired with
a reverse primer comprising the last 20 nt of the polymerase promoter, along
with all other shRNA components as well as a XhoI restriction endonuclease site
(Figure 3.5). A clear band consistent with the expected size (between 382 - 464
bp depending on construct) was gel puriﬁed and ligated into pGEM-T Easy. The
XhoI site facilitated screening for full-length inserts by digestion of recombinant
plasmids with this enzyme. Sequencing of linearised plasmids revealed two clones
that contained slightly diﬀerent promoter sequences for the U6 4 promoter (Figure
3.6) while, all other clones returned appropriate sequences for the plasmids of
interest. The zebraﬁsh U6 4 promoter showed some variation to the remaining
Figure 3.3 (preceding page): Alignment of zebraﬁsh U6 snRNA promoters
Sequence alignment of complete zebraﬁsh U6 promoters. Dashes () Indicates a
gap and asterisks () indicates a conserved base across all promoters. Phyloge-
netic tree was generated utilising a Clustal Omega multiple sequence alignment
and is indicative of the relative conservation of the U6 promoters
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Figure 3.4: The RPPH1 ribonuclease P RNA component H1 gene and pro-
moter.
A Synteny analysis of zebraﬁsh (ZF NC 007113.5), human
(NC 000014.8 [22], mouse (NC 000080.6) [8]and dog (NC 006597.3 [28].
RPPH1 genes. In each of the mammalian species the RPPH1 gene is located
on the antisense strand of the PARP1 gene in the ﬁrst exon. In the zebraﬁsh
the RPPH1 gene has been translocated to the sense strand and occurs in
the ﬁnal exon of the antisense METTL17 gene which is approximately 10 kb
downstream of the PARP1 gene. B Sequence of the zebraﬁsh H1 promoter
region. The bolded sequences indicate the consensus OCT, STAF, PSE and
TATA motifs with mismatches represented by lowercase letters [71].
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zebraﬁsh U6 promoters in both the PSE and SPH elements, but most signiﬁcantly
a variant U6 promoter was identiﬁed (U6 4v2) with three base substitutions within
the OCT motif (Figure 3.6).
For all promoter shRNA expression constructs, the ﬁrst nucleotide of the predicted
shRNA was located at the +1 position directly after the promoter sequence and
was a guanine (G) residue, corresponding to the ﬁrst nucleotide of the native U6
snRNA. All ﬁnal shRNA expression constructs consisted of either the full-length
zebraﬁsh U6 or H1 promoter, a shRNA sense sequence, a loop sequence 3′-TTC
AAG AGA-5′, an shRNA antisense sequence, and a termination sequence 3′-TTT
TTT GGA ATC TAG A-5′ and were cloned into pGEM-T Easy.
3.2.4 Optimisation of plasmid DNA transfection in zebraﬁsh
ZF-4 cells
Fish cells in culture are diﬃcult to transfect using typical lipid or polymer transfec-
tion reagents and there is comparatively little research into how diﬀerent transfec-
tion reagents work in the cell lines. Only a single paper had previously described
transfection of ZF-4 cells using the Amaxa nucleofector [137], which achieved over
70% transfection eﬃciency. Therefore, a study of ten diﬀerent transfection meth-
ods using eGFP and sheGFP plasmids was performed to identify the most eﬀective.
In addition to the chemical reagents the Amaxa Nucleofector and Invitrogen Neon
Transporator were used to transfect both ZF4 and EPC cell lines to determine the
suitability of these methods. The eﬀectiveness of the transfection methods was
estimated by the observation of eGFP expression under a ﬂuorescence microscope
and by ﬂow cytometry to count eGFP positive cells and trypan blue staining to
estimate necrotic and apoptotic cells. Seven widely used chemical transfection
agents were tested: Lipofectamine, Lipofectamine 2000, Lipofectamine RNAi (In-
vitrogen), X-tremeGENE (Roache), Polyfect (Qiagen), Fugene, and Fugene HD
(Promega) following the manufacturers recommendations.
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Figure 3.5: Cloning and construction of shRNA expression vectors
The one-step PCR method used to generate Polymerase III promoters. PCRs
used forward primers paired with long unique reverse primers comprising all
shRNA components. All ﬁnal PCR products consisted of a polymerase III
promoter either U6 or H1 shRNA sense (Passenger) , hairpin loop, shRNA
antisense (Guide), termination sequence 3′-TTT TTT GGA A-5′ and XbaI site.
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
   1     CTATTATAGC TCTGCTCTAG TGAGAGCAGC TTCCTTGTGT CGGAGTGTTT 50 
                     # 

   1     CTA-TATAGC TCTGCTCTAG TGAGAGCAGC TTCCTTGTGT CGGAGTGTTT 49 
 
 

   51    TGTGCTCTTA TCCAAGGCAG GGGGGATCTG CGCATGCCTG TGGGGGGAGG 100 
 

   50    TGTGCTCTTA TCCAAGGCAG GGGGGATCTG CGCATGCCTG TGGGGGGAGG 99 
 
 

   101   AGAAGGACAC GTGAACAAAA GCTCCTCGAT GTCACACAGG AAGTTCAGGA 150 
                  

   100   AGAAGGACAC GTGAACAAAA GCTCCTCGAT GTCACACAGG AAGTTCAGGA 149 
 
            	

   151   ACTCATCCAA TCACTCTAAA GAAACGGCCT GTTTCCTTCG CATACGcTTA 200 
                                            # ##        

   150   ACTCATCCAA TCACTCTAAA GAAAAGGCCT GTTTCCTTCG CATAaGtgTA 199 
                                                         TACGTTTA 


   201   CAGCTCCAAA ACTCTACGGT AAACCTACATA AACTGCTGG TTTTCAAATT 250 
                  

   200   CAGCTACAAA ACTCTACGGT AAACCTACATA AACTGCTGG TTTTCAAATT 249 
 


   251   TTAAAGAATT TAAGGGTTTA CAGGTTTACT ACTACACAGTG ATTTACTGA 300 
                  

  250   TTAAAGAATT TAAGGGTTTA CAGGTTTACT ACTACACAGTG ATTTACTGA 299 
 


   301   CACATGTAAG TGTAAATGAG TTGAATAAGT AAGTAAGCTA TATACCACACA 350 
 

   300   CACATGTAAG TGTAAATGAG TTGAATAAGT AAGTAAGCCA TATACCACACA 349 
                                  Y 
       		     

  351   TGAACCACAT ACCCAGAAGT CACTGGTATA TATAGCCGTC CTCCAGACTCC 400 


   350   TGAAACACAT ACCCAGAAGT CACTGGTATA TATAGCCGTC CTCCAGACTCC 399
        YWCCCRVMAT SCMYYRCR T ATA 

      

  400   CCAGCTCAA- AGTCGTA 417 
                           # # 

  401   CCAGCTCAAT CGTCGAA 417
Figure 3.6: Alignment of zebraﬁsh U6 4 variant promoters
Clustal W2 [67] sequence alignment of U6 4v1 and U6 4v2 variant promoters.
Overall similarity 407/405 bp 98.07%. snRNA promoter elements and consensus
sequences are indicated in Bold. OCT Motif occurs in the 3′ to 5′ orientation.
Mismatches between promoters are indicated by #. Mismatches between ze-
braﬁsh U6 4 promoters and consensus sequences indicated by lowercase letters.
U6 snRNA gene / Hairpin transcription start site designated as +1.
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Analysis of chemically transfected cells 72 hours post-transfection by ﬂuorescence
microscopy showed that a very low level of transfection was achieved for each agent
(Data not shown) and conﬁrmed by ﬂow cytometry (Figure 3.7). The highest level
of eGFP expression was evident in the cells transfected using Fugene HD, however
the inconsistency of the transfection and the low levels of transfection suggested
that it would be very diﬃcult to accurately and consistently diﬀerentiate eGFP
expression levels between various conditions. The various chemical transfection
reagents were also quite toxic (Figure 3.7) as measured by cell counts following
trypan blue staining and the chemical transfection methods were judged to be not
suitable for analysing suppression of eGFP in ZF-4 cells. However lipofectamine
2000 transfection of Vero cells is a well established method and would be used for
all transfections of mammalian cells.
In an attempt to increase transfection rates of eGFP in ZF4 cells, electroporation
eﬃciencies were tested using a Nucleofector machine (Amaxa). Three diﬀerent
electroporation solutions were provided by the manufacturer; solutions R, V, and
T. A number of diﬀerent programs are additionally available to optimise transfec-
tion, and a combination of four electroporation programs which have been success-
fully used in our laboratory in other cell lines were trialed with each solution and
screened for GFP expression (Figure 3.7) and toxicity. Each program was tested
using 2.5 μg of plasmid DNA per 1×106 cells, as suggested by the manufacturer
(Figure 3.7).
Analysis of electroporated cells for eGFP expression showed that the transfection
eﬃciency varied signiﬁcantly depending on both the solution and program used
as well as the consistency and the toxicity observed in the ZF-4 cells following
transfection. The combination of solution T and program T-20 resulted in the
most consistent transfection eﬃciency and the lowest toxicity. The transfection
eﬃciency was similar to that observed with Fugene and signiﬁcantly below that
previously reported [137]. It seems likely that discrepancies in transfection eﬃca-
cies between the published studies and the observed eﬃcacies maybe related to
either the passage number or growth conditions of the ZF-4 cells used. However a
transfection eﬃciency of 52 ± 6 percent is suﬃcient for the purposes of this study.
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Figure 3.7: Transfection of ZF-4 Cells
Chemical and nucleofection methods of transfection of plasmid DNA into ze-
braﬁsh ZF-4 cells. eGFP expression left hand graph measured via ﬂow cy-
tometry. Toxicity of transfection reagent estimated by Trypan Blue staining
and manual cell counting right hand graph via haemocytometer. Error bars
are indicative of the standard error of the mean (SEM) calculated from du-
plicate FACS analysis of or cell counts from three separate transfection experi-
ments. Statistical signiﬁcance was measured by ANOVA with Tukey’s post tests
* P≤0.05 was considered signiﬁcantly diﬀerent to untransfected. n = 3
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3.2.5 The zebraﬁsh U6 and H1 promoters express shRNAs
To validate the ability of the zebraﬁsh U6 and H1 promoters to express func-
tional shRNAs, the putative sequences were used to construct six vectors pZFU6-
1sheGFP, pZFU6-2 sheGFP,pZFU6-3 sheGFP, pZFU6-4v1sheGFP, pZFU6-4v2sheGFP
and, pZF-H1sheGFP, in which the relevant polymerase III promoter mediates
expression of a shRNA molecule targeting eGFP. Additional constructs using
chicken and mouse promoters (pCH-U6sheGFP and pM-U6sheGFP, respectively)
have previously been shown to strongly express shRNAs in a wide variety of
cells [27,195,383], while the construct pFUGU-sheGFP has been shown to be an eﬀec-
tive silencer of eGFP in Blueﬁn gill (BF-2) cells [401] and more recently Epithelioma
papulosum cyprini (EPC) cells (Fathead Minnow) and Chinook salmon embryonic
(CHSE-214) cells [182] and were therefore used as controls. Two irrelevant control
vectors; pZFU6-2 Irrelevant and pCHU6-4 NP, were used to express an irrelevant
shRNA as negative controls in ZF-4 and Vero cells, respectively. The U6-2 pro-
moter was used to drive the irrelevant sequence as preliminary work showed that
the U6-2 promoter was the most active in the cell line tested (Data not shown).
RNA extracted from transfected ZF4 cells at 72 hours and Vero cells at 48 hours
was probed for the expression of sheGFP using an RNase protection assay. A
19 nt band was detected in RNA samples from ZF4 cells transfected with all
zebraﬁsh U6 and H1 plasmids and the fugu positive control. No sheGFP expression
was detected in RNA samples from the negative control or from either the pCh-
U6sheGFP or pM-U6sheGFP (Figure 3.8). Detection of miR-16 as a loading
control in all transfected and control RNA samples conﬁrmed the presence of
small RNAs in each case.
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Figure 3.8: RNase Protection Assay for the quantitation of sheGFP expression
in cell culture
Zebraﬁsh ZF4 cells and Vero cells were co-transfected by nucleofection and co-
transfected with lipofectamine 2000 respectively with the shRNA expression
vectors and peGFP-N1 as labeled. Small RNAs were isolated by TrizolTMat
72 h post-transfection and hybridised with a complementary sheGFP γ-P32-
ATP radiolabelled RNA oligonucleotide. In addition, a γ-P32-ATP radiolabelled
RNA oligonucleotide corresponding to miR-16 was used as a loading control
across all samples. Representative of n = 2
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3.2.6 Zebraﬁsh polymerase III promoters can decrease eGFP
expression in native zebraﬁsh cells but not mam-
malian Vero cells
To analyse the activity of the zebraﬁsh polymerase promoters for shRNA ex-
pression, plasmids pZFU61sheGFP, pZFU64v2sheGFP, pZFH1-sheGFP, pFUGU-
sheGFP, pMU6-sheGFP and pCHU6-sheGFP were co-transfected with peGFP-
N,1 and the expression of eGFP monitored by ﬂuorescence microscopy and ﬂow
cytometry. Analysis of Vero cells by ﬂuorescence microscopy showed there was
no eGFP expressed in the untransfected cells (Not shown), and that cells trans-
fected with peGFP-N1 alone expressed eGFP at a similar level to cells trans-
fected with both peGFP-N1 and pCHU6-Irrelevant (Irrelevant) [Figure 3.9 A].
Detailed analysis by ﬂow cytometry identiﬁed the previously characterized con-
trol mouse and chicken expression plasmids strongly and signiﬁcantly p≤0.01 re-
duced eGFP MFI - pMU6sheGFP (13.05± 6.55, p ≤ 0.01) and pCHMU6sheGFP
(26.55 ± 6.05; p ≤ 0.01) (Figure 3.9B). Additionally the zebraﬁsh pZFH1sheGFP
construct also signiﬁcantly reduced eGFP MFI (69.13± 11.65; p ≤ 0.05). None of
the other zebraﬁsh or the fugu promoters showed any decrease in eGFP expression
in Vero cells.
The promoter shRNA constructs were then tested in the homologous zebraﬁsh
ZF-4 cell line for comparison that revealed strikingly diﬀerent results to the cor-
responding analysis in Vero cells (Figure 3.10). No eGFP expression was detected
from the untransfected cells (Not Shown), and the cells transfected with peGFP-
N1 alone expressed eGFP at a very similar level to the cells co-transfected with
peGFP-N1 and pZF4-Irrelevant. However, ﬂuorescence microscopy indicated that
eGFP knockdown was comparable between pZFU6-1sheGFP, pZFU6-2sheGFP,
pZFU6-3sheGFP and pZFU6-4v1sheGFP but no silencing was observed by either
the pMU6sheGFP or pCHU6sheGFP plasmids (Figure 3.10 A). Statistical analysis
of the Mean Fluorescence Intensity (MFI) [Figure 3.10 B] indicated that in ZF4
cells there was a signiﬁcant reduction in eGFP MFI following co-transfection with
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pZF-U6-1 shEGFP
pZF-U6-2 shEGFP
pZF-U6-3 shEGFP
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Figure 3.9: shRNA knockdown of eGFP using zebraﬁsh polymerase III pro-
moters in mammalian Vero cells
A Fluorescent microscope images of eGFP expression in Vero West African
Monkey Kidney cells following co-transfection with shRNA constructs and
peGFP-N1. An irrelevant non-silencing vector was used as a control. Im-
ages are representative of triplicate transfections. B eGFP Knockdown in Vero
cells. Flow cytometry results for eGFP knockdown in co-transfected Vero cells.
eGFP knockdown was measured as the relative percentage decrease in mean
ﬂuorescence intensity (% MFI), normalised to the MFI of the respective irrel-
evant controls (100%) following transfection. Error bars are indicative of the
standard error of the mean (SEM) calculated from duplicate FACS analysis of
three separate transfection experiments. Statistical signiﬁcance was measured
by ANOVA with Tukey’s post tests P≤0.05 was considered signiﬁcant. n = 3
Chapter 3. Expression of shRNA molecules in zebraﬁsh ZF-4 cell culture 83
pU6-1sheGFP (48.19±5.92; p ≤ 0.01), pU6-2sheGFP (39.95±4.91; p ≤ 0.01), pU6-
4v1sheGFP (38.01±4.67; p ≤ 0.01), as well as a lesser but still signiﬁcant reduction
of eGFP MFI following co-transfection with pU6-3sheGFP (32.76±4.02; p ≤ 0.01)
and with pFUGU-sheGFP (25.15± 3.09; p ≤ 0.05) p ≤ 0.05. No other constructs
induced signiﬁcant silencing in ZF4 cells. Finally, the variant U6 4 promoter U64v2
showed signiﬁcantly less eﬃcient knockdown of eGFP than the U64v1 promoter
at (23.61± 5.24; p ≤ 0.05).
3.3 Utilisation of the chicken Pank-1 Intron 5
for the delivery of shRNAs in zebraﬁsh ZF-
4 cells
The chicken Pank 1 (pantothenate kinase 1) ﬁfth intron was originally cloned and
spliced into eGFP by Dr. Kristie Jenkins in our laboratory as a vector for the
introduction of shRNAs into chicken cells and eggs. As this vector was available
and preliminary experiments suggested that the splicing of the intron out of eGFP
was eﬀective in zebraﬁsh cells (Figure 3.12 A). It was utilised in this study as an
additional method of introduction of an shRNA into zebraﬁsh ZF4 cells. The Pank
1 gene was chosen for this purpose as it natively encodes the miRNA miR107 and
by utilising this intron it is hoped to eventually use nuclease-mediated homologous
end joining approaches to modify the intron to contain an shRNA expressed in
concert with miR107. miR107 is homologous to miR103 and has been predicted to
occur or experimentally conﬁrmed in over 30 species according the current miR-
Base database [124,125,190]. In the zebraﬁsh the Pank-1 gene has been duplicated
and occurs on chromosomes 6 Pank 1a and 12 Pank 1b and miR107 is contained
within both ﬁfth introns, the Pank 1 b gene in zebraﬁsh is considered the homo-
logue to the chicken and mammalian Pank 1 genes [366] as it is most conserved.
Alignment of the miRNAs (Figure 3.11) reveals a single nucleotide shift in the
predicted mature siRNA sequence [339].
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Figure 3.10: shRNA knockdown of eGFP using zebraﬁsh polymerase III pro-
moters in ZF4 cells.
shRNA knockdown of eGFP using zebraﬁsh pol III promoters. A Fluores-
cent Microscope images of eGFP expression in zebraﬁsh ZF4 cells following
co-transfection with shRNA constructs and peGFP-N1. Irrelevant represents
non-silencing vector. Images are representative of triplicate transfections. B
eGFP Knockdown in ZF4 cells. Flow cytometry results for eGFP knockdown
in co-transfected ZF4 cells. eGFP knockdown was measured as the relative
percentage decrease in mean ﬂuorescence intensity (% MFI), normalised to the
MFI of the respective irrelevant controls (100%) following transfection. Error
bars are indicative of the standard error of the mean (SEM) calculated from
duplicate FACS analysis of three separate transfection experiments. Statisti-
cal signiﬁcance was measured by ANOVA with Tukey’s post tests P≤0.05 was
considered signiﬁcant. n = 3
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To test expression of intronic miRNAs in the zebraﬁsh ZF-4 cells the CMV pro-
moter was replaced with the Xenopus EF1α promoter and the two constructs
compared to test whether the artiﬁcially inserted intron would be spliced out
as predicted in the zebraﬁsh ZF-4 cells. Following transfection the expression
of eGFP was determined by ﬂow cytometry compared to the expression from
unmodiﬁed peGFP-N1 plasmids and plasmids pCMVeGFP-Intron, pEF1αeGFP-
Intron and those plasmids encoding irrelevant shRNAs pCMVeGFP-Intron-PB
and pEF1αeGFP-PBFigure 3.12. Generation of the pCMVeGFP-intron and pCMVeGFP-
Intron-PB was performed by Dr. Jenkins and modiﬁcation of the promoters and
all analysis and experimental work was performed by Brian Clarke.
To construct the Pank 1 intron vectors used in this study the original pCMVeGFP-
Intron construct generated by Dr. Jenkins was used as the template to extract the
entire GFP-intron construct via endonuclease digestion using the HpaI and SalI
endonucleases. The HpaI nuclease site occurs within the conserved poly A region
in both template and receiving vectors and maintains the in frame connection of
the eGFP-intron construct. The Xenopus EF1α promoter region was extracted
from the pT2-002 vector kindly provided by Dr. Scott Tyack, utilising a XhoI
digest removing the entire promoter region. The EF1α and Intron constructs
were simultaneously ligated into a pUC-018-sv40polyA vector pre-digested with
SalI and HpaI again provided by Dr. Tyack. Conﬁrmation of correct insertion
and insert direction was accomplished utilising digestion with ScytometryalI, as
both SalI sites in the inserts and vector will be deleted only if both inserts are
incorporated into the vector and by digestion of inserts with EcoRI and BamHI to
generate a unique 1789 base product followed by sequencing using the M13 primer
combination. This combination of digests was used for both the shRNA positive
and negative constructs.
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gga-mir-107       -CUCUUUGCUUUCAGCUUCUUUACAGUGUUGCCUUGUGGCAUGGAGUUCAAGCAGCAUUG 59  
dre-mir-107a      UCUGUGUGCUCUGAGCUUCUUUACAGUGUUGUCUUGUGGCAUGGAGAUCAAGCAGCAUUG 60  
dre-mir-107b      UCUGGCCACUCUGGGCUUCUCUACAGUGUUGCCUUGUAGCCUGGUGAUCAAGCAGCAUUG 60  
                   **     ** *  ****** ********** ***** ** *** * *************    
 
gga-mir-107       UACAGGGCUAUCAAAGCA---UGGA---- 81  
dre-mir-107a      UACAGGGCUAUCACAGCACACUGAACAGC 89  
dre-mir-107b      UACAGGGCUUUCAGCGUGUACAGAAC--- 86 
                  ********* ***  *      * *     

Figure 3.11: Alignment of miR107 from zebraﬁsh and chicken
ClustalW2 [67] sequence alignment of miR107 a and b from zebraﬁsh and the
chicken miR107. Matches are indicted by * and the predicted mature siRNA
sequence indicated by red font and the mismatch within the mature sequence
highlighted by blue.
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3.3.1 Splicing analysis of Pank 1 Intron 5 and delivery of
shRNAs into ZF-4 cells
Transfection of the pCMVeGFP-Intron vector into ZF-4 cells resulted in the strong
expression of eGFP in transfected cells (Figure 3.12 A). Analysis of relative mean
ﬂuorescence intensity by ﬂow cytometryindicated that the four eGFP intron plas-
mids pCMVeGFP-Intron, pEF1αeGFP-Intron, shRNAs pCMVeGFP-Intron-PB
and pEF1αeGFP-PB showed similar levels of eGFP expression in ZF-4 cells and
each of the plasmids resulted in slightly lower eGFP expression than the unmodi-
ﬁed peGFP-N1 (Figure 3.12 B). Using the primers eGFPintronF and eGFPintronR
to amplify a 583 bp fragment of eGFP spanning the spliced intron was conﬁrmed
(Figure 3.12 B) along with a longer approximately 4 kb amplicon corresponding to
unspliced plasmid DNA this larger amplicon occurred irrespective of reverse tran-
scription and sequencing conﬁrmed it to correspond to the unspliced GFP and is
a likely artifact of incomplete DNase digestion of circular plasmid DNA.
Utilising a two step method of artiﬁcially poly-A tailing non coding RNAs includ-
ing miRNAs and shRNAs, followed by qRT-PCR the relative expression of miR107
encoded from plasmids with or without the addition of the shRNA into the intron
as determined. Addition of an extra shRNA into the Pank 1 intron resulted in a
slight decrease (Figure 3.12 E) in the observed levels of miR107 following trans-
fection however the presence of native miR107 potentially masking this drop as
the low transfection eﬃciency of ZF-4 cells results in only a small yet signiﬁcant
increase in miR107 post transfection of plasmids containing the Pank 1 intron rel-
ative to peGFP-N1 transfections. Expression of mature shPB transcripts resulted
in the predicted observation of an approximately 80 nucleotide product in con-
structs containing the shRNA and no product in either untransfected, peGFP-N1
or pCMVeGFP-Intron and pEF1αeGFP-Intron constructs (Figure 3.12 C).
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3.4 Discussion
The research performed in this chapter has characterized zebraﬁsh polymerase III
promoters. Speciﬁcally, a number of native zebraﬁsh U6 promoters and the native
H1 promoter were tested for their ability to silence an eGFP reporter by expression
of an shRNA against this gene in both zebraﬁsh ZF4 cell and Vero West African
monkey kidney cell line. For comparison, mouse, fugu and chicken U6 promoters
were tested in parallel.
The expression of shRNA molecules targeting eGFP from zebraﬁsh U6 1, U6
2, U6 3 and U6 4 v2 promoters all strongly, and signiﬁcantly, reduced eGFP
expression in ZF4 cells. In contrast, expression of those shRNAs from either the
mouse and chicken U6 promoters did not reduce the expression of eGFP in this
cell line. The shRNAs produced from the zebraﬁsh H1 promoter and the U6-4
promoter each reduced the expression of eGFP slightly, although the reduction
was not signiﬁcant. In the mammalian Vero cell line, the reverse was observed,
with shRNAs expressed by the teleost U6 promoters unable to reduce expression of
eGFP but both the mouse and chicken U6 promoters produced suﬃcient shEGFP
Figure 3.12 (preceding page): Transfection of Gallus Gallus Pank 1 intron
in ZF4 cells and shRNA and GFP expression.
A Transfection of Pank1 GFP intron constructs ultiising either EF1α results in
GFP expression in ZF-4 cells. B RT-PCR using primer pair GGAPank1GFP
F and GGAPank1GFP F results in clear ampliﬁcation of both spliced GFP
mRNA and ampliﬁcation of plasmid DNA. C Polyadenalation of small nu-
clear RNA fraction and RT-PCR using the PAM-urp reverse and shPB-1207
F primer pair identify expression of PB-1207 shRNA only in constructs con-
taining the additional hairpin. D Flow cytometry results for eGFP expression
in transfected ZF4 cells. eGFP expression was measured as the relative per-
centage of in mean ﬂuorescence intensity (% MFI), normalised to the MFI of
the peGFP-N1 control (100%) following transfection. E RT-qPCR of miR107
levels post transfection of peGFP-N1 and peGFP intron plasmids. ΔΔCT is
calculated relative to the small nuclear RNA 5S and the level of miR107 calcu-
lated relative to peGFP-N1 (1) . In all graphs error bars are indicative of the
standard error of the mean (SEM) calculated from duplicate FACS or RT-qPCR
analysis of three separate transfection experiments. Statistical signiﬁcance was
measured by ANOVA with Tukey’s post tests P≤0.05 was considered signiﬁ-
cant. indicates signiﬁcant diﬀerence to peGFP-N1. # indicates signiﬁcant
diﬀerence between pCMVeGFP-Intron and pCMVeGFP-IntronPB. † indicates
signiﬁcant diﬀerence between pEF1αeGFP-Intron and pEF1αeGFP-IntronPB.
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molecules to strongly suppress eGFP expression. However, shRNAs produced by
the zebraﬁsh H1 promoter weakly, but signiﬁcantly, reduced eGFP expression in
Vero cells.
The zebraﬁsh H1 promoter was identiﬁed and compared to those in mouse, chicken
and human. The zebraﬁsh H1 promoter contained each of the conserved sequence
elements identiﬁed in the other H1 promoter sequences, with all promoter elements
present in the same order in each species. The zebraﬁsh H1 promoter was the only
promoter able to reduce eGFP expression in both the zebraﬁsh and mammalian
cell cultures. Two previous comparisons of mammalian U6 and H1 promoters
ﬁrstly in mice brains and endothelial cells [231] and secondly in Vero cell cultures [42],
highlighted that the U6 promoter was a much more eﬀective promoter than the
H1 promoter. Our research indicates that the zebraﬁsh is no exception at least in
ZF4 cells.
This study identiﬁed an additional zebraﬁsh U6 promoter (U6 4) to the three pre-
viously characterized in this organism. Genomic analysis indicated the presence
of a common variant (U6 4v2) with 3 nucleotide alterations in the OCT motif,
which was much less eﬀective than the U6 4v1 promoter at reducing eGFP expres-
sion. This result is consistent with previous work that indicated that either the
complete or partial removal of the OCT motif resulted in reduced expression of
the H1 snRNA gene in mice and HeLa cells [260]. This information may be useful
if attenuation of the promoters is required for future applications.
Interestingly, both pMU6 sheGFP and pCHU6-4 sheGFP appeared to signiﬁcantly
increase the expression of eGFP above the level observed in the pZFIrrelevant
control in ZF4 cells. As neither of these constructs showed evidence of expression
of shRNAs following co-transfection, it remains possible that the pZFIrrelevant
construct is causing a moderate non-speciﬁc knockdown of expression from the
peGFP-N1 plasmid, consistent with other studies suggesting that high levels of
RNAi molecules have a non-speciﬁc inhibitory aﬀect on the normal cellular func-
tions [112,128,129,403].
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The chicken Pank 1 intron was utilised as an additional method of introducing
potentially silencing shRNAs into zebraﬁsh cells, as it allow entry into the RNAi
silencing pathway earlier that expression of distinct shRNAs from polymerase III
promoters. Using the eGFP-intron constructs It was observed that splicing of the
intron was preserved in the non-native ZF-4 cell line and that miR107 encoded
within the same intron was preserved and excised as predicted. The addition of
an shRNA into the intron preserved the splicing of the eGFP gene and did not
disrupt the correct secondary folding of the intron for Drosha family proteins to
excise both miR107 and the PB hairpins from the mRNA and the progression
of the hairpins into the miRNA pathway and the production of mature miRNAs.
Whilst these experiments have not demonstrated silencing from either the artiﬁcial
miR107 or the non-targeting PB the Pank-1 intron system will be further tested by
the addition of shRNAs targeting VHSV in following chapters of this document.
Utilisation of the Pank 1 intron allows us to potentially couple an shRNA with
a ubiquitously expressed miRNA, miR107 by the utilisation of endonuclease me-
diated homologous end joining and the GFP-pank1 constructs used in this study
represent the ﬁrst steps in generating these vectors and transgenics.
In this study a functional zebraﬁsh H1 and a new zebraﬁsh U6 promoter, along
with a variant of the latter have been identiﬁed. Expression of shRNAs from
these and three other previously characterized zebraﬁsh U6 promoters has been
shown in a zebraﬁsh cell line. The newly identiﬁed U6 promoter showed similar
levels of activity to previously characterised zebraﬁsh U6 promoters and the H1
promoter showed much lower eﬃcacy as measured by eGFP MFI reduction fol-
lowing co-transfection with peGFP-N1. Importantly the requirement for species-
matched promoters was demonstrated for eﬀective expression of, and knockdown
by, shRNAs, supporting previous evidence that there are inherent diﬀerences be-
tween mammalian and avian U6 promoters compared with their teleost counter-
parts and that the chicken Pank 1 intron 4 when cloned into eGFP is additionally
an eﬀective method of introduction of shRNAs into zebraﬁsh cell culture.

Chapter 4
Knockdown of viral haemorrhagic
septicaemia virus using shRNAs
in vitro
4.1 Introduction
Chapter 3 detailed the comparison of zebraﬁsh polymerase III promoters, which
resulted in the identiﬁcation of the zebraﬁsh H1 promoter, a novel U6 promoter,
and a “variant” U6 promoter (U6-4). This work led to the construction of eﬃ-
cient plasmids for short-hairpin (shRNA) expression. Chapter 3 also characterised
the relative strength of each promoter resulting in the use of the U6-2 promoter
throughout the remainder of the work described in this chapter. Additionally the
chicken pantothenate kinase 1 (Pank 1) intron construct was successfully used to
express shRNA molecules in zebraﬁsh ZF-4 cells. To further explore the poten-
tial for developing RNAi-based transgenic antiviral strategies, the zebraﬁsh U6-2
promoter was used, in combination with intronic-derived shRNAs, to target VHS
virus.
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VHS virus is an important disease of marine ﬁnﬁsh, in particular salmoid species
worldwide [336] including farmed rainbow trout, salmon, turbot and Japanese ﬂoun-
der [158]. Production losses as a result of direct mortalities can be between 50%
and 100% in high-density ﬁsh farms. The eﬀect of VHS virus infection is, how-
ever, not limited to the farms since it also infects a wide array of wild marine and
freshwater wild ﬁsh [121]. VHS virus is a 11 - 12 kb negative-sense RNA virus of the
genus novirhabdoviridus and the family rhabdoviridae [320]. The viral genome con-
sists of genes encoding the structural nucleoprotein (N), a polymerase-associated
phospho-protein (P), a matrix protein (M), a transmembrane glycoprotein (G), a
polymerase (L) protein along with a single non-structural nonvirion (NV) protein.
Importantly for this work, a zebraﬁsh model of infection was previously established
at a variety of developmental stages [265]. Moreover, the transmembrane glycopro-
tein and the viral polymerase genes have previously been shown to be eﬀectively
knocked down by siRNAs [43,325], shRNAs [184], and long-dsRNA molecules [182].
The use of shRNA molecules targeting viral genes has been an extremely suc-
cessful method of inhibiting viral replication in a wide variety of cell culture sys-
tems [184,376]. In addition, they have been used with some success in vivo following
lentiviral transduction [162] or nasal inoculation [40]. The shRNAs induce eﬀective
knockdown by inducing the endogenous RNA interference process [51,110]. Tran-
scribed shRNAs are exported from the nucleus by Exportin-5 and processed by
the RNase-III enzyme Dicer into small dsRNA molecules of between 19 and 23 bp,
called siRNAs. One strand of the processed siRNA; the complementary “guide”
strand, is incorporated into the RNA-induced silencing complex (RISC) and me-
diates the sequence-speciﬁc cleavage of the target mRNA [129,134]. Using RNAi
sequence-speciﬁc molecules to target viral genes allows for the targeting of genes
and gene regions inaccessible by conventional methods. Application of complexes
containing multiple shRNAs that target numerous genes and diﬀerent regions of
the same genes dramatically reduces the likelihood of viral escape [35,132].
This project used the zebraﬁsh U6-2 promoter to generate constructs expressing
shRNAs, targeting diﬀerent regions of each of the G and L genes (3 each). These
constructs were transfected into zebraﬁsh ZF-4 cells, and the eﬀect on G and L
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gene expression and viral proliferation determined. To test the sequence-speciﬁcity
of the inhibition, the expression of IFNφ1 and the IFN-induced MxA genes was
also analysed following transfection. The most successful shRNA targeting the G
gene of VHS virus was additionally cloned into the pCMVEGFP-intron construct
and transfected into infected ZF-4 cells. Viral loads and IFNφ1 genes were again
tested.
4.2 shRNA design and construction
Six shRNAs, 3 targeting each of the G and L genes, were designed against VHS
virus strain (23.75) [Accession number FN665788.1] using the Dharmacon siRNA
Design tool. Sequences were 21 nt long with a total GC content of less than
50%. To identify eﬀective shRNAs, siRNA sequences were further screened using
the criteria outlined previously [353]. Brieﬂy, potential siRNAs were scored for the
stability of the duplex formed between nucleotides 6 - 11 on the sense, and 14 -
9 on the antisense, strands. Those siRNAs with a central duplex ΔG of ≥ −12.9
kcal/mol were discarded, ΔG scores were calculated as described in [114] shRNA
sequences and ΔG scores are shown for selected shRNAs in Table 4.1. shRNA
expression plasmids were constructed using the one-step PCR method described
previously 3.5. The U6-2 forward PCR primer and speciﬁc shRNA reverse primer
were used to amplify the zebraﬁsh U6-2 promoter region and attach the speciﬁc
shRNA at the start of transcription (+1). Completed constructs were ligated into
the pGEM-T easy vector system. The control shRNA expression plasmid pZF-
U6-2shEGFP was constructed as described in [71] and Section 3.2.3. The empty
vector plasmid control was created by cutting the pGEM-T vector with EcoRI
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and religating.
Table 4.1: shRNA Sequences
shRNA Name Sequence Score ΔG (kcal/mol)
G1207 TT GGA GAC AAA CAC AAT GCT C 4 -12.4
G0906 AT GTT GGT GAT GAG ATG GTT G 4 -13.1
G1076 TG ACT ACT GCC TCA TAG TCA C 4 -14.8
L3082 AT TTG GTG ACG AAC ATT TCG G 5 -13.5
L0832 TC AGA GAA CCG GTT AAA CAA G 4 -14
L1005 TC ACT GAC CTC TTG AAT TGC C 4 -13.6
The shRNA target regions of the VHS virus G and L genes were screened for con-
servation using rVista [240] (Appendix D). A high level of conservation was observed
across all included VHS virus sequences and the related viruses IHN virus (Gen-
bank NC 001652) and Snakehead rhabdovirus (Genbank NC 000903). (Figure
4.1). The predicted secondary structure of the G and L genes of VHS virus strain
23.75 was determined using mFOLD [405] to provide an estimate of the relative
availability of sites for RISC interactions. shRNA molecules were preferentially
selected based on regions of low complexity (Figure 4.3) and target availability,
since previous analyses of shRNA and siRNA target eﬃciency have identiﬁed that
these molecules are signiﬁcantly more eﬀective when they target regions where the
ΔG is ≤ -19 to ≥ -10 kcal/mol [330,375]. Finally, the complete G gene, as well as
relevant regions of the L gene, was sequenced to ensure the VHS virus inoculum
had not undergone single point mutations in regions of the genome to be targeted.
4.2.1 shRNA screening
As well as ensuring that the shRNA speciﬁcally targeted conserved regions of the
VHS virus genome, it was also crucial that shRNAs be designed to avoid interac-
tions with the zebraﬁsh genome since these molecules can be incorporated within
miRISC and function as potential miRNAs [52,80,94]. The increasing sophistication
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Figure 4.1: Relative conservation of shRNA targets.
Sequence conservation was determined by MUSCLE alignment and sequence
display generated with weblogo [76]. Relative conservation of individual residues
in the mRNA sequence target by the individual shRNAs is indicated by letter
height.
Chapter 4. Knockdown of viral haemorrhagic septicaemia virus using shRNAs in
vitro 98
-16
8
-13
82
14
81
-
21
49
-
-22
68
-28
73
29
59
-
44
82
-
-45
57
-49
25
50
53
-
11
00
7-
N P M G NV L
3` 5`
sh
G0
90
6 
sh
G1
20
7
sh
G1
07
6 
sh
L0
85
2
sh
L1
00
5
sh
L3
08
2
Viral mRNA transcription level
Figure 4.2: Structural organisation of the VHS virus genome and locations of
sequences targeted by the indicated shRNAs.
The VHS virus genome consists of a single open reading frame that encodes
the various viral proteins, including the nucleocapsid protein (N), polymerase-
associated phospho-protein (P), matrix protein (M), surface glycoprotein (G),
the non-virion protein (NV), and viral polymerase (L). The start and ﬁnish
of each gene are indicated numerically on the genome. As with all (-) ssRNA
viruses, VHS virus mRNA is more heavily expressed towards the 3′ end of
the genome as indicated by the gradient. Positions of shRNA targets on the
Glycoprotein (G) and viral polymerase (L) genes are indicated with shRNA
molecules named for the 5′ most base pair.
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Figure 4.3: Targets of shRNAs on the VHS virus glycoprotein mRNA sec-
ondary structure
The folding of the VHS virus G gene RNA was predicted by thermodynamic
energy rules included in the MFOLD software [405] using the sequence VHS virus
23.75 (Genebank accession number U28799.1). shRNA target sites are boxed
and highlighted.
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of miRNA target analysis has shown that miRNA targeting is complex and so
three separate tools were utilised to identify potential interactions with the ze-
braﬁsh genome as shRNA / siRNA, or miRNA. Both strands of the shRNAs, in
their totality and the potential seed regions 5′ (bases 2 - 13), and the loop sequences
were screened independently against the entire Danio Rerio Refseq database us-
ing the BLASTN [10], optimising the search for short sequences. shRNAs that had
less than 4 mismatches within the seed region or 12 consecutive bases matching
regardless of the base positions were discarded (data not shown). Two additional
search tools, RNAhybrid [296] and Targetscan [209], were also used. These calculate
RNA binding eﬃciency across the whole shRNA, and the seed region, respectively.
Any potential shRNA that had the potential to function as a miRNA capable of
binding either non-speciﬁcally to the VHS virus genome or the zebraﬁsh genome,
was discarded.
4.3 Growth of VHS virus in ZF-4 cells
4.3.1 Viral haemorrhagic septicaemia virus growth kinet-
ics in ZF-4 cells.
Zebraﬁsh ZF-4 cells are typically grown at 28 ◦C. However, VHS virus growth is
highly temperature dependent [103,169,187] with virus replication completely inhib-
ited at temperatures greater than 15 ◦C. Therefore, the temperature was lowered
to room temperature overnight (approximately 21 ◦C) and the cells then infected
with virus and incubated at 15 ◦C.Not surprisingly, ZF-4 cells grown at 15 ◦C
showed signiﬁcantly slower growth than at higher temperatures. There was some
evidence of cell death in the days immediately following incubation at the lower
temperature (Figure 4.4) although overall the cells appeared healthy. Following in-
fection with VHS virus, the viability of the ZF-4 cells was assessed by qualitatively
estimating the conﬂuence of the monolayer (Figure 4.4 A). A signiﬁcant decrease
in cell viability compared to uninfected cells was observed at 1 day post infection
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(pi) following inoculation at an MOI of 1, at 2 day pi with an MOI of 10-1, and
at 5 day pi with an MOI of 10-2. Extracellular virus particles were titrated daily
pi, with maximum values of around 108 TCID50. Based on these experiments, it
was concluded that MOIs of less than 10-1 would be most useful for subsequent
experiments, with cells and supernatants assayed at 5 day pi for CPE and viral
load. Typical ZF-4 uninfected and infected cells and CPE are shown in Figure
4.5.
4.3.2 The eﬀect of nucleofection on VHS virus growth in
zebraﬁsh cells
It was next necessary to determine whether the stress of nucleofection and rela-
tively rapid temperature changes would alter either viral replication or plasmid-
mediated expression. Utilising the transfection methods determined in the pre-
vious chapter 3.7, ZF-4 cells were transfected with pEGFP-Max and pZFU6-
2shEGFP and allowed to recover and attach at 28 ◦C for 6 h to 24 h. Cells were
then moved to room temperature (21 ◦C to 23 ◦C) for a further 3 h to 12 h before
ﬁnal transfer to 15 ◦C (Figure 4.6). EGFP expression, as assessed by ﬂow cy-
tometry and was found to be reduced by around 30%., However, the eﬃciency of
transfection as determined by the number of EGFP positive cells was not altered
by the change in temperature (Figure 4.6 A & B). Cell viability was assessed by
Trypan blue staining at 24 h post incubation at 15 ◦C and showed that there was
no signiﬁcant decrease in cell viability following insulation at lower temperature
(data not shown).
To determine whether transfection of non-speciﬁc shRNA (shEGFP) or plasmid
would aﬀect virus growth, transfected cells were inoculated with a range of MOI
of VHS virus, and supernatants harvested to determine virus titres. Nucleofection
alone, or with either plasmid, reduced ZF-4 susceptibility to VHS virus infection
slightly although this eﬀect was not statistically signiﬁcant, and there was no diﬀer-
ence between transfection with shRNA delivery plasmid compared to pEGFP-N1
Chapter 4. Knockdown of viral haemorrhagic septicaemia virus using shRNAs in
vitro 102
1 2 3 4 5 6 7 8
104
105
106
107
108
(Limit of 
Detection) 103
Days post infection
TC
ID
50
 
MOI 1
MOI 10-1
MOI 10-2
Figure 4.4: VHS virus replication in ZF-4 cells
Supernatant was harvested from infected ZF-4 cells, at 24 h intervals and virus
titres determined by serial dilution and end point TCID50 titration using the
Reed & Muench method following VHS virus infection [295]. Virus growth was
determined from 2 independent experiments.
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Uninfected ZF-4
VHS virus MOI ZF-4
Figure 4.5: Preliminary infection of ZF-4 cells with VHS virus
Uninfected and infected ZF-4 cells following incubation at 15 ◦C. Natural blank
areas of uninfected ZF-4 monolayer are indicated with a black arrow. This is a
normal phenomenon of ZF-4 cells. Grey arrows indicate remaining monolayer
beneath the lifted infected cells. White arrows indicate typical VHS virus CPE
consisting of ﬂoating, rounded, and bunched cells.
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Figure 4.6: Zebraﬁsh ZF-4 transfection with pEGFP-Max and infection with
VHS virus
A Relative mean ﬂuorescence intensity of cells either untransfected, or trans-
fected with pEGFP-Max at the indicated temperatureB Flow cytometry results
for EGFP described in panel A, expressed as a percentage of sampled cells. C
Supernatant virus titres determined by TCID50 assay for indicated ZF-4 cells
post inoculation with VHS virus. D Expression of IFNφ1 or MxA analysed by
real-time PCR in indicated zebraﬁsh ZF-4 cells. The results are shown as mean
of two independent experiments and error bars indicate SEM. βActin served as
the reference gene.
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plasmid (Figure 4.6). This suggests the nucleofection and temperature reduction
strategy determined was suitable for eﬀective shRNA expression in ZF-4 cells.
Viral loads post nucleofection were greater than viral loads observed in cells not
treated by nucleofection (Figure 4.6 C) at equivalent time points post infection.
It may be that the combined stress of the nucleofection and repeated temperature
changes over the days immediately prior to challenge decreased the endogenous
resistance of the cells to the viral infection. There was however, no diﬀerence in
the expression of MxA or IFNα in transfected and untransfected cell layers (Figure
4.6 D).
4.4 shRNA mediated VHS virus suppression
4.4.1 Transfection of shRNA plasmids reduces VHS virus
replication
ZF-4 cells were qualitatively analysed post transfection and infection for the pres-
ence of viral cytopathic eﬀects (CPE). Some evidence of viral CPE was observed
in all infected cell layers at all MOIs. CPE was consistent with typical observa-
tions of VHS virus and rhabdoviral CPE observed in other studies [13,116]. ZF-4
cells became rounded and swollen, and readily detaching from the monolayer into
ﬂoating clumps of rounded cells that then clustered into typical rhabdoviral grape
cluster formations [185]. Observations of cell layers are included from the highest
MOI 10-1 as an example (Figure 4.7) as this infection level showed the greatest
variation between the shRNA plasmids [21,71].
To accurately quantify the reduction of viral replication following transfection and
infection, supernatants were titrated in EPC cells (Figures 4.8 and 4.9). EPC cells
form a consistent monolayer and readily grow the virus at 15 ◦C. Transfection of
the non-speciﬁc shEGFP did not signiﬁcantly reduce VHS virus titres relative
to transfection with the empty vector control. All three shRNAs targeting the
glycoprotein (G) gene (shG0906, shG1076, and shG1207) reduced viral titres at
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all MOIs tested relative to both the empty vector and shEGFP controls. All three
G gene shRNAs prevented virus production completely at inoculation of 10-5 MOI,
and shG0906 and shG1207 also completely inhibited virus growth at 10-4 MOI.
Of the three shRNAs targeting the polymerase (L) gene, shL0852 and shL3082
reduced viral titres at MOIs between 10-2 and 10-5 compared to both control
transfections. However, only shL3082 could completely prevent virus production
at 10-5 MOI.
4.4.2 Eﬀect of shRNA expression on MxA and IFNφ1 ex-
pression.
Interferon stimulation by dsRNA species, including shRNAs and siRNAs, [43,307,324,325]
and resulting activation of the anti-viral pathways has been previously shown to
impact on VHS virus replication and pathogenicity in vivo [171,350]. Therefore, ex-
periments were performed to ensure that the observed reductions of CPE, virus
titre, and viral genomic RNA were a direct result of the transfection of shRNAs
and not an indirect anti-viral eﬀect.
Poly(I:C) is a dsRNA mimic, which added to cell culture media induces a strong
IFN response primarily through TLR-like receptors (TLRs) after endocytosis as
well as later via RLRs after export to the cytoplasm in mammals. It can be
assumed to be the same in zebraﬁsh, and was included as a positive control.
Stimulation of ZF-4 cells with poly(I:C) 6 hours prior to inoculation with MOI
10-1 or 10-2 virus, led to a signiﬁcant reduction in virus titres relative to ZF-4 cells
transfected with both an empty vector and vector expressing an shRNA targeting
eGFP (shEGFP) [Figure 4.10]. pZFU6-2shEGFP did not inhibit virus growth
or CPE (data not shown) indicating that properly folded shRNAs do not induce
signiﬁcant IFN responses.
To further ensure that the use of shRNA molecules did not induce an interferon
response, two zebraﬁsh immune genes, interferon and the down-stream interferonβ
stimulated gene (ISG) MxA were quantiﬁed by qRT-PCR at 40 hours post-transfection,
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shG0906 shG1076 shG1207
shL1207 shL0805 shL3082
Figure 4.7: Cytopathic eﬀect of VHS virus on ZF-4 cells is inhibited by speciﬁc
shRNA transfection
Light microscopy demonstrating cytopathic eﬀects produced by inoculation of
VHS virus onto ZF-4 cells (3 days post-inoculation at 10-1 MOI) transfected with
the empty vector or the indicated shRNA plasmids compared to uninoculated
cells. Natural blank areas of ZF-4 monolayer are indicated with a black arrow.
This is a normal phenomenon of ZF-4 cells. Grey arrow indicates remaining
monolayer beneath the lifted infected cells. White arrows indicate typical VHS
virus CPE, ﬂoating, rounded, and bunched cells. Scale bar = 100μm
Chapter 4. Knockdown of viral haemorrhagic septicaemia virus using shRNAs in
vitro 108
10
-1
10
-2
10
-3
10
-4
10
-5
1×100
1×101
1×102
1×103
1×104
1×105
1×106
1×107
1×108
1×109
T
C
ID
50
Empty Vector
shEGFP
10
-1
10
-2
10
-3
10
-4
10
-5
1×100
1×101
1×102
1×103
1×104
1×105
1×106
1×107
1×108
1×109
Multiplicity of infection
T
C
ID
50
shEGFP
shG1076
**
***
10
-1
10
-2
10
-3
10
-4
10
-5
1×100
1×101
1×102
1×103
1×104
1×105
1×106
1×107
1×108
1×109
Limit of detection
shEGFP
shG0906
***
*** ***
****
10
-1
10
-2
10
-3
10
-4
10
-5
1×100
1×101
1×102
1×103
1×104
1×105
1×106
1×107
1×108
1×109
Limit of detection
Multiplicity of infection
shEGFP
shG1207
***** ***
*** ***
Figure 4.8: shRNA molecules targeting VHS virus glycoprotein (G) inhibit
VHS virus replication
ZF-4 cells were grown under standard culture conditions and transfected as
previously described with shRNA (shEGFP) vector or speciﬁc G gene shRNAs.
Cells were infected with the indicated MOI and supernatant harvested at 72
hours and assayed by TCID50. Graphs indicate mean (n = 2) and error bars
indicate SEM. All statistical analysis was performed by ANOVA with Tukey’s
post-test for multiple comparisons. Experiments on all shRNAs were conducted
together and analysed by ANOVA as a single experiment. * p ≥ 0.05 *** p ≥
0.01 *** p ≥ 0.001 relative to shEGFP plasmid.
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Figure 4.9: shRNA molecules targeting VHS virus polymerase (L) have a range
of eﬀects on VHS virus replication
ZF-4 cells were grown under standard culture conditions and transfected as
previously described with shRNA (shEGFP) vector or speciﬁc L gene shRNAs.
Cells were infected with the indicated MOI and supernatant harvested at 72
hours and assayed by TCID50. Graphs indicate mean (n = 2) and error bars
indicate SEM. All statistical analysis was performed by ANOVA with Tukey’s
post-test for multiple comparisons. Experiments on all shRNAs were conducted
together and analysed by ANOVA as a single experiment. * p ≥ 0.05 *** p ≥
0.01 *** p ≥ 0.001 relative to shEGFP plasmid.
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Figure 4.10: The eﬀect of poly(I:C) on VHS virus replication in ZF-4 cells
ZF-4 cells were grown under standard culture conditions and transfected as
previously described with either a control (empty vector) or shRNA (shEGFP)
vector, or incubated with poly(I:C) (10 g/ml) for 6 hours. Cells were infected
at the indicated MOI and supernatant harvested at 72 hours and virus titrated
by TCID50. Graphs show means (n = 2) and error bars indicate SEM.
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the same time point as when infection was performed. Only one shRNA plasmid,
shL1005 induced a signiﬁcant increase in either MxA or IFN (Figure 4.11). Inter-
estingly, this plasmid was also the sole shRNA that failed to suppress VHS virus
replication in these cells. Further investigation and RNA stability and folding
analysis revealed this shRNA showed signiﬁcantly decreased RNA stability when
analysed by mFOLD [405]. These data suggest that properly designed and folded
shRNAs do not induce a signiﬁcant immune response in zebraﬁsh and that the
observed reduction of VHS virus (as measured by CPE, titre and mRNA) is the
direct result of RNA interference (Data not shown).
4.5 Intron-mediated knockdown of VHS virus in
vitro.
As an alternative to the pol III shRNA transfection method, the Pank1 5b GFP
intron methodology was trialed. Relevant constructs of the most eﬀective shRNA
identiﬁed in the previous section 4.4 (shG0906) as well as an shRNA scramble
control (shScramble) were prepared (see Table 4.2 for shScramble and shG09096
sequences). Utilising the same nucleofection protocol as for the shRNA pol III
expression plasmids, the GFP intron plasmids were successfully transfected into
the ZF-4 cells. However, upon temperature reduction to 15 ◦C, expression of GFP
was signiﬁcantly reduced compare to at 28 ◦C (see 4.12 A). Transfected cells were
inoculated with VHS virus at MOIs of 10-1 and 10-2. Transfection of neither the
GFP - shScramble nor GFP - shG0906 plasmids resulted in a reduction of VHS
virus titre. qRT-PCR analysis of MxA and IFNβ in ZF-4 cells post transfection
showed that neither of the transfected plasmids induced signiﬁcant levels of either
mRNA (data not shown).
To analyse the reduction of GFP expression, relative expression at 28 ◦C and 15 ◦C
was determined by FACS see Figure 4.12 B). In addition, the relative expression
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Figure 4.11: The eﬀect of poly(I:C) and shRNA expression on IFN and MxA
in ZF-4 cells at 15 ◦C
ZF-4s were grown under standard culture conditions (Untransfected) or incu-
bated with poly(I:C) (10 μg/ml) or transfected with appropriate shRNA ex-
pression vectors, and the expression of IFNφ1or MxA was analysed by real-time
PCR. The results are shown as the mean of two independent experiments and er-
ror bars indicate SEM. βActin served as the reference gene. A shRNA molecules
targeting the G gene. B shRNA molecules targeting the L gene.
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of both the inserted shRNAs as well as the native miR-107 was determined (Figure
4.12 C and
Table 4.2: Sequence of shRNA Scramble and G0906 sequences
shRNA Name Sequence Score ΔG (kcal/mol)
G0906 AT GTT GGT GAT GAG ATG GTT G 4 -13.1
Scramble TG GTT GGT GAT GAA TTG GTA GA 5 -14.7
4.6 Discussion
The primary aims of both Chapter 3 and 4 were to develop an optimised shRNA
expression system for use in zebraﬁsh, by the identiﬁcation and comparison of novel
zebraﬁsh type 3 RNA pol III promoters. This Chapter described the identiﬁcation
of 5 functional shRNA sequences, which proved to be eﬀective for the reduction of
VHS virus titre compared to either an shRNA targeting eGFP or to a virus speciﬁc
shRNA subsequently shown to fold incorrectly. As part of an important further
assessment of alternatives to pol III promoters, this Chapter also extended this
work to insert the most eﬀective shRNA into a previously generated eGFP Pank
1 intron. However, the temperature required for VHS virus replication inhibited
the eﬀectiveness of the intron to express shRNAs. Therefore, the opportunity to
inhibit VHS virus replication was impaired.
This study has identiﬁed 5 shRNA constructs that can strongly and signiﬁcantly
reduce VHS virus replication in zebraﬁsh cells. Targeting the glycoprotein gene
Figure 4.12 (preceding page): Pank1 intron is not a suitable method for in-
troducing shRNA expression in ZF-4 cells at 15 ◦C
A Relative mean ﬂuorescence intensity of eGFP expression at 28 ◦C and 15 ◦C re-
spectively. B Percentage transfection eﬃciency of cells transfected with pEGFP-
max or pEGFP-intron plasmids. C shScramble expressionD shG906 expression
EmiR107 expression. The results are shown as the mean of two independent ex-
periments, and error bars indicate SEM. U6 snRNA served as the reference gene
for all qRT-PCR analysis. All statistical analysis was performed by ANOVA
with Tukey’s post-test for multiple comparisons. * p ≥ 0.05. ** p ≥ 0.01. ***
p ≥ 0.001at 15 ◦C relative to the relevant sample at 28 ◦C
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was more eﬀective than targeting the viral polymerase, particularly at higher levels
of viral infection. shRNA eﬀectiveness also appears to be speciﬁc for VHS virus.
One identiﬁed shRNA was shown to fold incorrectly which not only prevented its
action on the VHS virus genome, but also induced a small interferon response. In
addition, the Pank 1 intron inserted into GFP with either scramble or the most
eﬀective shRNA, shG0906, did not reduce VHS virus titre signiﬁcantly as the
reduction in temperature from 28 ◦C to 15 ◦C appears to signiﬁcantly modify the
secondary folding of the intron such that either the intron is no longer eﬃciently
removed from the GFP mRNA or the shRNA and endogenous miRNA are no
longer excised.
As is discussed elegantly in [324], an ideal control to demonstrate speciﬁcity of action
of the shRNAs would be the use of a heterologous virus control. However, prelim-
inary infection experiments of ZF-4 cell with Infectious Hematopoietic Necrosis
virus (IHN virus), a closely related member of the novirhabdovirus family, showed
no evidence of CPE or viral RNA (data not shown). Despite the absence of this
additional control, the lack of signiﬁcant induction of either MxA or IFNβ follow-
ing transfection of shRNAs, along with the spread of relative knockdown between
diﬀerent shRNAs tested, provided strong evidence of a speciﬁc response.
The in silico identiﬁcation of microRNA targets is very complex and, despite sig-
niﬁcant research, remains a poorly understood ﬁeld. The rapid development of
small RNAseq and tools for cross-linked immuno-precipitation (CLIP), such as in-
dividual nucleotide-resolution CLIP (iCLIP) and photoactivatable ribonucleoside-
enhanced CLIP (PAR-CLIP), have rapidly increased the resolution of miRNA
target investigation. Application of these tools has led to the in vitro and in
vivo validation of in silico predictions of miRNA target and seed site predictions.
Unfortunately this had led to the realisation that in many cases miRNA target
prediction algorithms were ﬂawed or simply incorrect.
One major concern about the use of RNAi-based therapies for treatment of viral
infections is the potential for virus escape mutants that would then be resistant.
This is especially important in the case of RNA viruses as they are notoriously
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prone to mutation during replication often enabling escape from immune system
defence mechanisms [35]. Considering such mutations may also help escape attack
by sequence-dependent RNA silencing, highly conserved regions of the glycopro-
tein and polymerase genes were chosen as primary target areas. The viral L gene
has previously been shown to be a diﬃcult target for RNAi inhibition [307] requir-
ing constitutive expression of three independent shRNAs to produce a signiﬁcant
decrease in the number of infected cells by FACS. However, since that study used
diﬀerent shRNAs, it was diﬃcult to say deﬁnitively if the diﬃculty of targeting the
viral gene is related to the folding of the L mRNA, the selection of the shRNAs
or the requirement of the virus for lower levels of polymerase to produce func-
tional infectious particles. VHS virus is typical of rhabdovirus species in that the
further the gene is from the 5′ end of the genome the lower the expression of the
gene [109,159].
The application of RNAi has been of signiﬁcant impact in probing gene function
and is now promising to provide new strategies in the development of novel ther-
apeutics. The versatility of RNAi makes this technology particularly attractive
in the pursuit of therapies directed against viral diseases, including the many vi-
ral diseases of livestock. In the present study, it was shown that VHS virus, like
other single-stranded RNA viruses, was susceptible to degradation via the RNAi
pathway. Replication of VHS virus was eﬃciently suppressed using pol III-driven
shRNA-mediated RNAi, thereby providing a novel avenue for research into the
future prevention of VHS and other virus infections.
Chapter 5
Creation and characterisation of
transgenic zebraﬁsh
5.1 Introduction
The investigation of novel zebraﬁsh type 3 RNA pol III promoters for the expres-
sion of shRNAs in zebraﬁsh resulted in the characterisation of the zebraﬁsh H1
promoter and a novel zebraﬁsh U6 promoter and the construction of highly eﬃ-
cient plasmids for shRNA expression (see Chapter 3). These plasmids were used
to drive the expression of shRNAs designed to target either the glycoprotein (G)
or polymerase (L) genes of VHS virus. Following transfection, ﬁve of the six tested
shRNA molecules eﬀectively reduced VHS virus replication 10 fold or more across
a range of MOIs. The identiﬁed promoters and shRNAs enable generation of ex-
pression cassettes utilising the medaka ﬁsh Tol-2 transposon system for generating
shRNA expressing strains of zebraﬁsh (Figure 5.3).
The medaka ﬁsh Tol-2 element is an autonomous transposon that encodes a trans-
posase. This Tol-2 transposase can act upon any sequence bounded by the 200
and 150 base pairs of DNA from the left (TLE) and right ends (TRE) of the Tol-2
sequence, respectively (Figure 5.1). The TLE and TRE Tol-2 sequences contain
essential terminal inverted repeats and subterminal sequences, with DNA inserts
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of up to 11 kb able to be inserted between the TLE and TRE without reducing
transpositional activity [361]. The Tol-2 transposon system has been shown to be
active in many diﬀerent species, including zebraﬁsh, Xenopus, chicken, mouse, and
human both in vitro and in vivo [173,361].
In the Tol-2-based method of transgenic zebraﬁsh generation, a transposon-donor
plasmid and synthetic in vitro transcribed mRNA (Figure 5.1) encoding the trans-
posase will be microinjected into fertilized eggs. The transposase protein will be
translated from the injected mRNA and excise the transposon construct from
the donor plasmid, leading to stable integration of the excised DNA into the
genome [173–175,361]. The injected mRNA and the transposase protein will gradu-
ally degrade, and, after transposase activity has dissipated, the Tol-2 insertions
become stable. The integration events occur during early stages of embryonic
development with, some occurring in cells destined to produce primordial germ
cells. By outcrossing the injected founder (F0) ﬁsh, germline transmission of
Tol-2 insertions can be selected for in the F1 generation (Figure 5.2) [173–175,361].
While transgenic integration of RNAi inducing molecules has been established in a
range invertebrate models, for example, Drosophila, aedes aegypti mosquitos, and
Bombix mori silkworms [3,157,165], the integration of transgenic RNAi constructs in
vertebrates has not been as simple to accomplish. As has been discussed in depth
previously, the delivery of shRNA molecules via retroviral vectors to induce tissue
speciﬁc integration of the RNAi cassette resulted in the non-speciﬁc inhibition of
the endogenous miRNA pathway and increased morbidity and hepatic disease in
mice [119,126–129]. Attempts to generate transgenic knockdown zebraﬁsh have met
with mixed success. Recently, however, there has been a resurgence in attempts to
create heritable transgenic zebraﬁsh which express shRNA or miRNA like hairpins
that target genes of interest [15,96,333]. A reliable constitutively-expressed shRNA
system for zebraﬁsh has still yet to be realised, with the results discussed in this
chapter providing insight into the non-speciﬁc and varied eﬀects of RNAi previ-
ously observed in zebraﬁsh.
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Figure 5.1: Tol-2 transposable elements and basic shRNA vector.
A Structure of full-length Tol-2, with coding regions of the Tol-2 gene are in-
dicated by solid lines (exons) and dotted lines (introns). Grey boxes and white
boxes show coding regions and untranslated regions, respectively. Black arrow-
heads in boxes at both ends indicate 12 bp terminal inverted repeats (TIRs). B
Structure of the Tol-2 vector with the green ﬂuorescent protein (GFP) expres-
sion cassette and pol III expressed shRNA. The minimal Tol-2 vector contains
200 and 150 bp of DNA from the left and right ends, which include TIRs (black
arrows) and subterminal regions (open boxes).
Modiﬁed from [173–175,361].
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5.2 Construction and characterisation of Tol-2
expression plasmids
To facilitate the generation of an appropriate transposon plasmid for the produc-
tion of transgenic zebraﬁsh the pT2-002 was kindly provided by Dr Scott Tyack
(CSIRO, Geelong, Australia) (Figure 5.3 A). This plasmid contained the chicken
β-actin and human cytomegalovirus immediate early promoters (CAGGS) [147], to
drive expression of eGFP in chickens, as well as the Tol-2 TLE and TRE elements.
The Xenopus EF1α promoter was ampliﬁed from pEF-eGFP plasmid using the
primers EF1αBglII-F and EF1αBamHI-R and inserted into the BglII and BamHI
sites of the pT2-002 plasmid to generate pTol2-EF1α:GFP. Insertion of the pol III
type 3 shRNA construct was achieved by XhoI and SalI restriction enzyme diges-
tion of the pZFU6-2shG906 or pZFH1shG906 plasmids and ligation into pTol2-
EF1α:GFP-U62:shG0906 and pTol2-EF1α:GFP-H1:shG0906 respectively (see Fig-
ure 5.3). To test for eﬀective expression the plasmids were transfected into ZF-4
cells and expression of EGFP observed by ﬂuorescence microscopy (Figure 5.3 B),
while, expression of shRNAXenopus was measured by qRT-PCR (Figure 5.3 C).
Figure 5.2 (preceding page): Transgenesis in zebraﬁsh.
A Transposase gene is transcribed in vitro to produce 5′ capped and poly-A
tailed mRNA. The mRNA and Tol-2 construct containing the Xenopus EF1α
promoter eGFP and the relevant pol III type 3 promoter expressing either the
control shRNA or shG0906 are co-injected into fertilized zebraﬁsh eggs. B
Single-cell zebraﬁsh eggs injected with the Tol-2 constructs become the F0 gen-
eration. Germ cells of the FO ﬁsh are mosaic, and crossing with wild-type ﬁsh
yields nontransgenic ﬁsh and transgenic ﬁsh heterozygous for the Tol-2 inser-
tion. In this ﬁgure chimeric larvae are represented by random scattering of
green ﬂuorescence and heterozygous F1 ﬁsh by fully green adult ﬁsh.
Figure modiﬁed from [173–175,361].
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5.3 Full strength pol III promoters lead to high
levels of mutation and mortality in zebraﬁsh.
5.3.1 Microinjection of zebraﬁsh embryos
The Tol-2 transposon plasmids and transposase mRNA was introduced into ze-
braﬁsh by microinjection into fertilized eggs collected from wild-type mating ze-
braﬁsh pairs at the single cell stage. Eﬃciency of transposon incorporation and
required doses of Tol-2 system components were determined by titration of trans-
posase and control pTol2-EF1α:eGFP plasmid, with a 3:1 ratio of plasmid DNA
to transcribed capped mRNA at a ﬁnal concentration of 120 ng/μl determined to
be the most eﬀective solution. Increasing the DNA:RNA ratio past this concen-
tration resulted in increased mortality of embryos following expression of control
plasmid with no eﬀective increase in EGFP positive larvae (data not shown).
5.3.2 shRNA overexpression increases mortality and de-
velopmental defects in zebraﬁsh larvae
U6 and H1 shRNA expression plasmids were microinjected using the optimised
DNA:RNA rations and concentrations. Zebraﬁsh were injected with pTol2-EF1α:GFP-
U6:shRNA, and pTol2-EF1α:GFP-H1:shRNA were screened at 72 hpf for survival,
Figure 5.3 (preceding page): Construction and validation of pTol2-
EF1α:GFP-pol III:shRNA expression plasmids.
A The CCAGS promoter was excised from pT2-002 with BglII and BamHI
and the vector backbone used as the basis for the zebraﬁsh transposon plas-
mid. The EF1α promoter was ampliﬁed by PCR and ligated with the
same enzymes to form pTol2 EF1α:eGFP. The relevant pol III promoter and
shRNA cassette was also ampliﬁed by PCR and ligated into the XhoI site
using XhoI and SalI. The resultant plasmid was named pTol2-EF1α:GFP-
pol III:shRNA. B pTol2-EF1α:GFP, pTol2-EF1α:GFP-U6:shRNA, and pTol2-
EF1α:GFP-H1:shRNA were transfected into ZF-4 cells as indicated and EGFP
expression was monitored 72 hours post-transfection by ﬂuorescence microscopy.
Speciﬁc details of plasmids are included in Appendix B. C Expression of shRNA
hairpins from relevant U6 and H1 promoters. Expression was determined from
2 independent transfection and error bars indicate SEM.
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EGFP expression and normal morphology. Both pTol2-EF1α:GFP-U6:shRNA and
pTol2-EF1α:GFP-H1:shRNA transgenes induced signiﬁcantly decreased survival
of zebraﬁsh at 3 dpf and 7 dpf, as well as over the longer-term (Figure 5.4 A). No
zebraﬁsh that tested positive for expression of pTol2-EF1α:GFP-U6:shRNA, sur-
vived more than 7 weeks post fertilisation (wpf) (Figure 5.4 B). pTol2-EF1α:GFP-
H1:shRNA injected zebraﬁsh also showed decreased survival at all time points
compared to the controls(Figure 5.4 A & B) however, they did show signiﬁ-
cantly greater survival than pTol2-EF1α:GFP-U6:shRNA injected ﬁsh. In addi-
tion to decreased survival pTol2-EF1α:GFP-U6:shG0906, and pTol2-EF1α:GFP-
H1:shG0906 and transgenics were less common, and showed increased development
deformities than either control zebraﬁsh cells injected with either phenol red only
(WT), or pTol2-EF1α:eGFP compared to the latter (Figure 5.4 A & B).
Developmental deformities observed following transgene incorporation represented
a wide range of phenotypes (Figure 5.5A -G), which were spread relatively evenly
across the animal (Figure 5.5 H). This pattern of phenotypes matched well with
very early investigations of the eﬀects of RNAi-inducing long-dsRNA in zebraﬁsh
described in [269,371] (Figure 5.5 A) .
5.3.3 shRNA over-expression inhibits zebraﬁsh develop-
ment
The zebraﬁsh is a popular model of development and as such the stages of ze-
braﬁsh development are extremely well characterised. Determining the staging of
zebraﬁsh development by features is the a preferred method of determining the
stage of zebraﬁsh development [49,186,278] rather than simply counting the hours post
fertilization, as a large number of environmental and genetic factors can inﬂuence
the rate of zebraﬁsh development. In particular, water temperature [278], chemical
additives such as phenyl 2-thiourea (PTU) that is commonly added to maintain
the transparency of zebraﬁsh larvae, and manipulation can cause changes to the
timing of zebraﬁsh development.
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Figure 5.4: Expression of shRNAs from pol III type 3 promoters results in re-
duced survival and increased developmental defects in zebraﬁsh larvae and adults.
A Relative survival of zebraﬁsh. Surviving zebraﬁsh were counted weekly
following three independent rounds of injections of each construct; EGFP,
U6, and H1 indicate pTol2-EF1α:GFP, pTol2-EF1α:GFP-U6:shRNA, and
pTol2-EF1α:GFP-H1:shRNA respectively, WT indicates zebraﬁsh injected with
Danieu buﬀer and phenol red dye only. Mean percentage survival was calculated
from zebraﬁsh surviving at 7 dpf. B Eﬀects on zebraﬁsh up to 7 dpf. Mean
percentage of GFP positivity, survival, and nonspeciﬁc developmental defects
are shown for transgene cassettes included in A Numbers of injected zebraﬁsh
in each group are included below. * p ≤ 0.05 compared to WT, † p ≤ 0.05
compared to EGFP.
Name n
WT 400
EGFP 212
U6 461
H1 385
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In addition to the obvious morphological abnormalities and increased mortality,
at 3 dpf it was apparent that embryos injected with shRNA expression constructs
were smaller, less developed, and more likely to remain within the chorion (Fig-
ure 5.6 A). Standard length of zebraﬁsh embryos (SL) is a consistent measure of
zebraﬁsh development (Figure 5.6 B), which has been used to estimate develop-
mental stage of zebraﬁsh larvae [186,278]. Standard length (SL)of larvae is considered
in this project to be the minimum straight line distance from the tip of the snout
to the posterior tip of the notochord [278] (Figure 5.6). In addition the head to
trunk angle (HTA) , which determines the angle, formed between a line connect-
ing the snout and midpoint of the head and anther between this point and the
caudal tip of the tail was assessed at 3 dpf (Figure 5.6 C). To quantify this slow-
ing of normal development the mean HTA and SL of zebraﬁsh larvae groups was
determined at 3 dpf and 7 dpf respectively. pTol2-EF1α:GFP-U6:shRNA, and
pTol2-EF1α:GFP-H1:shRNA groups were signiﬁcantly slower to develop relative
to the two controls, pTol2-EF1α:GFP and phenol red only, at both time points
and pTol2-EF1α:GFP-U6:shRNA, showed a further signiﬁcant retardation slower
at 7 dpf compared to pTol2-EF1α:GFP-H1:shRNA (Figure 5.6 D & E).
Figure 5.5 (preceding page): Expression of shRNAs in developing zebraﬁsh
increases overt morphological abnormalities
Light microscope images at 72 hpf of A WT zebraﬁsh head (dorsal view) B
WT zebraﬁsh head (ventral view) CWT zebraﬁsh tail ventral view and injected
embryos with developmental deformitiesD - G.H Comparison of the frequency
of developmental defects at 72 hpf to head or tail of embryos.1 mm scale bars.
Name n
WT 400
EGFP 212
U6 461
H1 385
Chapter 5. Creation and characterisation of transgenic zebraﬁsh 128
B
H
TA
 (D
eg
re
es
)
WT eGFP U6 H1
110
120
130
140
150
160
170
180
C D
St
an
da
rd
 L
en
gt
h 
(m
m
)
WT GF
P U6 H1
2.5
3.0
3.5
4.0
4.5
5.0
†
*
#
*
†
pEF1_:eGFP U6:shG0906pEF1_:eGFP H1:shG0906pEF1_:eGFP
A
E
Chapter 5. Creation and characterisation of transgenic zebraﬁsh 129
5.3.4 shRNA overexpression causes increased mortality and
developmental abnormalities in zebraﬁsh in a sequence
independent manner
To ensure that the shG0906 shRNA was not mediating a non-speciﬁc RNAi re-
sponse, additional shRNA vectors were created using the U6 and H1 promoters
including the shRNA scramble or a second anti-VHS virus shRNA shG1207: pTol2-
EF1α:GFP-U62:shScramble, pTol2-EF1α:GFP-U62:shG1207, pTol2-EF1α:GFP-
H1:shG1207, and pTol2-EF1α:GFP-H1:shScramble using the same strategy was
used as for pTol2-EF1α:GFP-U62:shG0906 and pTol2-EF1α:GFP-H1:shG0906 plas-
mids (see Figure 5.2). To test for eﬀective expression the plasmids were trans-
fected into ZF-4 cells and expression of EGFP observed by ﬂuorescence microscopy
and expression of shRNAs measured by qRT-PCR. shRNA expression and EGFP
ﬂuorescence from these plasmids were equivalent to that observed from pTol2-
EF1α:GFP-U62:shG0906 and pTol2-EF1α:GFP-H1:shG0906 (Data not shown).
Figure 5.6 (preceding page): shRNA overexpression inhibits zebraﬁsh devel-
opment.
A Fluorescent microscope images of EGFP expression in zebraﬁsh injected with
the indicated constructs at 3 dpf. B Head to Trunk angle (HTA) in 3 dpf
embryos indicated with blue lines between snout and midpoint of the head and
this point and the caudal tip of the tail. The red box indicates the measured
angle. C Measurement points of standard length indicated by thick red lines
and total standard length indicated by blue dotted lines. D Head to Trunk
angle of zebraﬁsh larvae, measured as described previously using ImageJ at
3 dpf. n = phenol red (WT) (30), pTol2-EF1α:eGFP (EGFP) (30), pTol2-
EF1α:eGFP U6:shG0906 (U6) (30) and pTol2-EF1α:eGFP H1:shG0906 (H1)
(30). E) Standard length of zebraﬁsh larvae, measured as described previously
using ImageJ at 7 dpf, using the same constructs as above. All ﬁgures are
representative of at least 3 independent inoculations. * p ≤ 0.05 relative to the
Phenol Red control (WT), † p ≤ 0.05 indicates diﬀerence to pTol2-EF1α:GFP
(EGFP), # p ≤ 0.05 indicates diﬀerence to pTol2-EF1α:GFP-H1:shG0906 (H1),
pTol2-EF1α:GFP-U6:shG0906 (U6).
Name n
WT 400
EGFP 212
U6 461
H1 385
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The various shScramble and shG1207 plasmids were also introduced into zebraﬁsh
embryos by microinjection and subjected to the same measurements as the original
shRNA vectors (Figure 5.7). The new transgene vectors induced no signiﬁcant in-
creases in survival, or decreased non-speciﬁc developmental abnormalities relative
to the equivalent shG0906 shRNA constructs (Figure 5.7 A - D), suggesting that
the observed development abnormalities and mortality are unrelated to sequence-
speciﬁc responses.
5.3.5 Mortalities and developmental defects induced by
shRNA overexpression is not dependent on p53
Expression of shRNAs from pol III promoters appears to induce dose-dependent
developmental defects and phenotypes in zebraﬁsh embryos. However, anti-sense
nucleic acid analogues with a morpholine backbone, called morpholinos (MO) have
previously been shown to induce tumor-protein p53 (p53) related mortality in
zebraﬁsh [301], which are similar to those observed in this study [39,197,301]
MOs bind to target mRNA via Watson-Crick base pairing in a similar manner
to RNAi inducing molecules however the modiﬁcations in the chemical makeup
of the oligonucleotides prevents the MOs inducing RISC or RNase H mediated
degradation of mRNA, with MO’s acting by inhibiting translation or normal splic-
ing [39,97,101,138,340,346]. However, MO inhibition of translation has been shown to
induce non-speciﬁc neural defects in 15-20% of all MO experiments carried out in
zebraﬁsh [101,301]. These non-speciﬁc defects are proposed to derive from the acti-
vation of p53 and consequent p53-induced apoptosis [39,101,301]. A MO that targets
the translation start site of p53 is eﬀective at inhibiting non-speciﬁc phenotypes
following injection of many MOs [101,301].
To ensure that non-speciﬁc p53 induced apoptosis was not responsible for the
phenotypes of delayed development, phenotypic defects and increases in mortality
following shRNA injection in zebraﬁsh, p53 morpholinos were co-injected alongside
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Figure 5.7: shRNA induced developmental defects are independent of shRNA
sequence.
A shRNA sequences and predicted secondary structures B Percentage of EGFP
positive zebraﬁsh at 7 dpf following inoculation with shRNA expression plas-
mids. C Survival of zebraﬁsh at 7 dpf following inoculation with shRNA ex-
pression plasmids. D HTA at 3 dpf. Graphs shown with mean from at least
3 independent microinjection rounds, and error bars represent SEM. Statistical
analysis by Two-way ANOVA. * p ≤ 0.05 relative to the Phenol Red control
(WT), † p ≤ 0.05 indicates diﬀerence to pTol2-EF1α:GFP (EGFP)
Name n
WT 317
EGFP 381
U6 320
H1 400
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shRNA and eGFP expression plasmids and transposase mRNA. Injection of p53-
speciﬁc morpholinos did not rescue aﬀect transgene incorporation but also did not
result in rescue of normal development. It is therefore unlikely that p53 induced
apoptosis is an explanation for the phenotypes observed following shRNA injection
into developing zebraﬁsh (See Figure 5.8).
5.3.6 shRNA overexpression inhibits miRNA expression
in developing zebraﬁsh
Over-expression of shRNA molecules has previously been shown to inhibit the
normal accumulation and functions of endogenous miRNAs [128]. To determine
whether a similar response could be occurring in these zebraﬁsh, qRT-PCR was
used on six diﬀerent miRNA targets to determine whether shRNA expression was
impacting on the normal levels of these miRNAs. These miRNAs were previously
identiﬁed to either be crucial or representative of the normal development, or from
diﬀerent miRNA biogenesis pathways. In particular, miR-451 has been identiﬁed
as a dicer independent miRNA and is dependent on catalytic cleavage by Ago2 for
cleavage into a mature miRNA from a pri-miRNA [65,280,389], and so may be more
sensitive to Ago2 sublimation and inhibition.
Following microinjection RNA was harvested at 7 dpf from pooled embryos, and
relative miRNA expression determined by qRT-PCR. The expression of individual
miRNAs failed to reach statistical signiﬁcance as the miRNAs changed expression
by less than 50%. However, when the relative expression across all six miRNAs was
examined by ANOVA, pTol2-EF1α:GFP-U6:shG0906 signiﬁcantly reduced overall
miRNA expression in 7 dpf zebraﬁsh larvae (p ≤ 0.05) (Figure 5.9).
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Figure 5.8: Over-expression of shRNA does not induce p53-related develop-
mental defects in developing zebraﬁsh.
A Chemical structures of morpholino, RNA, and DNA backbones (Modiﬁed
from [341]). B Mean-survival of zebraﬁsh embryos co-injected with (Dark grey
bars) or without (Light grey bars) p53 morpholino in addition to the relevant
transgene and transposase. C Relative transgenisis as determined by percentage
of GFP positive embryos by ﬂuorescence microscopy at 7 dpf D Standard length
of zebraﬁsh larvae, measured as described previously using ImageJ at 7 dpf.
Error bars show SEM. Statistical analysis by Two-way ANOVA. Injections were
performed on at least three independent occasions for each construct.
Name n
WT 278
EGFP 345
U6 300
H1 465
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Figure 5.9: Over-expression of shRNA reduces miRNA levels in developing
zebraﬁsh.
Following microinjection of zebraﬁsh embryos with the relevant Tol-2 con-
structs; U6 (pTol2-EF1α:GFP-U6:G0906), H1 (pTol2-EF1α:GFP-H1:G0906),
EGFP (pTol2-EF1α:GFP) or the WT (phenol-red only) control pooled 7 dpf
zebraﬁsh were homogenised from three independent rounds of injection. Rel-
ative expression of the 6 independent miRNAs indicated was determined via
ΔΔCt compared to WT and 5S as the endogenous control.
Name n
WT 368
EGFP 297
U6 314
H1 295
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5.4 Modiﬁcation of pol III promoters to modu-
late shRNA expression
The initial aim of this study was to validate the potential for the highly eﬀective
U6 and H1 promoters identiﬁed in Chapter 3 to mediate the in vivo expression
of shRNAs targeted at VHS virus. However, these promoters have proven to
be inappropriate for use in vivo. Therefore shRNA expression vectors were con-
structed using modiﬁed U6 and H1 promoters to express the most eﬀective shRNA
sequences at potentially tolerable levels in zebraﬁsh.
The pol III promoters were altered to remove speciﬁc promoter elements and
weaken the promoters. To determine whether modiﬁcation of the promoters would
result in reduced expression of the shRNAs, and whether such reduced expression
would result in rescue of normal development and survival, eight modiﬁed pro-
moters were designed (Figure 5.10).
The zebraﬁsh U6 promoter was modiﬁed to remove the Oct-1 element (U6-Oct),
to shorten the promoter to approximately half its original length (U6-Half), to
remove the SPH element from the PSE (U6-SPH) and to remove the TATA box
(U6-TATA). The H1 promoter was similarly modiﬁed; however, as the DSE of
the H1 promoter contains both an Oct-1 and a SPH element, both the SPH and
Oct-1 elements were removed instead (H1-DSE) (Figure 5.10). In the case of the
U6-SPH and H1-SPH constructs, the spacing between the SPH element and the
+1 site of transcription was maintained by the insertion of random nucleotides.
The U6-TATA and H1-TATA were constructed by the ampliﬁcation of two over-
lapping regions, which were subsequently joined by recombinant PCR. shG0906
and shScramble were added to the start site of transcription by one-step PCR
as described in Chapter 4. Following PCR ampliﬁcation the resulting promoter -
shRNA constructs were inserted into the pTol2-EF1α:eGFP vector using the XhoI
and SalI cloning sites.
Injection of the constructs containing the modiﬁed promoters into zebraﬁsh em-
bryos elicited a clear reduction in overt developmental defects and a signiﬁcant
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Oct-1 SPH TATA
SPH TATA
Oct-1 TATA
SPH TATA
Oct-1 SPH
Oct-1 SPH TATAPSE
SPH TATAPSE
TATAPSE
Oct-1 SPH TATA
Oct-1 SPH PSE
H1 Promoter modificationU6 Promoter modification
U6
U6 Oct
U6 Half
U6 SPH
U6 TATA
H1
H1 Oct
H1 DSE
H1 SPH
H1 TATA
Figure 5.10: Summary of the modiﬁed U6 and H1 promoters.
Graphical representation of modiﬁcations made to the indicated promoter ele-
ments to ablate expression in second-generation Tol-2 constructs.
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increase in survival (Figure 5.11 B) This was evident for all modiﬁcations to the
U6 or H1 promoters relative to the unmodiﬁed promoter. The levels of shRNA
expression from the modiﬁed promoters were reduced as expected (Figure 5.11
A) which correlated to the increased survival of the zebraﬁsh larvae to 7 dpf.
Modiﬁcation to remove the DSE elements from either promoter by either remov-
ing the Oct-1 motif or the Oct-1 and SPH as appropriate resulted in 86% and
45% reduction in shG0906 expression in the U6 and H1 driven promoters respec-
tively. Removal of any part of the PSE of either the U6 or H1 promoter resulted
in complete block of transcription from all constructs (Figure 5.11 A). As well
as increasing overall survival of the zebraﬁsh larvae modulation of shRNA dose
additionally partially rescued zebraﬁsh development at 3 dpf (Figure 5.11 C) and
7 dpf (Figure 5.11 D). All modiﬁcations made to the U6 promoter signiﬁcantly
increased developmental stage as determined by HTA relative to both eGFP only
expression and unmodiﬁed U6. Only the H1 DSE modiﬁed promoter lead to a
signiﬁcantly increased HTA relative to the H1 promoter (Figure 5.11 C). Likewise
at 7 dpf, modiﬁcation of promoters to reduce shRNA expression resulted in the
dose dependent rescue of zebraﬁsh developmental delay.
5.5 Over-expression of human Argonaute 2 and
Exportin-5 in zebraﬁsh larvae partially
rescues developmental abnormalities and
mortality from over-expression of shRNA
molecules
Dose-dependent increases in mortality and deformities of zebraﬁsh following ex-
pression of shRNAs suggested that the introduced shRNAs were having sequence
speciﬁc oﬀ-target eﬀects or that the volume of shRNA molecules being introduced
was greater than could be tolerated by the organism. Considering the observed
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Figure 5.11: Relative quantitation of shRNA expression following promoter
modiﬁcation.
A qRT-PCR analysis of shG0906 expression 2 dpf in embryos injected with
shRNA expression constructs. B Mean percentage survival of microinjected ze-
braﬁsh embryos with modiﬁed promoters at 7 dpf. C Individual HTA at 3 dpf.
D Standard lengths of zebraﬁsh larvae at 7 dpf. For visualisation purposes a
representative sample of individual values are displayed from a single injection
round in C & D. However, mean and SEM displayed, were calculated from at
least 3 rounds of injections and n = 30 for each construct micro-injected.* indi-
cates P ≤ 0.05 diﬀerence to eGFP (No shRNA control). †, p ≤ 0.05 diﬀerence to
U6 (Full-strength U6 promoter), # p ≤ 0.05 diﬀerence to H1 (Full-strength H1
promoter). Total numbers of zebraﬁsh injected for this experiment are included
below:
Name n Name n
eGFP 397
U6 267 H1 297
U6 Oct-1 240 H1 Oct-1 310
U6 Half 211 H1 PSE 209
U6 SPH 301 H1 DSE 297
U6 TATA 391 H1 TATA 414
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eﬀect was dose-dependent and that multiple shRNA molecules introduced simi-
lar patterns of abnormal development and mortality, it seemed more likely that
the amount rather than the sequence of the introduced was responsible for the
problems observed. Xpo-5 and Ago2 have previously been identiﬁed as rate lim-
iting steps aﬀected by expression of shRNAs in mice [128,129]. To investigate this,
plasmids encoding Flag-tagged hAgo2 and hXpo5 (pQE60-Exp5 and pIRESneo-
Flag/HA Ago2) were kindly provided by Dr Scott Tyack. Capped and poly-A
tailed mRNA was transcribed from the plasmids following linerisation with XbaI
and HpaI, respectively (Figure 5.2). Expression of Flag tagged proteins was con-
ﬁrmed by Western blot analysis (Figure 5.12 B).
Previous work has shown that Xenopus embryos injected with shRNA and siRNA
constructs did not respond to RNAi induction until human argonaute2 (hAgo2)
mRNA was co-injected along with the RNAi inducing molecules [113,227]. Inter-
estingly for this project, this work implies that RNAi functions in developing
organisms might not be mature at all stages of organism development and further
demonstrates that hAgo2 is functional in Xenopus. Many of the RNAi genes are
highly conserved across species and MUSCLE alignment of Ago2 and Xpo-5 from
zebraﬁsh and human indicated showing homology (Figure 5.12 A). The function-
ality of hAgo2 in Xenopus as well as the high sequence conservation, particularly
across the functional domains, suggests that the human proteins are likely to also
be functional in zebraﬁsh [128,129,364].
To assess whether over-expression of either hXpo5 or hAgo2 in zebraﬁsh produced
deleterious eﬀects, the panel of developmental assays were repeated on zebraﬁsh
embryos microinjected with mRNA encoding hXpo5 (Figure 5.13 A - D) and
hAgo2 (Figure 5.13 E - H) at concentrations between 50 - 300 pg/nL. Over-
expression of hXpo5 signiﬁcantly inhibited zebraﬁsh larvae growth at 3 dpf and 7
dpf at 300 pg/nl as well as at 100 pg/nL at 7 dpf. Over-expression of hAgo2 at
200 pg/nL signiﬁcantly decreased zebraﬁsh size and length at 7 dpf but did not
signiﬁcantly decrease rates of survival to 7 dpf or HTA at 3 dpf. There was also
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 Human   1            MYSG---AGPALAPPAPPPPIQGYAFKPPPRPDFGTSGRTIKLQANFFE  
 Zebrafish  1  MYPIGAAGATELFQGRPSSGSDVSAPASPPAPQEYVFKPPQRPDFGTMGRTIKLQANFFE  
    
 Human   47  MDIPKIDIYHYELDIKPEKCPRRVNREIVEHMVQHFKTQIFGDRKPVFDGRKNLYTAMPL  
 Zebrafish  61  MEIPKLEVYHYEIDIKPEKCPRGVNREIVEHMVQHFKTQIFGDRKPVYDGRKNLYTAMPL  
    
 Human   107  PIGRDKVELEVTLPGEGKDRIFKVSIKWVSCVSLQALHDALSGRLPSVPFETIQALDVVM  
 Zebrafish 121  PIGRDKVELEVTIPGEGKDRSFKVAIKWMSCVSLQALHEALSGRLPNIPFETIQALDVVM  
    
 Human   167  RHLPSMRYTPVGRSFFTASEGCSNPLGGGREVWFGFHQSVRPSLWKMMLNIDVSATAFYK  
 Zebrafish 181  RHLPSMRYTPVGRSFFTPSEGCSNPLGGGREVWFGFHQSVRPSLWKMMLNIDVSATAFYK  
    
 Human   227  AQPVIEFVCEVLDFKSIEEQQKPLTDSQRVKFTKEIKGLKVEITHCGQMKRKYRVCNVTR  
 Zebrafish 241  AQPVIEFMCEVLDFKSIEEQQKPLTDSQRVKFTKEIKGLKVEITHCGQMKRKYRVCNVTR  
   
                        PAZ Domain 
 
 Human   287  RPASHQTFPLQQESGQTVECTVAQYFKDRHKLVLRYPHLPCLQVGQEQKHTYLPLEVCNI  
 Zebrafish 301  RPASHQTFPLQQENGQTIECTVAQYFKDKYKLVLRYPHLPCLQVGQEQKHTYLPLEVCNI  
 Human   347  VAGQRCIKKLTDNQTSTMIRATARSAPDRQEEISKLMRSASFNTDPYVREFGIMVKDEMT  
 Zebrafish 361  VAGQRCIKKLTDNQTSTMIRATARSAPDRQDEISKLMRSANFNTDPYVREFGVMVRDDMT  
    
 Human   407  DVTGRVLQPPSILYGGRNKAIATPVQGVWDMRNKQFHTGIEIKVWAIACFAPQRQCTEVH  
 Zebrafish 421  EVNGRVLQAPSILYGGRNKAIATPVQGVWDMRNKQFHTGIEIKVWAIACFAPQRQCTELL  
    
 Human   467  LKSFTEQLRKISRDAGMPIQGQPCFCKYAQGADSVEPMFRHLKNTYAGLQLVVVILPGKT  
 Zebrafish 481  LKAFTDQLRKISRDAGMPIQGQPCFCKYAQGADSVEPMFKHLKYTYQGLQLVVVILPGKT  
    
 Human   527  PVYAEVKRVGDTVLGMATQCVQMKNVQRTTPQTLSNLCLKINVKLGGVNNILLPQGRPPV  
 Zebrafish 541  PVYAEVKRVGDTVLGMATQCVQVKNVQKTTPQTLSNLCLKINVKLGGVNNILLPQGRPLV  
   
                       PIWI Domain 
 
 Human   587  FQQPVIFLGADVTHPPAGDGKKPSIAAVVGSMDAHPNRYCATVRVQQHRQEIIQDLAAMV  
 Zebrafish 601  FQQPVIFLGADVTHPPAGDGKKPSIAAVVGSMDAHPSRYCATVRVQQHRQDIIQDLATMV  
    
 Human   647  RELLIQFYKSTRFKPTRIIFYRDGVSEGQFQQVLHHELLAIREACIKLEKDYQPGITFIV  
 Zebrafish 661  RELLIQFYKSTRFKPTRIIYYRDGISEGQFNQVLQHELLAIREACIKLEKDYQPGITFVV  
    
 Human   707  VQKRHHTRLFCTDKNE----------------------------------RGTSRPSHYH  
 Zebrafish 721  VQKRHHTRLFCMDRNERVGKSGNIPAGTTVDTKITHPFEFDFYLCSHAGIQGTSRPSHYH  
    
 Human   733  VLWDDNRFSSDELQILTYQLCHTYVRCTRSVSIPAPAYYAHLVAFRARYHLVDKEHDSAE  
 Zebrafish 781  VLWDDNHFTSDELQVLTYQLCHTYVRCTRSVSIPAPAYYAHLVAFRARYHLVDKEHDSAE  
    
 Human   793  GSHTSGQSNGRDHQALAKAVQVHQDTLRTMYFA  
 Zebrafish 841  GSHTSGQSNGRDQQALAKAVQIHQDTLRTMYFA  
 
Human   1  MAMDQVNALCEQLVKAVTVMMDPNSTQRYRLEALKFCEEFKEKCPICVPCGLRLAEKTQV  
 Zebrafish  1  MGEQMRALCEELIKAVNVMMEAESSQTYRLEAFKFIEDFKEKSPFCVECGLQLAEKSQT  
   
Importin-beta N-terminal 
 
 Human   61  AIVRHFGLQILEHVVKFRWNGMSRLEKVYLKNSVMELIANGTLNILEEENHIKDALSRIV  
 Zebrafish  60  AVIRHFGLQILEHVVKFRWNNMAPQDKLQLKNCTMGMLSNGTHPILQEECHVKDALSRIV  
   
                                                    Exportin 1-like 
 
 Human   121  VEMIKREWPQHWPDMLIELDTLSKQGETQTELVMFILLRLAEDVVTFQTLPPQRRRDIQQ  
 Zebrafish  120  VEMIKREWPQQWPDMLKEMEALTALGDAQTELVMLVLLRLAEDVITFQTLPSQRRRDIQQ  
    
 Human   181  TLTQNMERIFSFLLNTLQENVNKYQQVKTDTSQESKAQANCRVGVAALNTLAGYIDWVSM  
 Zebrafish  180  TLTQNMDSVFTFLLGILQLHVNEYSKMKCVAGLDLKMKAHLRVGVATLNTLAGYIDWVSL  
    
 Human   241  SHITAENCKLLEILCLLLNEQELQLGAAECLLIAVSRKGKLEDRKPLMVLFGDVAMHYIL  
 Zebrafish  240  SHITSQNCRLLEILCLLLSEPELQLEAAECLLIAISRKGKLEERKPFMVLFDEAAMNYIL  
    
 Human   301  SAAQTADGGGLVEKHYVFLKRLCQVLCALGNQLCALLGADSDVETPSNFGKYLESFLAFT  
 Zebrafish  300  SAAQSS--GGIDERRYTFLKRLCQVLCALGSQVCSLVGSDVEVQVPVNLNKYLEALLAFT  
    
 Human   361  THPSQFLRSSTQMTWGALFRHEILSRDPLLLAIIPKYLRASMTNLVKMGFPSKTDSPSCE  
 Zebrafish  358  THPSQFLRSSTQMTWGIIFRHEILSKDPVVGQMAIKYLRATRINLVKTGFPSKNDCPGCE  
    
 Human   421  YSRFDFDSDEDFNAFFNSSRAQQGEVMRLACRLDPKTSFQMAGEWLKYQLSTFLDAG---  
 Zebrafish  418  FSRVDFDSDEDFNSSFNSSRAQQGEAVRLTCRIVPFKAFQIARDWMQYQISTPIDAGKTT  
    
 Human   478  -SVNSCSAVGTGEGSLCSVFSPSFVQWEAMTLFLESVITQMFRTLNREEIPVNDGIELLQ  
 Zebrafish  478  DNCKAVLALGTTEKGLCSPLSPSVVQWEAMTTFTENVFGQLFKILEKEKLPIDEGMALLQ  
    
 Human   537  MVLNFDTKDPLILSCVLTNVSALFPFVTYRPEFLPQVFSKLFSSVTFETVEESKAPRTRA  
 Zebrafish  538  IAVNFETRDPLILSCVLTIVSTLFPILTHRPHFLPQVLFKIFSAITFELVDERKAPRTRA  
    
 Human   597  VRNVRRHACSSIIKMCRDYPQLVLPNFDMLYNHVKQLLSNELLLTQMEKCALMEALVLIS  
 Zebrafish  598  VKNVRRHACSSIIRICRDYSDFMLPCFDLMYEHVKRLFSDELLLTQLEKCALMEALILIS  
    
 Human   657  NQFKNYERQKVFLEELMAPVASIWLSQDMHRVLSDVDAFIAYVGTDQKSCDPGLEDPCGL  
 Zebrafish  658  NQFKDYKKQKAFLEELMAPVTALWLSEEMRSVLWDPATFLTFVGADQEISDSDTDEQMGI  
    
 Human   717  NRARMSFCVYSILGVVKRTCWPTDLEEAKAGGFVVGYTSSGNPIFRNPCTEQILKLLDNL  
 Zebrafish  718  NRSRISLCVHTILGVVKRARWPADADQAKAGGFVVRTASDGTPVYRNPCAEALQALLPNL  
    
 Human   777  LALIRTHNTLYAPEMLAKMAEPFTKALDMLDAEKSAILGLPQPLLELNDSPVFKTVLERM  
 Zebrafish  778  LALIRTNNSLFLPENITRLSKTFARVYDITDMEKNCVLGISQVVLDSYEAAVYKNFAERM  
    
 Human   837  QRFFSTLYENCFHILGKAGPSMQQDFYTVEDLATQLLSSAFVNLNNIPDYRLRPMLRVFV  
 Zebrafish  838  QGFFSSLFENCYHVLGNVGPCLQQDFYGIEGLAEQIVGSAFNHLDSVPDHRLR-------  
    
 Human   897  KPLVLFCPPEHYEALVSPILGPLFTYLHMRLSQKWQVINQRSLLCG--EDEAADENPESQ  
 Zebrafish  891  -PLIHILEITIFHTFAKVVF--FFFSKKQRLNFRWQIINQRASLSAQEEEEAYEENHVTQ  
    
 Human   955  EMLEEQLVRMLTREVMDLITVCCVSKKGADHSSAPPADGDDEEMMATEVTP-----SAMA  
 Zebrafish  948  EMVEEQLLRLVTREVMDLLSVTCITRKCPEVNANKEEADGDEEMVSMDSSQGNQVNTPSD  
    
 Human   1010  ELTDLGKCLMKHEDVCTALLITAFNSLAWKDTLSCQRTTSQLCWPLLKQVLSGTLLADAV  
 Zebrafish 1008  ELSDLGKCLLQSEDIYMTVLTICFNCLSWKDTVNCQRTAGVLCWTLLKQVQGGNLLPEAV  
    
 Human   1070  TWLFTSVLKGLQMHGQHDGCMASLVHLAFQIYEALRPRYLEIRAVMEQIPEIQKDSLDQF  
 Zebrafish 1068  TWLFASVLKGLQMHGQHEGCNVALTQLALLIYESLRPRYAELRLIMNQIPDVQADALEQF  
    
 Human   1130  DCKLLNPSLQKVADKRRKDQFKRLIAGCIGKPLGEQFRKEVHIKNLPSLFKKTKPMLETE  
 Zebrafish 1128  DQKIQ-PGASKLGEKKKKEQFRRLIAGTVGKPLAQQFKKEVHIRNLPSLFKKPKPTKD-L  
    
 Human   1190  VLDNDGGGLATIFEP  
 Zebrafish 1186  LENNEDATLISLFTPDHDRC  

Xpo5     Ago2
A
B
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no signiﬁcant diﬀerence in miRNA expression at 3 dpf following inoculation with
100 pg/nl to 200 pg/nl mRNA relative to phenol red control (WT).
Studies next sought to determine if co-injection of zebraﬁsh embryos with shRNA
constructs and either hAgo2 or hXpo5 or both simultaneously would rescue nor-
mal development. Embryos were therefore injected with either phenol red con-
trols (WT), pTol2-EF1α:GFP-U62:shG0906 (U6 Uninfected), pTol2-EF1α:GFP-
H1:shG0906 (H1 uninfected), either 100 pg/nL hAgo2 or hXpo5 with phenol red, or
with pTol2-EF1α:EGFP (GFP), pTol2-EF1α:GFP-U62:shG0906 (U6), or pTol2-
EF1α:GFP-H1:shG0906 (H1) or alternatively with both hAgo2 and hXpo5 ( each
100 pg/nL) in the presence or absence of the respective test plasmids. None of
the combinations of injections were able to signiﬁcantly improve either survival of
zebraﬁsh larvae (Figure 5.14 A & E) or prevent gross morphological abnormalities
of zebraﬁsh larvae following overexpression of shRNAs (Figure 5.14 B & D). How-
ever, increased hAgo2 expression following microinjection of mRNA signiﬁcantly
increased zebraﬁsh development at 7 dpf of both pTol2-EF1α:GFP-U6:shG0906 of
pTol2-EF1α:GFP-H1:shG0906 transgenic zebraﬁsh and similarly increased hXpo5
expression rescued development of pTol2-EF1α:GFP-H1:shG0906 but not pTol2-
EF1α:GFP-U6:shG0906 at 7 dpf (Figure 5.14 C & D, G & H).
In addition, co-injection of both hAgo2 and hXpo5 as well as the expression of
hAgo2 alone but not hXpo5 alone was able to rescue normal miRNA expression
in pooled zebraﬁsh larvae (Figure 5.15). Interestingly, as observed in Section
Figure 5.12 (preceding page): Alignment of human and zebraﬁsh Argonaute
2 and Exportin 5 proteins.
A Clustal W2 [67] alignment of human Ago2 (NP 036286.2) and from Xpo5 (NP
065801.1) and zebraﬁsh Ago2 and Xpo5 (NP 699226.2 and NP 001921422.4
respectively). Non conserved amino acids are indicated by Bold text. The
Ago2 Paz domain is highlighted in Red and the Piwi domain highlighted in
Blue. The Xpo5 Importin-beta N-terminal domain is highlighted in Green and
the Exportin 1-like domain is highlighted in Pink. B Expression of Flag tagged
Xpo5 and Ago2 protein expressed following microinjection with pQE60-Exp5
and pIRESneo-Flag/HA Ago2, respectively. Protein was harvested from pooled
zebraﬁsh larvae and expression of Xpo5 and Ago2 assessed by Flag antibody.
GAPDH was included as a loading control.
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5.3.6, there were no signiﬁcant diﬀerences between individual miRNAs but overall
miRNA expression observed were signiﬁcantly restored.
5.6 Discussion
The work presented in thesis collectively details the construction of a Tol-2-based
approach for the constitutive expression of shRNAs targeting VHS virus in trans-
genic zebraﬁsh. Native zebraﬁsh promoters were characterised in Chapter 3 and
eﬀective shRNA molecules identiﬁed in Chapter 4. However, combining these
promoters and shRNAs with Tol-2 vectors in zebraﬁsh embryos resulted in signiﬁ-
cant mortality, development defects and developmental delay. Indeed, of the 1134
Figure 5.13 (preceding page): Characterisation of hXpo5 and hAgo2 over-
expression in zebraﬁsh larvae.
A Percentage survival of zebraﬁsh embryos inoculated with 50 - 300 pg/nL
pQE60-Exp5 (Xpo5) to 7 dpf. B Head to Trunk angle of zebraﬁsh embryos in-
oculated with 50 - 300 pg/nL pQE60-Exp5 at 3 dpf. Mean and SEM indicated
from representative samples. qRT-PCR was performed on technical triplicates
from 3 independent injection sessions. C Head to trunk angle of representative
(n=30) sample of zebraﬁsh larvae at 3 dpf. Dark grey symbols are representa-
tive of single injections. Black symbols are representative of hAgo2 co-injections
or of hAgo2 only and light grey symbols representative of hXpo5 only or hXpo5
co-injection. D Standard length of zebraﬁsh larvae at 7 dpf. Symbols and
samples as per (C). E Percentage survival of zebraﬁsh embryos inoculated with
50 - 300 pg/nL pIRESneo-Flag/HA Ago2 (Ago2) to 7 dpf. F Head to Trunk
angle of zebraﬁsh embryos inoculated with 50 - 300 pg/nL pIRESneo-Flag/HA
Ago2 at 3 dpf, with mean and SEM indicated from representative samples n=30
from 3 independent injection sessions. G Standard length of zebraﬁsh larvae
inoculated with 50 - 300 pg/nL pIRESneo-Flag/HA Ago2 at 7 dpf, Mean and
SEM indicated from representative samples n=30 from 3 independent injection
sessions H qRT-PCR determined expression of miRNAs from pooled n=10 ze-
braﬁsh embryos inoculated with 50 - 300 pg/nL pIRESneo-Flag/HA Ago2 at 7
dpf, with mean and SEM indicated from representative samples. qRT-PCR was
performed on technical triplicates from 3 independent injection sessions.
Name n Name n
WT 762
pQE60-Exp5 pIRESneo-Flag/HA Ago2
50 pg/nL 240 50 pg/nL 310
100 pg/nL 421 100 pg/nL 321
200 pg/nL 301 200 pg/nL 234
300 pg/nL 367 300 pg/nL 214
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overall zebraﬁsh injected with a full strength U6 promoter driving any shRNA,
none survived 7 weeks post-fertilisation. The weaker H1 promoter did not induce
such dramatic mortalities; however, quantitative and qualitative measures of de-
velopment demonstrate that the level of shRNA induced from this promoter also
signiﬁcantly increased mortality over expression of control plasmids and impacted
on normal development of zebraﬁsh larvae.
Reduction of global miRNA levels has previously been demonstrated to signiﬁ-
cantly inhibit the development of zebraﬁsh and Xenopus using either morpholino
Figure 5.14 (preceding page): Expression of hAgo2 and hXpo5 can reduce
mortality and developmental abnormalities in zebraﬁsh larvae expressing shRNA
molecules
A Mean survival of zebraﬁsh larvae at 7 dpf following injection with pTol2-
EF1α:EGFP (GFP), pTol2-EF1α:GFP-U6:shG0906 (U6 uninjected), pTol2-
EF1α:GFP-H1:shG0906 (H1 uninjected) expression plasmids only (white bars).
Along with hAgo2 only or hAgo2 and shRNA expression plasmids (plain grey
bars), hXpo5 only or hXpo5 and shRNA expression plasmids (patterned grey
bars). B Mean developmental abnormalities observed up to 7 dpf, samples
as per (A). Error bars indicate SEM. C Head to trunk angle of representative
(n=30) sample of zebraﬁsh larvae at 3 dpf. Dark grey symbols are representative
of single injections. Black symbols are representative of hAgo2 co-injections or
of hAgo2 only and light grey symbols representative of hXpo5 only or hXpo5 co-
injection. D Standard length of zebraﬁsh larvae at 7 dpf. Symbols and samples
as per (C). E Mean surviving zebraﬁsh larvae at 7 dpf following injection with
tol 2 system plasmid and transposase only (White bars) or following co-injection
with both 100 pg/nL hAgo2 and hXpo5 plasmid and transposon system (Grey
bars). F Mean percentage zebraﬁsh showing gross morphological deformities
following injection. Samples as per (E). G Head to trunk angle of representa-
tive (n=30) sample of zebraﬁsh larvae at 3 dpf. Tol-2 system only injections
(light grey symbols). Co-injection of RNAi components and Tol 2 components
(Black symbols). H Standard length of zebraﬁsh larvae at 7 dpf. Samples as
per (G). Mean and SEM displayed for each sample. Representative individual
samples indicated for HTA and standard length. * p ≤ 0.05 relative to pTol2-
EF1α:EGFP (GFP) only. † p ≤ 0.05 relative to pTol2-EF1α:GFP-U6:shG0906
(U6 uninjected). # p ≤ 0.05 relative to pTol2-EF1α:GFP-H1:shG0906 (H1
uninjected).
Name n Name n
WT 1262
U6 712 H1 675
hAgo2 541 hXpo5 476 hAgo2 & hXpo5 600
GFP 400 GFP 321 GFP 400
U6 301 U6 234 U6 465
H1 367 H1 214 H1 321
.
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or siRNA mediated knockdown of RNAi pathway components, such as Dicer [378]
and Ago [227]. In particular, siRNA inhibition of Dicer in zebraﬁsh larvae resulted
in the accumulation of pre-miRNAs, and concomitant lack of mature miRNAs,
leading to complete mortality by 10 dpf. Xenopus embryos have previously been
shown to be signiﬁcantly more sensitive to siRNA / shRNA saturation of miRNA
components. Xenopus larvae inoculated with siRNAs, required additional human
Dicer to maintain normal development and siRNA enable eﬀective activity. It fol-
lows that overexpression of shRNA molecules is likely interfering with the normal
incorporation of maternal and endogenous miRNAs at crucial stages of develop-
ment and that the observed developmental delays and abnormal morphology are
the result of prevention of normal miRNA function.
As dose dependent non-speciﬁc eﬀects of shRNA expression have previously been
noted in zebraﬁsh [371] and mice [119,126–129], modiﬁcation of promoters to speciﬁcally
introduce lower levels of expression were investigated. Modiﬁcations to the distal
sequence elements of either the U6 or H1 promoters resulted in approximately 50%
reduction in shRNA expression, whereas any modiﬁcations made to the proximal
sequence elements completely prevented shRNA expression. Non-speciﬁc short-
ening of the U6 promoter did not decrease the expression of shRNA beyond that
Figure 5.15 (preceding page): Expression of hAgo2 and hXpo5 restores normal
miRNA expression following shRNA overexpression.
A) Expression of zebraﬁsh miRNA panel in pooled zebraﬁsh samples from 3
independent rounds of injection at 7 dpf with Tol-2 system plasmid and trans-
posase only (White bars), as well as co-injection with hAgo2 and Tol-2 system
(Light grey bars with black patterns) and with hXpo52 and Tol-2 system (Light
grey bars with white patterns). B Expression of zebraﬁsh miRNA panel in
pooled zebraﬁsh samples from 3 independent rounds of injection at 7 dpf with
tol 2 system plasmid and transposase only (White bars), as well as co-injection
with hAgo2, hXpo5, and Tol-2 system (Light grey bars with black patterns).
Mean and SEM.
Name n Name n
WT 1262
U6 712 H1 675
hAgo2 541 hXpo5 476 hAgo2 & hXpo5 600
GFP 400 GFP 321 GFP 400
U6 301 U6 234 U6 465
H1 367 H1 214 H1 321
.
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of modifying the distal sequence element, conﬁrming the identiﬁcation of the key
promoter motifs in Chapter 3. The level of reductions in expression observed fol-
lowing promoter modiﬁcation were approximately similar to those observed for
the human H1 promoter [260].
Modulation of promoters to alter the toxicity observed from shRNA over-expression
has not been a common strategy for the generation of transgenic RNAi. Most mod-
iﬁcations to promoters have been to increase the amount of shRNA expression to
increase the eﬀectiveness of knockdown. However, there remains a major deﬁ-
ciency in the literature surrounding the eﬀect of shRNA expression in vivo and
in particular the eﬀects of destabilizing the normal conditions of miRNA tran-
scription and regulation in the early stages of development. A similar method of
promoter modulation for the human U6-8 promoter, by replacing the PSE with
the PSE from the U6-7 promoter, resulted in the reduction of hepatocellular toxi-
city in non-human primate models. In adult mammals, in particular mice [128] and
cynomolgus monkeys [343], the primary site of shRNA-induced toxicity has been in
the liver. The unmodiﬁed U6-8 promoter used to express shRNAs from an aden-
oviral vector TT-033 resulted in dose-dependent increases in alanine aminotrans-
ferase, aspartate aminotransferase and alkaline phosphatase, as well as decreases
in albumin and total cholesterol [343], all markers of dose-dependent liver toxicity.
This was supported by liver-bridge necrosis observed in non-human primates that
correlated strongly with shRNA levels determined by qRT-PCR [343]. These results
in non-human primate models are consistent with previous studies performed in
rodent models [128,343].
Ago and Exportin-5 protein(s) have been demonstrated to be limiting factors for
the expression of shRNA and siRNAs in other systems [63,128]. Elevated levels of
Ago proteins have been shown to elevate nonspeciﬁc toxicity of siRNAs in vitro or
in vivo [126,129,367], as well as increase levels of endogenous mature miRNAs and in-
crease RNAi eﬃciency [92,113,126,227]. The limited availability of Ago is also proposed
to be a mechanism for miRNA-dependent increases in mRNA expression by com-
petition for available Ago protein [126,227,287]. The nuclear karyopherin Exportin-5
has been identiﬁed as an essential component of the shRNA and miRNA pathways
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and is therefore a prime candidate for shRNA mediated saturation. Exportin-5
has been demonstrated to be limiting within the RNAi and miRNA pathways [128].
As well as preventing homeostatic translocation of endogenous miRNA precursors,
Exportin-5 saturation may also reduce Dicer expression and subsequent activity,
illustrating some of the complexity of the cellular mechanisms underlying RNAi
toxicity [34,126].
To isolate the RNAi components that may potentially be limiting the normal
functioning of the miRNA pathway in the zebraﬁsh larvae, Xpo5 and Ago2 were
overexpressed with or without competing shRNA molecules. Overexpression of
hXpo5, and hXpo5 and hAgo2, but not hAgo2 in zebraﬁsh larvae, partially res-
cued normal development. shRNA saturation has previously been shown to be
independent of the presence of an shRNA target suggesting an early component
of the RNAi pathway was involved. However, co-injection of both hXpo5 and
hAgo2 was signiﬁcantly better at rescuing normal zebraﬁsh development. To con-
clusively determine all the members of the RNAi pathway involved, future work
should focus on selective inhibition or overexpression of other factors shared by
shRNAs/miRNAs, such as Dicer or other components of the RNA-induced silenc-
ing complex [126,129]. If the miRNA pathway can be oversaturated as has been
shown by over expression of hXpo5 and hAgo2, eﬃcient and persistent RNAi in
vivo should potentially be possible with the use of minimal vector doses and/or in-
herently weakly expressed shRNAs. The observed rescue of zebraﬁsh development
with weaker modiﬁed pol III promoters supports this hypothesis.
Deliberately co-expressing known rate-limiting cellular RNAi factors can boost
shRNA potency and reduce toxicity [129,227]. However, the long-term outcomes of
this approach for the cell and organism remain to be studied. It is interesting
to note in this context that a series of recent ﬁndings have indicated that essen-
tial parts of the RNAi machinery are inherently dysregulated in several cancers
and many viruses speciﬁcally encode RNAi silencing suppressors [30,33,37,132]. This
suggests that, along with the strategies described above, an important goal for
future research should be determining the critical concentrations of RNAi com-
ponents and the tolerance of these components to external stimulation. This will
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allow researchers to adapt and ﬁne-tune strategies toward maximum eﬃciency and
minimum toxicity.
In this study, Tol-2 transgenesis and resulting shRNA expression occured very
early in development [25,173–175,361]. Normal miRNA expression has previously been
shown to be crucial in development in an array of in vivo models including mice,
chickens, Xenopus, non-human primates and zebraﬁsh. This dependence on nor-
mal functioning of the miRNA pathway to maintain cellular homeostasis is likely
to be directly related to the dose-dependent toxicity observed in this project. This
is the ﬁrst evidence of shRNA over expression resulting in induction of abnormal
development and miRNA pathway inhibition during early development.
Chapter 6
General discussion
6.1 Overview
Utilising a combination of polymerase III type 3 promoters to drive expression of
shRNA molecules targeting virus speciﬁc sequences and the medaka Tol2 trans-
poson system to integrate the expression cassette, this project aimed to create
transgenic zebraﬁsh that expressed shRNA molecules capable of eliciting anti-viral
immunity. Speciﬁcally, these molecules targeted regions of the VHS virus genome
in order to mediate resistance to VHS virus. This collectively represents a useful
proof-of-principle demonstration of polymerase III promoter shRNA technology
that can potentially be adapted to a range of ﬁsh species.
The application of vector-mediated shRNA gene silencing has necessarily depended
on suitable promoters to facilitate appropriate shRNA expression. These promot-
ers have been derived from a range of sources and have been utilised in a somewhat
opportunistic manner. For example, the human, chicken and mouse U6 and H1
promoters [51,79,191,276], the human and chicken 7SK promoters [27,82], the human U1
promoter [91], and the human ubiquitin C promoter [385], as well as viral promoters
such as the CMV early [386,399,400] and adenovirus E1b promoters [155] have all been
used. These promoters have also been used in combination to increase potential
151
Chapter 6. General Discussion 152
shRNA expression; for example, combining the zebraﬁsh U6 promoter and the
CMV early enhancer region [95].
Type 3 RNA pol III promoters have long been considered eﬀective for shRNA
transcription [51], and they have been the most commonly used promoter type for
this purpose. This project began by identifying and comparing zebraﬁsh type 3
RNA pol III promoters, since it was initially hypothesised that a zebraﬁsh pol III
promoter would likely direct higher shRNA expression in zebraﬁsh cells compared
with alternative heterologous promoters. Moreover, it was thought that utilisa-
tion of entirely native transgenes will likely prove less problematic for ethics and
regulatory bodies as well as the general public in the event that transgenic RNAi
models reached a commercial stage of development.
U6 promoters from a number of species have proven to be very eﬀective for shRNA
expression [51,276,393]. Therefore, the initial objective of this project was to iden-
tify and utilise zebraﬁsh U6 promoter(s) for this purpose, as well as a poten-
tially weaker zebraﬁsh H1 promoter as a back-up in case the U6 promoter should
overwhelm the native miRNA pathway. The identiﬁed promoters were tested for
their ability to transcribe shRNAs that could suppress eGFP in comparison with
shRNAs expressed by the widely used mouse U6 promoter [68,87,172,387] and chicken
U6 promoter [27,79,383]. These experiments conﬁrmed the hypothesis that native
zebraﬁsh U6 promoters were capable of mediating a higher level of gene knock-
down compared to heterologous U6 promoters. Conversely, it was found that the
mouse and chicken U6 promoters were signiﬁcantly more eﬀective in mammalian
(VERO) cells at mediating gene knockdown than the equivalent zebraﬁsh pro-
moters. In addition, the zebraﬁsh H1 promoter was demonstrated to be a much
weaker promoter than the U6.
Polymerase III promoters have been considered to be signiﬁcantly less complex
than their polymerase II counterparts and this relative simplicity, particularly the
location of all required elements upstream of the transcription start site makes
them attractive for shRNA expression. However, the identiﬁcation of species-
speciﬁcity in their eﬀectiveness at driving shRNA expression suggests a level of
Chapter 6. General Discussion 153
regulation not previously presumed, which may be relevant in this regard [71,79,354].
Interestingly the zebraﬁsh U6 promoters identiﬁed, contained reversed SPH and
Oct-1 promoter motifs when compared with previously identiﬁed mammalian and
avian U6 promoters [51,79,191,276]. Analysis of histone and chromatin interactions at
the site of pol III transcription, has also demonstrated that this process is sig-
niﬁcantly more complex than previously considered [180,274,282,377]. DNA context-
dependent epigenetic modulation of pol III transcription is a key issue, which
indicates that pol III transcription is signiﬁcantly less “plug and play” than sug-
gested by early work [51]. Combined with the data on the various U6 and H1
promoters it suggests that the pol III promoter element motifs and the context
of the potential tol 2 insertion site represent important determinants of promoter
activity in homologous or non-homologous cell lines than simply the species of
origin.
For the next step in the development of a potential virus-resistant zebraﬁsh, the
genome of VHS virus was targeted for RISC-mediated degradation by pol III-
expressed shRNAs. The work described in Chapter 4 tested in vitro shRNAs
targeting two genes of the VHS virus genome the glycoprotein (G) and polymerase
(L) genes. These were targeted in three independent locations per gene prior to
validation of the most eﬃcient sequences in vitro. This demonstrated that the
combination of the U6-2 polymerase III promoter and 5 of the 6 tested shRNAs
were capable of signiﬁcantly reducing the replication of VHS virus in zebraﬁsh
ZF-4 cells.
The determination of speciﬁcity for shRNA or siRNA molecules is dependent on
a thorough understanding of the rules and processes that govern the strand selec-
tion of interfering molecules and RISC mRNA interaction. This project invested
signiﬁcant eﬀort into eliminating unwanted sequence speciﬁc interactions, in par-
ticular those dependent upon the canonical seed region dependent interactions.
However, recent studies have highlighted that canonical RISC mRNA seed region
complexes may represent only a small fraction of sequence dependent RISC silenc-
ing [140]. The miRNA seed region has generally been considered to be a 6 - 8 base
region at the 5′ end of the miRNA, and these potential interactions were examined
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in detail and used to select for shRNA molecules in this project. However, there
are a number of well known exceptions to canonical seed region binding such as
the earliest identiﬁed miRNA C. elegans lin4, with the lin-4:lin-14 interaction de-
pendent on bulged nucleotides [131]. In contrast, the crucial cell-cycle and immune
function regulator, human miR-24, is dependent on recognition sequences spread
across the whole miRNA [279].
The anti-viral shRNAs identiﬁed in this project compare favorably with other
molecules previously identiﬁed to target VHS virus. In particular, these molecules
do not appear to induce a signiﬁcant interferon and / or stress response like that
observed by Schyth et al [324,325] and Ruiz et al [307].
The zebraﬁsh H1 and U6 promoters identiﬁed in this study were able to be used to
construct shRNA expression plasmids capable of suppressing VHS virus replication
in vitro by expressing shRNAs targeting the virus. However, the introduction
of these constructs into transgenic animals resulted in signiﬁcant mortality and
developmental defects. Indeed, no transgenic zebraﬁsh expressing a hairpin from
the U6 promoter survived past 7 weeks of age. These ﬁndings are consistent with
previous work performed in mice [126,128,129] and Xenopus [113,227] using lentiviral
vectors and mammalian U6 promoters to drive expression of siRNA type molecules.
Similar results were found in the original studies of RNAi in zebraﬁsh [2,269,371,396].
The best hypothesis for this is that the levels of shRNA molecules expressed are
above the level that the native pathway can tolerate and still maintain normal
processing of endogenous miRNAs.
To combat the signiﬁcant mortality, two alternative methods were used. Firstly,
the promoters were modiﬁed to reduce the expression of the shRNAs (See 6.1).
Secondly, mRNAs encoding human versions of RNAi components were co-injected
into the zebraﬁsh in order to increase their levels, and thus potentially alleviate
the “swamping” of this pathway by the over-expression of by shRNAs.
With respect to modifying the promoters, removal of the distal sequence element;
the Oct-1, and the Oct-1 and SPH motifs in the U6 and H1 promoters, respectively,
signiﬁcantly reduced shRNA expression between 5 and 20 fold depending on the
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modiﬁcation. Non-speciﬁc shortening of the U6 or H1 promoters had no greater
eﬀect than removing the Oct-1 motif, and any modiﬁcations made to the proximal
sequence elements or TATA box in either promoter resulted in the complete loss
of shRNA transcription. Most of the research surrounding modiﬁcations to pol III
promoters has focused on increasing promoter eﬃcacy [177,184,231,298,306,370]. How-
ever, the characterisation of the unusually short human H1 promoter [260], as well
as the identiﬁcation of the DSE and PSE regions of pol III promoters [193,259,313,318],
reveals that simple modiﬁcations can also decrease promoter activity as observed
in this study. Deceasing the dosage of introduced shRNA by modifying the poly-
merase III promoters eﬀectively rescued both embryo viability and normal devel-
opment.
Saturation of the native miRNA pathway, thereby preventing endogenous miRNA
processing, is not unique to genetic engineered systems. A number of mammalian
viruses, in particular adenoviruses [14,223], act to suppress the mammalian RNAi
pathway by introducing large quantities of RNA with miRNA-like helices. These
are then incorporated into Exportin-5 and prevent the normal uptake and export
of pri-microRNAs from the nucleus. Other inducers of RNAi pathway saturation
are extensively reviewed in Chapter 1 and are summarised in Figure 6.2. Our
data, as well as that presented in previous work [34,128], support the hypothesis that
Xpo5 saturation is a key mediator of this eﬀect. However, when exogenous human
Exportin-5 (hXpo5) was introduced into zebraﬁsh embryos, both in the presence
and absence of shRNA vectors a signiﬁcant increase in toxicity and developmental
abnormalities was observed. This increase in toxicity was observed in hXpo5
injected embryos only and not in either hXpo5 and human Argonaute-2 (hAgo2)
co-injections or in hAgo2 only. This may imply that Xpo5 may act as a brake
or limiting factor in the number of RISC incorporating molecules that enter from
the nucleus into cytoplasm. If this is the case then, modulation of shRNA toxicity
by over-expression of the RNAi pathway components will consistently lead to
increased toxicity unless alleviated by the artiﬁcial over-expression of additional
Ago2 as described in (Chapter 5) and in [47]. This leads to the hypothesis that it
is the imbalance of miRNAs in the cytoplasm, rather than the speciﬁc saturation
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Figure 6.1: Summary of the modiﬁed U6 and H1 promoters// Graphical repre-
sentation of modiﬁcations made to the indicated promoter elements that ablate
expression when delivered in second-generation tol 2 constructs.
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of the individual components, that is responsible for the eﬀects observed in this
study.
These results suggest that use of RNAi as a therapeutic is dependent on: eﬀective
and speciﬁc shRNA design to avoid IFN-type responses or oﬀ-target eﬀects, and
the dosage of interfering molecules introduced should also be carefully controlled
to limit its eﬀects on the native miRNA pathway.
6.2 Recommended future directions
6.2.1 shRNA expression
While the polymerase III type 3 promoters identiﬁed in this study have proven
extremely eﬀective in cell culture systems, the complications observed in vivo
suggest that they may not be the most eﬀective option for the future generation
of shRNA transgenic animals. Pol III type 3 promoters express an extremely
deﬁned hairpin which, when expressed in the manner utilised in this study, avoids
Drosha/DGRG8 interaction and excision. Similar to Exportin-5 (see Chapter 5),
Drosha processing of longer constructs is a potentially rate-limiting step, which
could minimise further downstream consequences of shRNA expression. However,
as has been repeatedly demonstrated [1,152,170,338], the expression of long and short
ncRNA fragments capable of processing by Drosha within the nucleus can induce
a robust interferon-dependent response both in vitro and in vivo [1,271,297,338].
As for an alternative approach, either inducible or virus speciﬁc promoters could
be utilised for the generation of transgenic zebraﬁsh. Both techniques would allow
the expression of viral shRNA molecules only as required following either addi-
tion or viral infection, respectively, thus avoiding expression during developmental
stages of the zebraﬁsh potentially minimising mortality and developmental issues.
However, in the case of an inducible promoter, such as a small molecule induced tet
promoter it is likely to need to be induced constantly, therefore there is a likelihood
of similar phenotypes being observed as with the adenoviral delivery of shRNA
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Figure 6.2: Summary of the RNAi pathway, including potential external me-
diators of saturation of individual pathway components
Schematic representation of RNAi pathway showing RNA species (rounded
boxes) and RNAi machinery (square boxes) within shaded boxes representing
the nucleus (orange) and cytoplasm (blue). Externally derived RNAi-inducing
elements; vector-encoded intronic shRNA, shRNA or miRNA, delivered siRNA
and viral RNA (bullet shaped boxes) and their potential risk of saturation of
the cellular RNAi pathway. Where there is experimental evidence for a speciﬁc
RNAi inducer type saturating this is indicated as follows: (virally derived RNAs
by hexagonal ﬁgure, miRNAs by bulged miRNA loop, shRNA by unbulged loop
and siRNAs by parallel lines. Red indicates experimental evidence derived from
this study. (Figure is modiﬁed from [129] with additional data from Chapter 5
as well as [14,17,37,43,63,79,113,117,119,126,129,132,150,177,227,243,263,323,325,335])
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molecules into adult mice [128]. In this study 49 independent shRNA constructs
were delivered into adult mice, 36 of which caused signiﬁcant liver damage follow-
ing disruption of the normal miRNA expression levels. Therefor long-term shRNA
expression using a small molecule inducible promoter or similar may not solve the
issues caused by overexpression of shRNA if these doses are still above the toler-
ated level. In addition, pragmatic concerns regarding the long-term interventions
required with an induced promoter for a potentially commercialised product also
indicate that inducible promoters are likely a poor choice in this context.
Virus or viral-RNA inducible promoters, such as Mx-1, interferon-α [7,72,192], STAT-
1 and STAT-2 [73], have been used to express mRNA speciﬁcally in response to
virus infection. These pol II promoters could also conceivably be used to drive
expression of shRNA molecules at speciﬁc times of need. However, a number of
studies [284,286,312,360,379] have identiﬁed that normal miRNA propagation is required
for the normal activation of both the innate and active immune responses. While
the importance of the direct RNAi response has been hotly debated in the context
of mammalian viral infections [20,54,77,78,230], the absence of normal miRNA process-
ing is refractory to the normal anti-viral response [5,229,329,331]. Overexpression of
shRNA molecules, as an anti-viral response ramps up, via expression of anti-viral
shRNAs linked with a virally-induced protein such as interferon-α or Mx-1, and
this may inhibit these important processes. Additionally, many viruses such as
IHNV in zebraﬁsh [224], as well as Ebola via the VP35 protein [29], and Dengue
Virus NS2a and NS4 proteins [256], among many others (as reviewed in [149]) speciﬁ-
cally interfere with IFN and MX production and as such would additionally inhibit
shRNA expression linked to these prominent anti-viral genes.
The shRNA design strategies utilised in this study have been reliable over the
course of a number of shRNA-based projects [27,195,196,353]. Quantitating whether
this design strategy is the most eﬀective or not is problematic as alternative ef-
fective strategies are rapidly commercialised and data surrounding their relative
eﬀectiveness is almost always impossible to obtain. However, since the design of
the shRNAs utilised within this and earlier projects, there has been signiﬁcant in-
vestment of research eﬀort in determining speciﬁc biochemical and stoichiometric
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properties that direct RISC incorporation and speciﬁc Ago protein interactions,
whist avoiding other aspects of the RNAi pathway [145]. Modiﬁcation of shRNA
design, perhaps to remove requirements for Dicer processing by shortening the
shRNA and by the inclusion of a G - U or U - G [218] at the loop simpliﬁes the
number of steps required for shRNA processing and is an interesting possibility for
potentially further minimising the likelihood of inhibiting the endogenous RNAi
pathways.
6.2.2 Tol2 and transgenic production
Tol2 constructs can transpose eﬃciently in a variety of cell types, including in de-
veloping embryos (either diﬀerentiating somatic cells or germ cells), and integrate
throughout the genome [173]. No reported preferential chromosome integration has
been reported [25,173], and no consensus DNA sequence observed in the 8 bp target
duplications created upon integration of Tol2. Moreover, transgenes cloned in the
Tol2 vector are reliably expressed in transgenic animals and cells, and there is no
evidence of gene silencing mechanisms by the host or integration site eﬀect on the
eﬃcacy of transcription. [25,173]. However, several of the factors that facilitate ef-
fective transposon integration make the Tol2-based vectors and constructs utilised
in this work problematic for introducing rational, precise and measured shRNA
dosages in transgenic animals. To overcome these potential issues, precision gene
targeting methods, such as nuclease-mediated homologous recombination using
Talens or CRISPR proteins [18,32,41,56,74,252], are recommended for future develop-
ment of transgenic RNAi delivery system.
In this study, it has been demonstrated, using an artiﬁcial EGFP-intron construct,
that the expression of an intronic miRNA was not signiﬁcantly perturbed by the
introduction of a second hairpin into the same intron, and that the secondary hair-
pin was expressed at similar levels to the primary miRNA (see Chapter3). This
represents an innovative approach that may provide an eﬀective method of intro-
ducing shRNAs at tolerated levels. Precision genome targeting methods, coupled
with homologous recombination again provide the mechanisms for achieving this
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in vivo single hairpin construct, targeting either an intron, or a 5′ untranslated-
region (UTR) where an identiﬁed miRNA which is expressed in appropriate tissues
occurs. The 5′ UTR is potentially preferable as modifying the secondary struc-
ture of an intron may introduce unintended consequences with respect to correct
intron processing. However, extensive in vitro and in vivo testing are required to
elucidate the most eﬀective methods. Application of such a method for generating
transgenic zebraﬁsh would also be signiﬁcantly more complex than the methods
utilised in the current study, and also precludes the use of a ﬂuorescent reporter
with screening of transgenics necessarily requiring molecular analysis. However,
since it would introduce a minimal amount of exogenous sequence, and it does
not require any additional promoters nor aﬀects the target site, it is inherently
attractive. Coupling the shRNA to an expressed tolerated miRNA should also
reduce the possibility of saturation of the endogenous system.
6.2.3 Multi-shRNA cassettes
Multiple eﬀective shRNA molecules are crucial for generating transgenics with
long term viral resistance. This is because the sequence speciﬁcity of RNAi, which
makes it ideal for degrading desired targets while leaving non-complementary se-
quences untouched, also makes it easy for viruses to evade or escape. Viruses,
particularly RNA viruses, alter their genomes by producing point mutations al-
lowing them to escape RNAi strategies that target a single sequence. Previous
work using a computational model of HIV replication [204,205] has suggested that
to prevent viral escape it was necessary to target multiple gene sequences with
high eﬃciency silencing molecules. Speciﬁcally, they found that targeting a single
sequence with a shRNA of average eﬀectiveness (e.g. reducing viral mRNA ex-
pression by 70%), would prevent viral escape in 0% of trials, while four individual
shRNAs of the same eﬃciency would prevent viral escape in 100% of trials. They
further demonstrated that RNAi inducing molecules of 60% eﬃcacy were unable
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to prevent viral escape even when ﬁve diﬀerent sequences were targeted. There-
fore, to prevent VHS virus escape, multiple gene sequences must be targeted with
molecules that have high suppressive activity.
The design and generation of constructs for the expression of multiple shRNAs
from either single or multiple transcription units is outside the scope of this the-
sis. However, the panel of both shRNAs and promoters identiﬁed does collectively
provides the basic elements required for such constructs, at least in vitro. There
has been substantial research, into diﬀerent approaches that enable the incorpora-
tion of multiple target sequences into a single construct. This may be necessary to
induce a coordinated RNAi strategy, which is able to both suppress the target virus
and prevent the potential evolution of viral escape mutants. The limitations of
these methods include improper processing of long transcripts, and the signiﬁcant
risk of toxicity caused by over-expression. In addition, shRNAs within a multi-
ple transcription unit have been found to produce a reduced level of suppression
compared to identical shRNAs expressed from individual vectors [146,243]. Proposed
explanations for these phenomena include positional eﬀects, such as a reduced ex-
pression of the hairpin placed in the last position of the construct. In addition,
there may be competition between hairpins expressed simultaneously for access to
critical components of the RNAi pathway including Exportin-5 and RISC compo-
nents [63,244], with simultaneous expression of shRNAs resulting in suppression of
each hairpin in direct proportion to the number of hairpins expressed. However,
the data remains inconclusive, and signiﬁcant further research is needed. Multiple
hairpins have been driven speciﬁcally from either pol II or pol III promoters utilis-
ing either single or multiple promoters in either a long stem or multiple individual
hairpins, respectively. Utilising a miRNA cluster, such as the hsa-let-7C cluster,
may provide an alternative strategy for incorporation of multiple hairpins within
a single construct, such that they do not compete with each other for potentially
limited nuclear or cytoplasmic processing components.
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6.2.4 The zebraﬁsh model
The majority of virology and immunology researchers work in mammalian models,
mostly small laboratory rodents, whereas ﬁsh virologists and immunologists have
traditionally focused upon rainbow trout (Oncorhynchus mykiss), Atlantic salmon
(Salmo salar) as well as common carp (Cyprinus carpio) and other commercially
important farmed ﬁsh (reviewed excellently in [245,266,267,336]). In contrast, despite
the earliest description of infection of zebraﬁsh with VHS virus dating back over
thirty years [326], the use of zebraﬁsh as a model of viral infection remains in its
infancy when compared to these models, or to the use of the zebraﬁsh as a model
of development and genetics.
However, the zebraﬁsh oﬀers great potential as a research model for ﬁsh immu-
nologists and virologists. It is far more easily housed than most commercially
farmed ﬁsh, and the genetic tools and methodologies available to the zebraﬁsh
researcher dwarf those validated or tested in any other ﬁsh species. Zebraﬁsh is
a particularly good model for diseases of carp because they belong to the same
family (Cyprinidae). A recent publication [208,224] describe the “whole-body” infec-
tion of zebraﬁsh larvae with a heat-adapted IHN virus. Which took advantage of
both the transparency of the zebraﬁsh and the availability of relevant ﬂuorescent
strains to track the infection throughout the larvae. While showing a predictable
pattern of infection, this work was signiﬁcant in being among the ﬁrst work to
utilise the power of the zebraﬁsh model for imaging, and to combine it with an in-
fection model. It is envisaged that the possibilities for live imaging, and transgenic
knock-in or knock-out zebraﬁsh will provide unique tools to elucidate the patterns
of viral infection in this important model [208,224]. In the context of virally-induced
shRNA expression, the model may provide crucial information as to the tissues
infected at early, intermediate and late stages of infection. These data would be
crucial for the determination of insertion sites to “hitchhike” shRNAs to miRNA
expression, and also for the selection of promoters for virally induced expression.
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6.2.5 Speciﬁc recommendations for in vivo shRNA expres-
sion in zebraﬁsh
The requirements for shRNA expression, cassette insertion, ease of inclusion of
multiple shRNA constructs, and the opportunities and resources of the zebraﬁsh
as a model are important considerations for the design of future projects for the
generation of disease-resistant ﬁsh. While the shRNAs identiﬁed in this project
were eﬀective at reducing virus growth and CPE in vitro the choice of constitutive
pol III promoters, as well as the use of the Tol2 system to randomly incorporate
the expression cassette has prevented the successful development of a zebraﬁsh
strain which expresses an shRNA which provides speciﬁc resistance to VHS virus.
To overcome the limitations of the systems used within this project to generate
an anti-viral zebraﬁsh, one proposal would be to use the Pank1B 5th intron as an
appropriate starting point for the generation of intron-derived shRNA delivery in
zebraﬁsh. Insertion of the shRNA into the site identiﬁed in this study as conserved
in zebraﬁsh provides an obvious starting point, as this delivery system worked ef-
fectively in vitro when driven as an EGFP intron by the CMV promoter. This
proposal avoids a number of the issues that were observed during this project; in
particular, the over-expression of the shRNAs during development that led to the
observed increases of developmental deformities and mortalities in the zebraﬁsh
larvae. This method of attaching the shRNA to an already tolerated and dupli-
cated miRNA is proposed to limit the likelihood of aﬀecting the natural processes
involving this miRNA and hopefully provides a tolerated level of expression of the
shRNA. As discussed previously, an alternative to the integration within a miRNA
expressing intron could be the use of virus speciﬁc promoters however these pro-
moters would drive expression of the shRNA only after the detection of the virus
by the cell and this may limit the eﬀectiveness of the shRNA or potentially inhibit
normal miRNA processing required for the endogenous virus response.
As well as replacing the promoters it is suggested that CRISPR nucleases are
utilised to provide a precision cleavage point, and homologous recombination to
insert the shRNA, or shRNA expression cassette into the desired location within
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the genome. This method of insertion provides a number of signiﬁcant advantages
over the Tol2 systems used in this project. By choosing the site of insertion the
eﬀect on surround genes can be minimalised as identiﬁed coding and conserved
sites within the genome can be avoided. As well as this advantage if the combina-
tion of a miRNA linked intron and CRISPR insertion is utilised it would provide
a minimal insertion size of 87 nt for a single shRNA. This minimal insertion size
and lack of an additional promoter may additionally make this method of insertion
more palatable from a regulatory / public perception perspective.
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Appendix A
Synthetic Oligonuclotides used in
this study
Name Sequence
PCR
zU6-1 F GAT TCC AAA TGG TGC ATG AG
zU6-1 R AGA TCA GCA GTC AGG CTC AG
zU6-2 F CTC GGT CAT TCA GTA AGA CG
zU6-2 R GAA CCA AGA GCT GGA GGG AG
zU6-3 F GTT TGA TGG GCC GTT GCT G
zU6-3 R GAA CTA GGA GCC TGG AGG AC
zU6-4 F GCT CTG CTC TAG TGA GAG CAG
zU6-4 R GAG CTG GGA GTC TGG AGG AC
zH1 F TCC TGC TAG GAC AGC GAG TG
zH1 R CTG TTC ATG AGC GCT ACG
qPCR
β-actin SYBR F CGA GCA GGA GAT GGG AAC C
β-actin SYBR R CAA CGG AAA CGC TCA TTG C
IFN F GAA TGG CTT GGC CGA TAC AGG ATA
IFN R GAT TGG CTT GGC CGA TAC AGG ATA
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VHSV G Gene R GGG TTG GGT CGC CAT GTT TC
VHSV G Gene F CCT CTG TCC GAC CTT GGT AG
Ago2 F CGC ATG TGT TAC GTG GCA TC
Ago2 R AAA GTG CTG GAC CAT GTG CT
Xpo5 F CAG CCA GTT TCT GAG GTC GT
Xpo5 R GTA CCT AGT GCG AGT ACG GC
U6 qPCR snRNA R AGA TGG AAC GCT TCA CGA AT
U6 qPCR snRNA F TTG CTT CGG CAG CAC ATA
H1 qPCR snRNA F GAG GTC ACC CAC TGA GTG CT
H1 qPCR snRNA R GTT GAT CCG CTG AAT GTG TG
MCP 138 F CGG CGT CAA GGA CTT TAT G
MCP 407 R GCG TTG TCT TCG GGA ATA C
MCP 952 F ATG CCC ACC TTC ACC TAC
MCP 1515 R CTG TTC GGT GGA CAA TGC
MCP 2857 F GTA CAG AGC CAC CTC TTG
MCP 3597 R CGT CTT GAG GAG CTG TTC
DNP-1851 F CAC CTT CGG CCT GGA CTA TGT G
DNP-2272 R TGC TGG CAG CGG GTA TCT TC
DNP-3161 F CCA GCA CCT TCG GCA ACA TC
DNP-3526 R TCG CCG ACC AGT ACC TGA AC
DNP-4374 F CGA CTT TGA GGA GAC GTT TG
DNP-3121 F ATG GTG TAC GCT TGC TTC
DNP-3572 R AGG CCA GAG TAC TGG ATG
DNP-4717 R TCC AGT CCA CCT TCT GTA TG
shRNA Construction
zU6-1shEGFP TCT AGA TTC CAA AAA AGC TGA CCC TGA
AGT TCA TCT CTC TTG AAG ATG AAC GTC
AGG GTC AGC AGA TCA GCA GTC AGG CTC
AG
zU6-2shEGFP TCT AGA TTC CAA AAA AGC TGA CCC TGA
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AGT TCA TCT CTC TTG AAG ATG AAC GTC
AGG GTC AGC GAA CCA AGA GCT GGA GGG
AG
zU6-3shEGFP TCT AGA TTC CAA AAA AGC TGA CCC TGA
AGT TCA TCT CTC TTG AAG ATG AAC GTC
AGG GTC AGC GAA CTA GGA GCC TGG AGG
AC
zU6-4 shEGFP TCT AGA TTC CAA AAA AGC TGA CCC TGA
AGT TCA TCT CTC TTG AAG ATG AAC GTC
AGG GTC AGC GAG CTG GGA GTC TGG AGG
AC
zH1 shEGFP TCT AGA TTC CAA AAA AGC TGA CCC TGA
AGT TCA TCT CTC TTG AAG ATG AAC GTC
AGG GTC AGC GGG TTA TGA CGT AGT
CG
TD391 TCT AGA TTC CTT TTT TCC GAA ATG
TTC GTC ACC AAA TTC TCT TGA AAT
TTG GTG ACG AAC ATT TCG GGA ACC AAG
AGC TGG AGG GAG
TD392 TCT AGA TTC CTT TTT TGA ACA AAT
TGG CCA AGA GAC TTC TCT TGA ATC
AGA GAA CCG GTT AAA CAA GGA ACC AAG
AGC TGG AGG GAG
TD393 TCT AGA TTC CTT TTT TGG CAA TTC
AAG AGG TCA GTG ATC TCT TGA ATC
ACT GAC CTC TTG AAT TGC CGA ACC AAG
AGC TGG AGG GAG
zH1-shVHSVG906 CTC GAG TTC CAA AAA AAC
AAC CAT CTC ATC ACC AAC ATT CTC
TTG AAA TGT TGG TGA TGA GAT GGT TGG
GGT TA TGA CGT AGT CTG CG
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pEGFP Intron F GTT ATC CCC TGA TTC TGT GG
pEGFP Intron R AAA ACT AGT ATA TTA ACG CTT ACA ATT
TAC GCC
zH1-shVHSVG906 F GTC GAC CAT CAA CTA CCC AAT CAC TGC
Xpo5 SP6 F TCT AGA ATT TAG GTG ACA CTA TAG ATG
GCG ATG GA
Xpo5 SP6 R GAA TTC TCA GGG TTC AAA GAT GGT GGC
SpeI U62 F AAA AAA CTA GTC TCG GTC ATT CAG TAA
GA
SpeI H1 F AAA AAC TAG TCA TCA ACT ACC CAA TCA
CTG C
M13 F CGC CAG GGT TTT CCC AGT CAC GAC
M13 R TCA CAC AGG AAA CAG CTA TGA C
H1 shScramble TCT AGA TTC CAA AAA AAC CAA CCA CTA
CTT AAC CA
U6 shScramble TCT AGA TTC CTT TTT ACC AAC CAC
H1-Oct F AAA ATC TAG ACT TCC CTT AAT GTT CGA
CCA C
H1-STAF AAA TCT AGA GAT TTG TGT ACA ATG CGT
TAA ATA AC
U62 OCT d AAA TCT AGA GCT TTA CAG TTT GAA
AAA TAC CAC AG
VHSV F624 ACC TCG CCC TGT CAA ACT CAT
VHSV R624 ATT GCC TTG ACC ACC CTG TGA
VHSV F1018 CTC ATT TCT CCT CTC AAA GTT TCG
VHSV R1018 CCG TCT GTG TTG TTG TCT ACC
shVHSVG2 F BamHI GAA TGG ATC CTC CCT CCA GCT CTT GGT
TC
shVHSVG2 R KpnI GAT AGG TAC CCG TTG GGA GCT CTC CCA TA
U62shVHSVG2 XhoI AAA ACT CGA GAT GTT CTG CGC ATG CCT
GTG
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U62 shVHSVG2 R TGC TTC CGG CTC GTA TGTTG
RNA Probes
LL91 GAU GAA CUU CAG GGU CAG C
mir-16 AUC GUC GUC CAU UUA UAA
CCG CGG ACA GAG GG
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Name Description Selection
pEGFP-N1 CMV-EGFP Expression Kanamycin
pGEM-T A-T Cloning Vector (Promega) Ampicillin
pUC118 Cloning Vector Ampicillin
pZFU6 1-shEGFP shEGFP Expression (pGEM) Ampicillin
pZFU6 2-shEGFP shEGFP Expression (pGEM) Ampicillin
pZFU6 3-shEGFP shEGFP Expression (pGEM) Ampicillin
pZFU6 4v1-shEGFP shEGFP Expression (pGEM) Ampicillin
pZFU6 4v2-shEGFP shEGFP Expression (pGEM) Ampicillin
pZFH1-shEGFP shEGFP Expression (pGEM) Ampicillin
pFugu-shEGFP shEGFP Expression (pGEM) Ampicillin
pT2-002 CAAGS Transposase Expression Ampicillin
pTPase mRNA SP6 Transposase Ampicillin
pMiniTol Mini Tol 2 Cloning Vector Ampicillin
pMTol BC1 Mini Tol 2 Cloning Vector + SV40 Poly A Ampicillin
pMTol BC2 EF1a GFP Tol 2 Ampicillin
pTol2-EF1α:GFP EF1a GFP Tol 2 and shRNA Expression Ampicillin
pTol2-EF1α:GFP-U62:shG0906 EF1a GFP Tol 2 and shRNA Expression Ampicillin
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pTol2-EF1α:GFP-H1:shG0906 EF1a GFP Tol 2 and shRNA Expression Ampicillin
pTol2-EF1α:GFP-U62:shScramble EF1a GFP Tol 2 and shRNA Expression Ampicillin
pTol2-EF1α:GFP-U62:shG1207 EF1a GFP Tol 2 and shRNA Expression Ampicillin
pTol2-EF1α:GFP-H1:shG1207 EF1a GFP Tol 2 and shRNA Expression Ampicillin
pTol2-EF1α:GFP-H1:shScramble EF1a GFP Tol 2 and shRNA Expression Ampicillin
pTol2-EF1α:GFP-U62-Half:shG0906 EF1a GFP Tol 2 and shRNA Expression Ampicillin
pTol2-EF1α:GFP-U62-Oct1:shG0906 EF1a GFP Tol 2 and shRNA Expression Ampicillin
pTol2-EF1α:GFP-U62-SPH:shG0906 EF1a GFP Tol 2 and shRNA Expression Ampicillin
pTol2-EF1α:GFP-U62-TATA:shG0906 EF1a GFP Tol 2 and shRNA Expression Ampicillin
pTol2-EF1α:GFP-H1-Oct1:shG0906 EF1a GFP Tol 2 and shRNA Expression Ampicillin
pTol2-EF1α:GFP-H1-Sph:shG0906 EF1a GFP Tol 2 and shRNA Expression Ampicillin
pTol2-EF1α:GFP-H1-PSE:shG0906 EF1a GFP Tol 2 and shRNA Expression Ampicillin
pTol2-EF1α:GFP-H1-TATA:shG0906 EF1a GFP Tol 2 and shRNA Expression Ampicillin

Appendix C
Accession number of VHS virus
glycoprotien and polymerase used
in sequence conservation analysis
Glycoprotien
Z93431.1 Z93430.1 Z93429.1 Z93428.1
Z93427.1 Z93426.1 Z93425.1 Z93424.1
Z93423.1 Z93422.1 Z93421.1 Z93420.1
Z93419.1 Z93418.1 Z93417.1 Z93416.1
Z93415.1 Z93413.1 Z93411.1 Z93410.1
Z93409.1 Z93408.1 Z93407.1 Z93406.1
Z93405.1 Z93404.1 Z93414.2 AM086383.1
AM086382.1 AM086381.1 AM086380.1 AM086379.1
AM086378.1 AM086377.1 AM086376.1 AM086375.1
AM086374.1 AM086373.1 AM086372.1 AM086371.1
AM086370.1 AM086369.1 AM086368.1 AM086367.1
AM086366.1 AM086365.1 AM086364.1 AM086363.1
AM086362.1 AM086361.1 AM086360.1 AM086359.1
AM086358.1 AM086357.1 AM086356.1 AM086355.1
AM086354.1 Z93412.2 F N665788.1 AB179621.1
227
Appendix C. Accession number of VHS virus glycoprotien and polymerase used in
sequence conservation analysis 228
FJ362515.1 AJ233396.1 X73873.1 NC000855.1
Y18263.1 JF792424.1 FJ460590.1 FJ460591.1
AB839745.1 AB839746.1 AB839747.1 AB839748.1
AF143863.1 AF143862.1 KF477302.1 KC778774.1
AB672614.1 FJ362510.1 GQ385941.1 X89213.1
AB490792.1 EU481506.1
